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vAbstract
Understanding the protein fitness landscape is important for describing how natural proteins evolve
and for engineering new proteins with useful properties. This mapping from protein sequence to pro-
tein function involves an extraordinarily complex balance of numerous physical interactions, many of
which are still not well understood. Directed evolution circumvents our ignorance of how a protein’s
sequence encodes its function by using iterative rounds of random mutation and artificial selection.
The selection criteria is based on experimental measurements, which permits the optimization of
protein sequence properties that are not understood. While directed evolution has been useful for
exploring protein fitness landscapes, these searches have been relatively local in comparison to the
vast space of possible protein sequences. Here, we present several classes of statistical models that
map protein sequence space on a larger scale. We use these simple models to interpret data from
SCHEMA recombination libraries, understand the evolutionary benefit of intragenic recombination,
and design optimized protein sequences. By training on directly on experimental data, these mod-
els implicitly capture the numerous and possibly unknown factors that shape the protein fitness
landscape. This provides an unrivaled quantitative accuracy across a massive number of protein
sequences.
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1Chapter 1
Introduction: Exploring protein
fitness landscapes by directed
evolution
A version of this chapter has been published as [1].
1.1 Abstract
Directed evolution circumvents our profound ignorance of how a protein’s sequence encodes its
function by using iterative rounds of random mutation and artificial selection to discover new and
useful proteins. Proteins can be tuned to adapt to new functions or environments by simple adaptive
walks involving small numbers of mutations. Directed evolution studies have shown how rapidly
some proteins can evolve under strong selection pressures and, because the entire ‘fossil record’ of
evolutionary intermediates is available for detailed study, they have provided new insight into the
relationship between sequence and function. Directed evolution has also shown how mutations that
are functionally neutral can set the stage for further adaptation.
1.2 Introduction
Millions of years of life’s struggle for survival in different environments have resulted in proteins
providing diverse, creative and efficient solutions to a wide range of problems, from extracting energy
from the environment to repairing and replicating their own code. Good solutions to biological
2problems can also be good solutions to human problems — proteins are widely used in the food,
chemicals, consumer products, and medical fields. Not content with nature’s protein repertoire,
however, protein engineers are working to extend known protein function to new environments or
tasks [2, 3, 4, 5] and to create new functions altogether [6, 7, 8].
Despite major advances, a molecular-level understanding of why one protein performs a certain
task better than another remains elusive. This is perhaps not surprising when we remember that a
protein often undergoes conformational changes during function and exists as a dynamic ensemble
of conformers that are only slightly more stable than their unfolded and non-functional states and
that might themselves be functionally diverse [9]. Mutations far away from active sites can influence
protein function [10, 11]. Engineering enzymatic activity is particularly difficult because very small
changes in structure or chemical properties can have big effects on catalysis. Thus, predicting the
amino acid sequence, or changes to an amino acid sequence, that would generate a specific behavior
remains a challenge, particularly for applications requiring high performance (such as an industrial
enzyme or a therapeutic protein). Unfortunately, where function is concerned, details matter, and
we just don’t understand the details.
Evolution, however, had no difficulty generating these impressive molecules. Despite their com-
plexity and finely tuned nature, proteins are remarkably evolvable: they can adapt under the pressure
of selection by changing their behavior, function, and even fold. Protein engineers have learned to
exploit this evolvability using directed evolution — the application of iterative rounds of mutation
and artificial selection or screening — to generate new proteins. Hundreds of directed evolution
experiments have revealed the ease with which proteins adapt to new challenges [12]. Notable recent
examples include a recombinase evolved to remove proviral HIV from the host genome (providing
a new strategy for treating retroviral infections) [13], a cytochrome P450 fatty acid hydroxylase
that was converted into a highly efficient propane hydroxylase (thereby proving that a cytochrome
P450 is fully capable of hydroxylating small alkanes, even though most propane-using organisms
use structurally and mechanistically unrelated enzymes) [14], a more than 40 ◦C increase in the
thermostability of lipase A (extending its application in biocatalysis to a whole new set of environ-
3ments) [15], and a variant of green fluorescent protein that tolerates having all its leucine residues
replaced with a non-natural amino acid, trifluoroleucine [16]. Roger Tsien won the Nobel Prize last
year for his work on the fluorescent proteins that have transformed biological imaging [17]. Directed
evolution had a key role by improving many features of fluorescent proteins, including emission and
excitation properties, quantum yield, multimerization state, and maturation rate [5, 18].
Directed evolution has become a common laboratory tool for altering and optimizing protein
function (as well as the function of other biological molecules and systems, including RNA, DNA
regulatory elements, biosynthetic pathways, and genetic regulatory circuits [19, 20, 21]). To under-
stand the power, and the limitations, of directed evolution, it is helpful to view it as a biological
optimization process. We therefore introduce the concept of evolution on a fitness landscape in
protein sequence space and use this framework to explain directed evolution strategies. Data from
laboratory evolution experiments have revealed important features of this fitness landscape and the
types of trajectories that can traverse it efficiently. This landscape picture can help explain why
decomposing a large functional hurdle into a series of smaller ones and exploiting protein modularity
and structural information are useful strategies for dealing with the combinatorial explosion of pos-
sible paths in an evolutionary search. This also helps us to appreciate the power of recombination
to generate functional sequences with numerous (mostly neutral) mutations, novel combinations of
which can give rise to new protein behaviors and therefore new starting points for optimization of
protein function.
There is little doubt that directed evolution is one of the most effective and reliable approaches
to engineering useful new proteins. Perhaps less well appreciated, however, is how much our un-
derstanding of protein function and evolution has been enriched by data from these experiments.
Directed evolution allows us to disconnect a protein from its natural context and observe how adap-
tation to different functional challenges can occur. These experiments can explore the boundaries
between biological relevance (the ability of a protein to contribute to the reproductive fitness of
an organism) and what is physically possible (the ability of a protein to carry out a specific func-
tion in vitro or in vivo) in ways that studies on natural proteins alone cannot. Directed evolution
4can test alternative adaptive scenarios, explore the range of possible solutions to a given functional
challenge, examine relationships between different protein properties (for example, trade-offs, in
which improvements in one property are accompanied by losses of another) and provide biophysical
explanations for evolutionary phenomena. Much has been discovered since these topics were first
reviewed in the context of temperature adaptation [22, 23]. In this review, we revisit some of these
early lessons and discuss new ones that have emerged.
1.3 Protein Fitness Landscapes
In his influential 1970 paper, John Maynard Smith eloquently described protein evolution as a
walk from one functional protein to another in the space of all possible protein sequences [24]. He
arranged all proteins of length L such that sequences differing by one amino acid mutation were
neighbors. Although the distance between any two sequences is small (that is, it equals the number
of mutations required to interconvert the sequences and is therefore ≤ L), this high-dimensional
space contains an incomprehensibly large number of possible proteins. For even a small protein of
100 amino acids there are 20100 (≈ 10130) possible sequences — more than the number of atoms
in the universe. Searching in this space for billions of years for solutions to survival, nature has
explored only an infinitesimal fraction of the possible proteins [25]. Furthermore, natural evolution
keeps only sequences that are biologically relevant; others are discarded, even if they represent
solutions to other interesting problems. There are so many proteins waiting to be discovered and
we can only dream about the extent of their capabilities. Directed evolution is one way to extend
protein function to new, non-natural tasks and convert dreams into actual proteins.
Each sequence in Maynard Smith’s protein space can be assigned a ‘fitness’, which in natural
evolution is a measure of the host organism’s ability to reproduce in a given environment: fitter
organisms reproduce faster and their genes spread throughout the population [26]. When artificial
selection is imposed, fitness is defined by the experimenter. High-fitness sequences satisfy all of
the criteria for a protein to function as desired, or at least to perform well in the assay used for
screening, and might include the ability to recognize one substrate but not another, to be expressed
5at high levels in a particular host organism, to not aggregate, and to have a long lifetime. Protein
evolution can then be envisioned as a walk on this high-dimensional fitness landscape, in which
regions of higher elevation represent desirable proteins, and iterations of mutation and artificial
selection continuously discover new sequences further uphill, with higher fitnesses (Figure 1.1A).
As with any optimization problem, the structure of the objective function (the fitness landscape)
influences the effectiveness of a search strategy [27]. Possibilities range from smooth, single-peaked
‘Fujiyama’ landscapes to rugged, multi-peaked ‘Badlands’ landscapes [28] (Figure 1.1B). The rougher
the landscape, the harder it is for evolution to climb. Local optima create traps that evolution cannot
escape from unless a side-step or even a temporary decrease in fitness is permitted, or if multiple
simultaneous mutations enable a jump to a new peak. The easiest landscape to climb is one that
offers many smooth, uphill paths to the desired fitness (the Fujiyama landscape).
This terrestrial landscape analogy should be interpreted cautiously, however, because it cannot
accurately represent the numerous possible paths that evolution can take to higher fitness (or the
even larger number of possible downhill paths). Although it is easy to visualize being caught on
a local optimum in a three-dimensional landscape, a local optimum in protein sequence space (in
which all possible mutations are deleterious) might be rare, unless stability has been compromised
and few new mutations can be accepted. For example, the introduction of stabilizing mutations can
increase a protein’s mutational robustness, opening new routes for further adaptation [29, 30].
The vast size of sequence space makes it impossible to characterize (or even model) more than
a minute fraction of this fitness surface. Despite this, several important features have emerged
from accumulated experimental studies. The first is the low overall density of functional sequences:
the vast majority do not code for any functional protein, much less the desired protein [31, 32, 33].
Another important feature is the uneven distribution of functional sequences. Although representing
a very small fraction of all possible sequences, functional sequences are often next to other functional
sequences [34, 35, 33]. Maynard Smith recognized that this feature was a requirement for evolution
by point mutation to be successful. Evolution can step one mutation at a time only if there is a
continuous network of functional proteins, otherwise mutation would always lead to lower fitness
6and evolution would stop [24]. Proteins are in fact robust to mutation — a significant fraction of
possible mutants retain their fold and function [36, 37].
Whereas natural evolution can discover new protein functions along circuitous paths that involve
many neutral or even slightly deleterious mutations, directed evolution does not have that luxury.
Because the possible evolutionary paths grow exponentially as mutations accumulate and there are
too many ways to take neutral or deleterious steps that do not ultimately lead uphill, directed
evolution is largely constrained to moving continuously uphill in an adaptive walk [38]. This is
often not a severe limitation because many interesting proteins are accessible by short and simple
adaptive walks. Although the resulting proteins, or even the mutations, might not be the same
as those discovered by more convoluted paths to the same fitness level, they nonetheless provide
valuable insights into protein function and routes of adaptation.
1.4 Strategies for Directed Evolution
Before we describe some of the key lessons that directed evolution studies have taught us about
protein function and evolution, we briefly discuss the experimental strategy. How the experiment is
performed obviously influences the outcome and, therefore, the information that is extracted from it.
Finding a sequence that performs a desired function in a vast space of possible sequences that is only
sparsely populated with functional ones might seem like a daunting task. Inefficient searches of this
space could take essentially forever and the task of the protein engineer is to choose a strategy that
will reach the objective and do so quickly and easily. Starting with a functional protein, directed
evolution uses repeated generations of mutation to create functional variation and selection of the
fittest variants to direct the search to higher elevations on the fitness landscape. It involves four
key steps (Figure 1.2). First, identifying a good starting sequence; second, mutating this ‘parent’ to
create a library of variants; third, identifying variants with improved function; and last, repeating the
process until the desired function is achieved. There are many options for the implementation of each
step, the choice of which can greatly affect both the efficiency and the endpoint of an evolutionary
search.
7Directed evolution (and, indeed, natural evolution) relies on the ability of proteins to function
over a wider range of environments or carry out a wider range of functions than might be biologically
relevant at a given time and therefore selected for. This ability to tolerate a non-natural environ-
ment or to exhibit ‘promiscuous’ functions at some minimal level provides the jumping-off point
for optimization towards that new goal. A good parent protein for directed evolution, therefore,
exhibits enough of the desired function that small improvements (expected from a single mutation)
can be reliably discerned in a high-throughput screen [38]. It is also easy to work with and suffi-
ciently stable to accommodate multiple, potentially destabilizing, mutations if the target function is
some other property. Some proteins are much more evolvable than others [12, 30, 39, 40]. Possible
molecular mechanisms that contribute to evolvability have been discussed, including the key role of
the chemical mechanism in enzyme functional evolution [41, 42] and the idea that evolvable proteins
exist in multiple closely related but functionally diverse conformations, the distribution of which is
easily altered by mutation [9]. These ideas, however, are still largely speculative, and little other
than the ability to accept mutations [30, 43] has been conclusively shown in laboratory evolution
experiments to contribute directly to allowing one protein to adapt to a new challenge more readily
than another protein. A good heuristic indicator of a protein family’s evolvability is its natural
functional diversity [40, 44]. Proteins that have adapted to exhibit a range of functions across their
family, for example members of an enzyme family that accepts a wide range of substrates (although
individual enzymes in the family might be specific) are likely to be adaptable in the laboratory.
The next step is to create a library of variants. As screening is often the most difficult experi-
mental step, the library is usually created to generate the highest probability of finding improved
proteins given the screening capability. Because most mutations are deleterious and multiple mu-
tations frequently inactivate proteins (see below), this usually involves a low mutation rate (one or
two amino acid substitutions per gene). If screening is not difficult (for example, there is a good
genetic selection), then the library can be constructed to generate the largest potential improvement.
This might mean a slightly higher mutation rate [45]. In either case, mutations can be introduced
randomly [2] or, if structural or mechanistic information is available, they can be made in a more
8directed manner [46, 47, 48] in an effort to increase the frequency of improved proteins and reduce
the load in the next step.
Screening (with high-throughput functional assays) or selection (for example, a genetic selection
in which hosts with improved proteins out-compete the others) is used to identify the library members
improved in the target property. A good screen or selection accurately assesses the target properties.
The rule ‘you get what you screen for’ is always useful to remember — screening (or selecting) for
something else is risky [49]. It is also important not to demand too much improvement in a single
generation. The hurdle must be tuned to the screening capacity and should usually be no greater
than the improvement that can be provided by a single mutation. If the desired function is beyond
what a single mutation can accomplish, the problem can be broken down into a series of smaller
ones that can be solved by the accumulation of single mutations, for example by gradually increasing
the selection pressure or evolving against a series of intermediate challenges [14]. The process of
mutation and selection is repeated until the fitness objective is met; the number of iterations required
obviously depends on the starting fitness and the improvement that can be achieved in each round,
but is often only five to ten generations.
1.4.1 Mutational steps
An evolutionary search relies on the presence of functional diversity in a population, which is the
result of underlying genetic variation. At the molecular level, this genetic variation can take many
forms; for example, point mutations, insertions, deletions, recombination, and circular permutation
[50, 51, 52]. To search efficiently and minimize the screening load, the underlying genetic variation
should be set to generate the highest probability of improvement. Statistically, random mutations
tend to be quite harsh, usually decreasing activity and sometimes destroying it altogether. Typically,
30–50% of single amino acid mutations are strongly deleterious, 50–70% are neutral or slightly
deleterious and 0.01–1% are beneficial [12, 30, 37, 53, 54, 55, 56]. If the fitness landscape is Fujiyama-
like with many smooth uphill paths, only beneficial mutations need to accumulate (either in multiple
rounds of mutagenesis and screening or by recombining beneficial mutations found in each round
9[57, 58]) until the desired fitness is reached. In a single-peaked landscape, all beneficial mutations
make a cumulative contribution to the desired function and all paths uphill eventually converge to
the same optimal solution.
Of course, no real protein landscape consists of a single peak. Most mutations are deleterious
and therefore most paths end downhill, with inactive proteins, rather than uphill at fitter sequences.
Furthermore, epistatic interactions occur when the presence of one mutation affects the contribu-
tion of another mutation. Such epistatic interactions lead to curves in the fitness landscape and
constrain evolutionary searches. Extreme forms of epistasis, in which mutations that are negative
in one context become beneficial in another (so-called sign epistasis [59]), create local optima on the
landscape that can frustrate evolutionary optimization. Epistatic interactions are a ubiquitous fea-
ture of protein fitness landscapes [60, 61]. We argue, however, that they are not important for most
optimizations by directed evolution, which instead follow one of many smooth paths that bypass the
more rugged, epistatic routes on this high-dimensional surface [62, 63, 64]. Among the numerous
mutational trajectories between a starting point and a solution, smooth uphill paths can often be
found (Figure 1.1C ).
1.4.2 Dealing with the combinatorial explosion
Knowing of epistatic interactions and local fitness optima, some protein engineers worry about the
need to make and find multiple mutations at one time. If multiple mutations are needed to climb
the peak, the combinatorial explosion of mutational possibilities makes them especially challenging
to find. For even a small protein of 100 amino acids, there are 1,900 single amino acid mutants and
more than 1.5 million double mutants. The number of possible sequences increases exponentially
with the number of mutations and a complete sampling of even just the double mutants is beyond the
capacity of most screens. Higher-throughput screening approaches have been developed to enable
sampling of more mutants and more combinations of mutations [4, 65, 66]. These screens can allow
multiple paths to be explored simultaneously, increasing the probability of discovering good adaptive
routes to higher fitness. However, higher-throughput screens or selections usually come at the cost of
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decreased accuracy, especially when a surrogate function that is more amenable to high-throughput
measurement is substituted for the desired function. Furthermore, increasing the mutation rate to
capture rare synergistic mutations can make it more difficult to identify improved single-mutation
variants because common deleterious mutations will tend to mask the rare beneficial ones. It is often
better, therefore, to focus on sampling single mutants with a higher quality, lower-throughput screen
rather than on increasing the throughput to capture multiple simultaneous mutations. Although a
search through single adaptive steps cannot find mutations exhibiting negative epistasis, there are
usually other, step-wise adaptive routes to the objective.
The high dimensionality of sequence space that makes finding simultaneous beneficial mutations
so difficult can be reduced by taking advantage of structural, functional or phylogenetic information
to focus mutations to those residues that are most likely to lead to the desired properties. For
example, the modularity of protein structures permits the separate optimization of protein domains
[14, 67]. Phylogenetic analyses suggest that nature might separately optimize other, structurally
non-obvious subunits, or ‘sectors’ [68], which could prove to be appropriate targets for directed
evolution. The search space can also be reduced by focusing mutations to specific residues in a
domain; for example, in an active site or binding pocket in which functional changes might be more
likely to occur [12, 46, 69, 70, 71]. This strategy only works, however, when the experimenter is
able to select the right residue combinations for random mutagenesis, leaving out the possibility of
finding surprising and informative solutions elsewhere. Numerous studies have shown, for example,
that many activating mutations lie outside enzyme catalytic sites and exert their influence through
mechanisms that might not be obvious from structural analysis [10, 11, 72].
1.4.3 Alternative search strategies
Evolution by the accumulation of single mutations has proven to be very effective at optimizing a
function or property that already exists or can be reached through a series of intermediate steps.
Some functions, however, simply can not be reached through a series of small uphill steps and instead
require longer jumps that include mutations that would be neutral or even deleterious when made
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individually. Examples of functions that might require multiple simultaneous mutations include the
appearance of a new catalytic activity or an activity on a substrate for which the parent and its single
mutants show no measurable activity. Because most mutations are deleterious, the probability that a
variant retains its fold and function declines exponentially with the number of random substitutions
[36, 37], and random jumps in sequence space uncover mostly inactive proteins. Thus, new functions
are extremely difficult to obtain without altering some aspect of the search.
One approach is to create a new starting point – a parent protein with at least some minimal
function and improve that by directed evolution [8]. Where natural examples of a desired function
are not practical or might not even exist, emerging protein design tools have identified functional
sequences [6]. Expanding the sequence space by the incorporation of non-natural amino acids can
also introduce a whole array of new functions and directed evolution can do the fine-tuning that
might be needed to optimize these novel designs [16]. Another approach is to find more conservative
ways to make multiple mutations; for example, using computational protein design tools to identify
sets of mutations that are likely to be compatible with structure retention [47].
An approach to making multiple mutations that is used extensively in nature is recombination.
Naturally-occurring homologous proteins can be recombined to create genetic diversity within protein
sequence libraries [73, 74, 75] (Figure 1.3A). It has been shown that mutations made by recombi-
nation are much less disruptive and generate functional proteins with much higher frequency than
random mutations [56] (Figure 1.3B). Recombination methods based on DNA sequence hybridiza-
tion direct crossovers to regions of high sequence identity and are generally limited to sequences
that are very similar (with more than 70% identity) [75], whereas various sequence-independent
methods can recombine at random [76, 77] or user-specified sites [78, 79]. Recombining homologous
proteins by choosing crossovers based on structural information allows the construction of libraries
of chimeric proteins that simultaneously exhibit high levels of functionality and genetic diversity
[80]. In all cases, the chimeric proteins inherit the best (and worst) residues the parents have to
offer, in new combinations that are not observed in nature.
Chimeric proteins can differ by tens or even hundreds of mutations from their parent sequences
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and still function. The conservative nature of recombination can be exploited to make whole families
of novel enzymes. For example, in one set of more than 6,000 chimeric cytochrome P450 proteins
with an average of 70 mutations from the closest parent, approximately half folded properly, and at
least 75% of these folded P450 proteins displayed enzymatic activity [80].
The new combinations of residues can give rise to novel properties [81]. Because many of the
mutations made by recombination are neutral or nearly neutral, recombination is an efficient way
to generate the neutral drifts (the accumulation of neutral mutations) that have been shown to
lead to increases in promiscuous functions [82, 83] and mutational robustness [84, 82]. For example,
members of the chimeric cytochrome P450 library exhibited higher enzymatic activity than any
of the three parents across a panel of 11 non-native substrates that included substrates on which
the parent enzymes showed no measurable activity [85]. Several P450 chimeras were also more
thermostable than the most thermostable parent enzyme, and dozens of thermostable chimeras
could be readily identified based on a small sampling of the library [86] (Figure 1.3C ). This approach
was subsequently used to generate dozens of highly stable, highly active fungal cellobiohydrolase II
enzymes that degrade cellulose into fermentable sugars (for biofuels applications, for example) [79].
1.5 Lessons from Directed Evolution
In addition to generating a plethora of novel proteins, directed evolution studies have elucidated
available pathways and molecular mechanisms of adaptation, shown a key role for stability in epistasis
and evolvability, identified important evolutionary trade-offs in protein properties, and revealed the
simultaneously conservative and exploratory nature of recombination, all of which have shed light on
long-standing questions in protein chemistry and evolutionary biology. First and foremost, directed
evolution experiments have shown time and again how rapidly proteins can adapt to exhibit new
functions and properties. Protein behavior can change dramatically on mutating a very small fraction
of the protein sequence. Directed evolution also provides a detailed view of the adaptive process.
A directed evolution approach to studying sequence-function relationships circumvents several
challenges associated with inferring mechanisms of adaptation using comparisons of evolutionarily
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related natural amino acid sequences [22, 23]. Such studies are confounded by the numerous, mostly
neutral mutations that accumulated during divergence of the sequences and the complex and largely
unknown selection pressures under which the natural sequences evolved. By contrast, the sequences
generated by directed evolution contain a small number of adaptive mutations that accumulated
under well-defined selective pressures. Furthermore, performing the evolution in the laboratory per-
mits access to the full ‘fossil record’ of evolutionary intermediates, the sequences, structures, and
functions of which can be analyzed in an attempt to explain how new properties were acquired
[11, 44, 72, 87]. Fasan and co-workers analyzed selected intermediates that arose during the directed
evolution of a cytochrome P450 fatty acid hydroxylase into a highly efficient and highly specific
propane monooxygenase [14, 72] (Figure 1.4). The gradual increase in activity on propane (as mea-
sured by total turnovers of propane to propanol — the property targeted during directed evolution)
was accompanied by other interesting changes in the enzyme’s behavior, the most notable of which
was the decrease in thermostability (as measured by T50; the temperature at which 50% of the pro-
teins are inactivated in 10 minutes). Activating mutations came at the cost of thermostability, to
the point that it became necessary to incorporate stabilizing mutations (generation nine in Figure
1.4) before further increases in activity could appear. This apparent trade-off between functionally
beneficial mutations and thermostability reflects the fact that most mutations are destabilizing and
therefore most activating mutations are also destabilizing. Because evolution favors the most likely
solutions over rarer ones, it favors marginal stability in the absence of selection for higher stability.
It also favors properties that are compatible with marginal stability [33]. Such trade-offs have also
been shown to constrain the evolution of antibiotic resistance enzymes [88] and will be discussed
further below.
The mutations that accumulated in the heme domain of the cytochrome P450 are depicted in
Figure 1.4B and are color-coded according to the generation in which they appeared. Many of
the mutations that conferred the increased activity on propane lie outside the substrate-binding
pocket, where they influence substrate recognition through mechanisms that are difficult to discern
from crystal structures or modeling. That the effects of the adaptive mutations are difficult to
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rationalize, much less predict, underscores how little we understand of how sequence determines
protein structure and function. Directed evolution deals with the details of molecular interactions,
and it is hoped that these details will eventually help protein design efforts [8].
Directed evolution can explore alternative evolutionary scenarios; for example, to identify other
possible solutions to the same functional challenge or to address whether multiple paths can lead
to the same solution, as was done with a laboratory-evolved β-lactamase variant that contains 5
mutations responsible for a 100,000-fold increase in cefotaxime resistance [63]. In this study, the
authors constructed variants with all 32 (25) combinations of the adaptive mutations, representing all
intermediate sequences along all 120 (5!) possible mutational pathways. They were able to estimate
the probability of each pathway based on the relative change in antibiotic resistance conferred to the
bacteria by each mutation along each path. Whereas most of the possible paths were constrained
by epistasis and were therefore highly unlikely, there were 18 different, simple uphill walks to the
final solution.
1.5.1 Empirical landscapes
Even the earliest directed evolution experiments noted how rapidly proteins could adapt to new selec-
tive pressures [2, 58], indicating the ready availability of smooth uphill paths in the fitness landscapes.
Stability, the ability to tolerate new environments and low-level side reactions or promiscuous func-
tions usually respond well to directed evolution. One study used a well-controlled set of experiments
to select for six different promiscuous activities starting from three different enzymes [12]. After
two rounds of directed evolution, yielding just 14 mutations, the promiscuous enzyme activities
(kcat/KM ) had increased by up to 150-fold over the activities of the parent enzymes. Interestingly,
these newly evolved activities came at little cost to the native enzymatic activities, suggesting a
particular robustness of the native functions to mutation and supporting a scenario for evolution of
new activities that allows both the native and novel activities to be displayed in the same gene for
some period of time [9].
As well as demonstrating the availability of smooth uphill paths, directed evolution has provided
15
insight into the molecular epistasis that curves the landscapes. Several studies have revealed a key
link between stability and epistasis, where the effect of a mutation can be conditional on the stability
of the parent sequence [36, 43, 9] (Figure 1.5). This was demonstrated, for example, in a study of
cephalosporin antibiotic resistance mutations in β-lactamase, in which the fitness effects of several
active site mutations were found to depend on the presence of a stabilizing M182T mutation [88]
(Figure 1.5A). These epistatic interactions are the result of catalytically beneficial but destabilizing
mutations in the active site that cannot be tolerated unless the stabilizing M182T mutation is
present. Without M182T, the active site mutations destabilize the enzyme to the point that total
activity is compromised.
Many examples of stability-mediated epistasis are best explained in terms of a protein stability
threshold, whereby stability is under selection only insofar as it allows a protein to fold and function
[36, 43, 82] (Figure 1.5). The consequences for evolution are profound: a protein with low stability
cannot accept more than a small fraction of the possible mutations because most mutations are
destabilizing. Thus, it can become trapped on a local optimum, unable to go further. As illustrated
in Figure 1.5B, proteins enjoying a larger margin above the minimal stability threshold can explore
many more mutations and can therefore continue to adapt to other tasks, such as acquiring activity
towards a new substrate or partner [30]. Stability-mediated epistasis is a mechanism whereby neutral
mutations can shape the available adaptive pathways during natural evolution as well as in the
laboratory. Experience has shown that when an evolutionary search in the laboratory seems to have
exhausted all options for further uphill steps, the incorporation of stabilizing mutations is able to
open up new adaptive routes [14].
Despite being performed on different protein folds with selection for different protein functions,
the repeated evaluation of thousands of random mutations has revealed the general features of
protein fitness landscapes. In addition to the uphill paths that lie alongside numerous less favorable,
epistatic routes there are an even larger number of side-steps in the protein fitness landscape. The
high frequency of neutral mutations observed during evaluation of random mutant libraries suggests
a myriad of sequences with essentially equivalent fitness. This is consistent with the existence of
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natural protein homologs that differ at several positions, the majority of which are functionally
neutral. Even sequences that are highly optimized are probably just one of many potential solutions
to a given functional challenge. Indeed, it is probably more accurate to imagine protein evolution
occurring on neutral networks, rather than on fitness landscapes in which each neighbor has a
different fitness [29, 62]. This pervasive neutrality is exploited when families of functional proteins
are constructed by recombination of homologous proteins [79, 80].
As discussed above in the context of stability-mediated epistasis, mutations that are neutral in
one context might not be neutral in all and therefore can provide new opportunities for evolution.
Directed evolution has shown an important role for stabilizing mutations (which can be functionally
neutral or only slightly deleterious) in adaptation. Laboratory evolution experiments have also
shown that purposefully accumulated neutral mutations alter promiscuous activities and create new
starting points for subsequent adaptive evolution [82, 83, 89]. Genetic drift and pre-existing diversity
might have a similarly important role in natural adaptive evolution [62].
1.5.2 Directed evolution to understand natural evolution?
An overall picture of the protein function landscape is therefore emerging from accumulating directed
evolution data. This picture offers a description of the physical features that all proteins (synthetic
or natural) must exhibit and the effects of mutations on these features. Extending the lessons
learned from directed evolution to natural evolution, however, requires caution because these search
processes operate under, for example, different time scales, population sizes, mutation rates, and
strength of selection. Furthermore, natural evolution works on a different fitness landscape and it is
unclear how the protein fitness assayed during directed evolution is related to the organismal fitness
that natural evolution optimizes. Differences reflect the consequences of interactions between the
protein and the cellular environment and might include constraints related to metabolic burden,
regulation, non-specific interactions, and other factors.
The ability to disconnect a protein from its in vivo function is a valuable asset of directed
evolution because it allows the exploration of physically possible proteins without the often-severe
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constraint of their being biologically relevant and contributing to organismal fitness. Thus, directed
evolution can be used to identify which features of proteins are dictated by their physical properties
versus those that are due to biological constraints or evolutionary origins and history. The labora-
tory evolution of the cytochrome P450 propane monooxygenase (Figure 1.4), for example, showed
the physical possibility, and indeed the ready availability, of such an enzyme, even though known or-
ganisms that live on small alkanes use mechanistically and evolutionarily unrelated enzymes for this
transformation [72]. Another example is the generation of proteins with combinations of properties
that are usually not found in natural proteins, such as high catalytic activity at low temperature
and high stability at elevated temperature [22, 23]. When properties seem to trade off like this, it
might be tempting to infer that such trade-offs are dictated by physical requirements, such as the
incompatibility between molecular rigidity that is needed for high stability and the flexibility that is
required for catalytic activity [90, 91]. If stability and enzymatic activity placed mutually exclusive
demands on protein flexibility, then highly active, highly stable enzymes could not exist (a state-
ment that protein engineers did not want to hear). Directed evolution, however, has little trouble
finding enzymes that are both highly active and highly stable when the experiments select for both
properties [92]. Clearly, such proteins are far rarer than highly active, marginally stable proteins
and, without a good reason, natural sequences would not exhibit both features [22, 23, 33, 93].
1.6 Conclusions
Despite the vast size of sequence space and the complex nature of protein function, the Darwinian
algorithm of mutation and selection provides a powerful method to generate proteins with altered
functions. This simple uphill walk on a fitness landscape in sequence space works because proteins
are wonderfully evolvable and can adapt to new conditions or even take on new functions with only
a few mutations.
In addition to providing useful proteins, directed evolution experiments have also taught us how
proteins adapt and shed light on processes at work during natural evolution [22, 62, 94]. These exper-
imental results allow us to look at sequence data in a functional context, providing a bridge between
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long-separated fields of evolutionary and molecular biology [95]. Directed evolution experiments
have been used to address important evolutionary questions about the average effects of mutations,
mechanisms of functional divergence, evolvability, and evolutionary constraints [12, 82, 93, 96].
With the growing number of applications for engineered proteins, directed evolution will continue
to be an important strategy for making proteins that are well adapted to new environments and new
functions. More advanced high-throughput screens and higher quality sequence libraries will make
the searches easier and will enable evolution to solve increasingly complex problems. Advances in
our understanding of proteins can be incorporated into library design, and the rapidly decreasing
cost of DNA synthesis will relieve many sequence construction constraints. Directed evolution will
help teach us how biological systems adapt to changing demands; it might also help us to address
some of today’s most challenging problems of providing effective treatments for disease or producing
fuels and chemicals from renewable resources.
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1.7 Figures
Figure 1.1: Directed protein evolution traverses a fitness landscape in sequence space. This fitness
is the measure of how well a given protein performs a target function. (A) The plot of fitness
against sequence creates the landscape for evolution. The transition through black-red-orange-yellow
represents increasing fitness. Although the details of this landscape are unknown, it is believed that
most sequences do not function (black) and that the rare functional sequences encoding natural
proteins are clustered near other functional sequences. However, this popular three-dimensional
representation does a poor job of illustrating the numerous paths available to evolution and the
numerous sequences in functional regions that do not encode functional proteins [97]. (B) Similar to
natural protein evolution, directed evolution moves along networks of functional proteins that differ
by a single amino acid, because selection requires a continuous uphill walk and does not permit the
fixation of non-functional sequences. Epistasis occurs when the effect of one mutation depends on
the presence of another, which can create landscape ruggedness and local optima. Landscapes could
range from the rugged ‘Badlands’ landscape (left panel), which is nearly impossible to climb by
mutational steps, to the ‘Fujiyama’ landscape (right panel), in which any beneficial mutation brings
the search closer to the optimum [28]. (C ) The presence of local optima might restrict some of the
mutational paths uphill (red line). However, the large number of alternative routes leaves plenty of
adaptive paths to a fitness optimum (green line).
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to create a library of variants; third, identifying variants 
with improved function and last, repeating the process 
until the desired function is achieved. There are many 
options for the implementation of each step, the choice 
of which can greatly affect both the efficiency and the 
endpoint of an evolutionary search.
Directed evolution (and, indeed, natural evolution) 
relies on the ability of proteins to function over a wider 
range of environments or carry out a wider range of 
functions than might be biologically relevant at a given 
time and therefore selected for. This ability to tolerate 
a non-natural environment or to exhibit ‘promiscuous’ 
functions at some minimal level provides the jumping-
off point for optimization towards that new goal. A good 
parent protein for directed evolution, therefore, exhibits 
enough of the desired function that small improve-
ments (expected from a single mutation) can be reliably 
discerned in a high-throughput screen38. It is also easy 
to work with and sufficiently stable to accommodate 
multiple, potentially destabilizing, mutations if the 
target function is some other property. Some proteins 
are much more evolvable than others11,29,39,40. Possible 
molecular mechanisms that contribute to evolvability 
have been discussed, including the key role of the chemi-
cal mechanism in enzyme functional evolution41,42 and 
the idea that evolvable proteins exist in multiple closely 
related but functionally diverse conformations, the dis-
tribution of which is easily altered by mutation8. These 
ideas, however, are still largely speculative, and little 
other than the ability to accept mutations29,43 has been 
conclusively shown in laboratory evolution experiments 
to contribute directly to allowing one protein to adapt to 
a new challenge more readily than another protein. A 
good heuristic indicator of a protein family’s evolvabil-
ity is its natural functional diversity40,44. Proteins that 
have adapted to exhibit a range of functions across their 
family, for example members of an enzyme family that 
accepts a wide range of substrates (although individual 
enzymes in the family might be specific) are likely to be 
adaptable in the laboratory.
The next step is to create a library of variants. As 
screening is often the most difficult experimental step, 
the library is usually created to generate the highest prob-
ability of finding improved proteins given the screening 
capability. Because most mutations are deleterious and 
multiple mutations frequently inactivate proteins (see 
below), this usually involves a low mutation rate (one or 
two amino acid substitutions per gene). If screening is 
not difficult (for example, there is a good genetic selec-
tion), then the library can be constructed to generate 
the largest potential improvement. This might mean a 
slightly higher mutation rate45. In either case, mutations 
can be introduced randomly1 or, if structural or mecha-
nistic information is available, they can be made in a 
more directed manner46–48 in an effort to increase the 
frequency of improved proteins and reduce the load in 
the next step.
Screening (with high-throughput functional assays) 
or selection (for example, a genetic selection in which 
hosts with improved proteins outcompete the others) is 
used to identify the library members improved in the 
target property. A good screen or selection accurately 
assesses the target properties. The rule ‘you get what 
you screen for’ is always useful to remember — screen-
ing (or selecting) for something else is risky49. It is also 
important not to demand too much improvement in 
a single generation. The hurdle must be tuned to the 
screening capacity and should usually be no greater 
than the improvement that can be provided by a single 
mutation. If the desired function is beyond what a 
single mutation can accomplish, the problem can be bro-
ken down into a series of smaller ones that can be solved 
by the accumulation of single mutations, for example by 
gradually increasing the selection pressure or evolving 
against a series of intermediate challenges13. The process 
of mutation and selection is repeated until the fitness 
objective is met; the number of iterations required obvi-
ously depends on the starting fitness and the improvement 
that can be achieved in each round, but is often only five 
to ten generations.
Mutational steps. An evolutionary search relies on 
the presence of functional diversity in a population, 
which is the result of underlying genetic variation. 
At the molecular level, this genetic variation can take 
many forms; for example, point mutations, insertions, 
deletions, recombination and circular permutation50–52. 
Figure 2 | Overview of directed evolution. The objective 
of directed evolution is to create a specific protein function 
through successive rounds of mutation and selection, 
starting from a parent protein with a related function. 
There are numerous options for implementing each step  
in the process, the choice of which can greatly affect  
the efficiency and success of the protein sequence 
optimization. A parent sequence (or sequences) is chosen 
based on its perceived proximity to the desired function 
and its evolvability. This parent sequence is then mutated 
to form a library of new sequences (error-prone PCR or 
other methods can be used to incorporate mutations 
randomly, recombination can be used to introduce 
mutations from other functional sequences or mutation 
sites can be chosen based on functional and/or structural 
information). These mutated sequences are evaluated  
for their ability to perform the desired function using a 
high-throughput screen or artificial selection. The fittest 
sequence (or sequences) is used as the parent for the next 
round of directed evolution, and this process is repeated 
until the engineering objective is met (usually after five  
to ten generations).
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Figure 1.2: The objectiv of direc ed evolution is to create a specific protein function through
successive rounds of mutation and selectio , starting from a parent protei with a related function.
There are numerous options for implementing each step in the process, the choice of which can
greatly affect the efficiency and success of the protein sequence optimization. A parent sequence (or
sequences) is chosen based on its perceived proximity to the desired function and its evolvability.
This parent sequence is then mutated to form a library of new sequences (error-prone PCR or other
methods can be us d to incorporate mutations randomly, recombination can be used to introduce
mutations from ther functio al seque ces or mutation sites can be chosen based on functional
and/or structural information). These mutated sequences are evaluated for their ability to perform
the desired function using a high-throughput screen or artificial selection. The fittest sequence (or
sequences) is used as the parent for the next round of directed evolution, and this process is repeated
until the engineering objective is met (usually after five to ten generations).
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non-natural amino acids can also introduce a whole 
array of new functions and directed evolution can do 
the fine-tuning that might be needed to optimize these 
novel designs15. Another approach is to find more con-
servative ways to make multiple mutations; for exam-
ple, using computational protein design tools to identify 
sets of mutations that are likely to be compatible with 
structure retention47.
An approach to making multiple mutations that is 
used extensively in nature is recombination. Naturally-
occurring homologous proteins can be recombined to 
create genetic diversity within protein sequence librar-
ies73–75 (FIG. 3a). It has been shown that mutations made 
by recombination are much less disruptive and generate 
functional proteins with much higher frequency than 
random mutations56 (FIG. 3b). Recombination methods 
based on DNA sequence hybridization direct cross overs 
to regions of high sequence identity and are gener-
ally limited to sequences that are very similar (with 
more than 70% identity)75, whereas various sequence- 
independent methods can recombine at random76,77 or 
user-specified sites78,79. Recombining homologous pro-
teins by choosing crossovers based on structural infor-
mation allows the construction of libraries of chim eric 
proteins that simultaneously exhibit high levels of 
functionality and genetic diversity80. In all cases, the 
chimeric proteins inherit the best (and worst) residues 
the parents have to offer, in new combinations that are 
not observed in nature.
Chimeric proteins can differ by tens or even hun-
dreds of mutations from their parent sequences and still 
function. The conservative nature of recombination can 
be exploited to make whole families of novel enzymes. 
For example, in one set of more than 6,000 chimeric 
cytochrome P450 proteins with an average of 70 muta-
tions from the closest parent, approximately half folded 
properly, and at least 75% of these folded P450 proteins 
displayed enzymatic activity80.
The new combinations of residues can give rise to 
novel properties81. Because many of the mutations made 
by recombination are neutral or nearly neutral, recom-
bination is an efficient way to generate the neutral drifts 
(the accumulation of neutral mutations) that have been 
shown to lead to increases in promiscuous functions82,83 
and mutational robustness84,85. For example, members 
of the chimeric cytochrome P450 library exhibited 
higher enzymatic activity than any of the three parents 
across a panel of 11 non-native substrates that included 
substrates on which the parent enzymes showed no 
measurable activity86. Several P450 chimaeras were also 
more thermostable than the most thermostable parent 
enzyme, and dozens of thermostable chimaeras could 
be readily identified based on a small sampling of the 
library87 (FIG. 3c). This approach was subsequently used 
to generate dozens of highly stable, highly active fun-
gal cellobiohydrolase II enzymes that degrade cellulose 
into fermentable sugars (for biofuels applications, for 
example)79.
Lessons from directed evolution
In addition to generating a plethora of novel proteins, 
directed evolution studies have elucidated available 
pathways and molecular mechanisms of adaptation, 
shown a key role for stability in epistasis and evolvability, 
identified important evolutionary trade-offs in protein 
properties and revealed the simultaneously conservative 
and exploratory nature of recombination, all of which 
have shed light on long-standing questions in protein 
chemistry and evolutionary biology. First and foremost, 
directed evolution experiments have shown time and 
again how rapidly proteins can adapt to exhibit new 
functions and properties. Protein behaviour can change 
dramatically on mutating a very small fraction of the 
protein sequence. Directed evolution also provides a 
detailed view of the adaptive process.
A directed evolution approach to studying sequence–
function relationships circumvents several challenges 
associated with inferring mechanisms of adaptation using 
comparisons of evolutionarily related natural amino acid 
sequences21,22. Such studies are confounded by the numer-
ous, mostly neutral mutations that accumulated during 
divergence of the sequences and the complex and largely 
unknown selection pressures under which the natural 
sequences evolved. By contrast, the sequences generated 
by directed evolution contain a small number of adaptive 
mutations that accumulated under well-defined selec-
tive pressures. Furthermore, performing the evolution 
Figure 3 | Recombination of homologous sequences. a  |  Recombination generates 
highly mutated sequence libraries. Multiple homologous parent sequences are divided 
into fragments, which can be chosen to minimize structural disruption73, and these 
fragments are recombined to form a combinatorial library of chimeric proteins.  
b  |  The mutations from homologous recombination (green) are much more conservative 
than random mutations (red). In β-lactamase, chimaeras with high levels of amino  
acid mutations (around 75) are 1016 times more likely to fold than sequences with 75 
random mutations56 c  |  Chimeric proteins contain new combinations of beneficial 
mutations. The histogram shows the distribution of thermostabilities (T
50
; the 
temperature at which 50% of the proteins are inactivated in 10 minutes) of 184 randomly 
selected chimeric cytochrome P450 enzymes made by structure-guided recombination. 
The thermostabilities of the three parents are marked by dashed red lines87. A significant 
fraction of chimaeras are more thermostable than any parent from which they are 
derived. Image in part b is modified, with permission, from REF. 56 © (2005) National 
Academy of Sciences, USA. Image in part c is modified, with permission, from Nature 
Biotech. REF. 87 © (2006) Macmillan Publishers Ltd. All rights reserved.
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Figure 1.3: (A) Recombination generates highly mutated sequence libraries. Multiple homologous
parent sequences are divided into fragments, which can be chosen to minimize structural disruption
[73], and these fragments are recombined to form a combinatorial library of chimeric proteins. (B)
The mutations from homologous recombination (green) are much more conservative than random
mutations (red). In β-lactamase, chimeras with high levels of amino acid mutations (around 75)
are 1016 times ore l kely to fold than sequenc s with 75 random mutations [56]. (C ) Chimeric
proteins contai new combinations of beneficial mutations. The histogram shows the distribution of
thermostabilities (T50; the temperature at which 50% of the proteins are inactivated in 10 minutes) of
184 randomly selected chimeric cytochrome P450 enzymes made by structure-guided recombination.
The thermostabilities of the three parents are marked by dashed red lines [86]. A significant fraction
of chimeras are more thermostable than any parent from which they are derived.
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in the laboratory permits access to the full ‘fossil record’ 
of evolutionary intermediates, the sequences, structures 
and functions of which can be analysed in an attempt 
to explain how new properties were acquired10,44,72,88. 
Fasan and co-workers analysed selected intermediates 
that arose during the directed evolution of a cytochrome 
P450 fatty acid hydroxylase into a highly efficient and 
highly specific propane monooxygenase13,72 (FIG. 4). The 
gradual increase in activity on propane (as measured by 
total turnovers of propane to propanol — the property 
targeted during directed evolution) was accompanied by 
other interesting changes in the enzyme’s behaviour, the 
most notable of which was the decrease in thermosta-
bility (as measured by T50; the temperature at which 
50% of the proteins are inactivated in 10 minutes). 
Activating mutations came at the cost of thermostability, 
to the point that it became necessary to incorporate 
stabilizing mutations (generation nine in FIG. 4) before 
further increases in activity could appear. This apparent 
trade-off between functionally beneficial mutations and 
thermostability reflects the fact that most mutations are 
destabilizing and therefore most activating mutations 
are also destabilizing. Because evolution favours the 
most likely solutions over rarer ones, it favours marginal 
Figure 4 | Directed evolution of a cytochrome P450 propane monooxygenase. Cytochrome P450 BM3 from Bacillus 
megaterium catalyses the hydroxylation of long-chain fatty acids and has no measurable activity on propane. This enzyme 
was converted into a highly efficient and specific propane monooxygenase over 13 rounds of directed evolution13,111,112.  
The large change in substrate specificity was achieved using an incremental approach that first involved screening on an 
intermediate substrate. Because the native substrate contains a long alkyl chain and the target function was activity on a 
short alkane, an intermediate-length alkane (octane), towards which the parent enzyme had low but measurable activity,  
was chosen as the initial directed evolution target. Once high octane activity was achieved, the selective pressure was 
switched towards activity on propane. a | Selected kinetic and biophysical properties of evolutionary intermediates  
from later generations (with generation five being the first propane active variant)72. Total catalytic turnovers (moles of 
propanol produced per mole of P450), K
M
 and k
cat
 are reported for propane hydroxylation. Thermostability is shown as T
50
  
(the temperature at which half of the enzyme inactivates after a 10 minute incubation). Variants were selected for total 
propane activity in all generations, except for generation nine, which was selected for T
50
. The mutations acquired during 
each generation are listed. Even small numbers of mutations can be responsible for large functional changes. b | The crystal 
structure of the fifth generation P450 haem domain (Protein Data Bank identifier: 3CBD), with the locations of the mutations 
from subsequent generations colour-coded as in part a. Beneficial mutations are distributed over the haem domain and many 
are tens of Å from the catalytic iron. Image in part a is modified, with permission, from (REF. 72) © (2008) Elsevier. 
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Figure 1.4: Cytochrome P450 BM3 rom Bacillus me aterium catalyses the hy roxylation of long-
chain fatty acids and has no measurable activity on propane. This enzyme was converted into a highly
efficient and specific propane monooxygenase over 13 rounds of directed evolution [14, 98, 99]. The
large change in substrate specificity was achieved using an incremental approach that first involved
screening on an intermediate substrate. Because the native substrate contains a long alkyl chain and
the target function was activity on a short alkane, an intermediate-length alkane (octane), towards
which the par nt nzyme had low but measurable activity, was chosen as the ini ial directed evolution
targ t. Once high octane activit was achieved, the selective pressure was s itch d towards ctivity
on propane. (A) Selected kinetic and biophysical properties of evolutionary intermediates from
later generations (with generation five being the first propane active variant) [72]. Total catalytic
turnovers (moles of propanol produced per mole of P450), KM and kcat are reported for propane
hydroxylation. Thermostability is shown as T50 (the temperature at which half of the enzyme
inactivates after a 10 minute incubation). Variants were selected for total propane activity in all
generations, except for generation nine, which was selected for T50. The mutations acquired during
eac generation are listed. Even small numbe s of utati ns can be responsible for large functional
changes. (B) The crystal struct re of the fifth generation P450 h me domain (Protein Data Bank
identifier: 3CBD), with th locations of the utations from subs quent generations color-coded as
in part A. Beneficial mutations are distributed over the heme domain nd many are tens of A˚ from
the catalytic iron.
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slightly deleterious) in adaptation. Laboratory evolution 
experiments have also shown that purposefully accu-
mulated neutral mutations alter promiscuous activities 
and create new starting points for subsequent adaptive 
evolution82,83,92. Genetic drift and pre-existing diver-
sity might have a similarly important role in natural 
adaptive evolution62.
Directed evolution to understand natural evolution? 
An overall picture of the protein function landscape is 
therefore emerging from accumulating directed evolu-
tion data. This picture offers a description of the physical 
features that all proteins (synthetic or natural) must 
exhibit and the effects of mutations on these features. 
Extending the lessons learned from directed evolution 
to natural evolution, however, requires caution because 
these search processes operate under, for example, dif-
ferent time scales, population sizes, mutation rates and 
strength of selection. Furthermore, natural evolution 
works on a different fitness landscape and it is unclear 
how the protein fitness assayed during directed evo lution 
is related to the organismal fitness that natural evo-
lution optimizes. Differences reflect the consequences 
of interactions between the protein and the cellular 
environment and might include constraints related to 
metabolic burden, regulation, non-specific interactions 
and other factors.
The ability to disconnect a protein from its in vivo 
function is a valuable asset of directed evolution because 
it allows the exploration of physically possible proteins 
without the often-severe constraint of their being bio-
logically relevant and contributing to organismal fitness. 
Thus, directed evolution can be used to identify which 
features of proteins are dictated by their physical prop-
erties versus those that are due to biological constraints 
or evolutionary origins and history. The laboratory evo-
lution of the cytochrome P450 propane monooxygenase 
(FIG. 4), for example, showed the physical possibility, and 
indeed the ready availability, of such an enzyme, even 
though known organisms that live on small alkanes use 
mechanistically and evolutionarily unrelated enzymes 
for this transformation72. Another example is the gener-
ation of proteins with combinations of properties that 
are usually not found in natural proteins, such as high 
catalytic activity at low temperature and high stability 
at elevated temperature21,22. When properties seem to 
trade off like this, it might be tempting to infer that such 
trade-offs are dictated by physical requirements, 
such as the incompatibility between molecular rigid-
ity that is needed for high stability and the flexibility 
that is required for catalytic activity93,94. If stability and 
enzymatic activity placed mutually exclusive demands 
on protein flexibility, then highly active, highly stable 
enzymes could not exist (a statement that protein engi-
neers did not want to hear). Directed evolution, however, 
has little trouble finding enzymes that are both highly 
active and highly stable when the experiments select for 
both properties95. Clearly, such proteins are far rarer than 
highly active, marginally stable proteins and, without a 
good reason, natural sequences would not exhibit both 
features21,22,32,96.
Figure 5 | Stability threshold and epistasis. Laboratory 
evolution studies have found many examples of mutational 
epistasis that are related to protein stability. The 
relationship between protein stability and epistasis is best 
explained in terms of a protein stability threshold, whereby 
stability is under selection only insofar as it allows a protein 
to fold and function36,43,91. a | Epistasis can arise as the result 
of the protein stability threshold. The G238S active-site 
mutation in this β-lactamase increases enzyme activity on 
cephalosporin antibiotics89. However, this mutation cannot 
be accepted into the wild-type sequence (MG) because the 
resulting protein (MS) is not sufficiently stable. Sequences 
with the beneficial G238S mutation can instead be reached 
by first finding the functionally neutral, but stabilizing, 
M182T mutation (sequence TG) and then incorporating the 
G238S mutation (sequence TS). b | Because most mutations 
are destabilizing, many of the single mutants of a protein 
close to the stability threshold (top panel) will be unstable 
and therefore inactive (red). This leaves few active mutants 
having beneficial mutations (green). A more stable protein 
(bottom panel) will be more tolerant to mutation, making 
more beneficial mutations available.
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Figure 1.5: Laboratory evolution studies have
found many examples of mutational epistasis that
are related to protein stability. The relationship
between protein stability and epistasis is best ex-
plained in terms of a protein stability threshold,
whereby stability is under selection only insofar as
it allows a protein to fold and function [36, 43, 82].
(A) Epistasis can arise as the result of the protein
stability threshold. The G238S active-site muta-
tion in this β-lactamase increases enzyme activ-
ity on cephalosporin antibiotics [88]. However,
this mutation cannot be accepted into the wild-
type sequence (MG) because the resulting pro-
tein (MS) i no sufficiently stable. Sequences
with the beneficial G238S mutation can inst ad
be reached by first finding the functionally neu-
tral, but stabilizing, M182T mutation (sequence
TG) and then incorporating the G238S mutation
(sequence TS). (B) Because most mutations are
destabilizing, many of the single mutants of a pro-
tein close to the stability threshold (top panel)
will be unstable and therefore inactive (red). This
leaves few active mutants having beneficial mu-
tations (green). A more stable protein (bottom
panel) will be more tolerant to mutation, making
more beneficial mutations available
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Chapter 2
Directed evolution of a magnetic
resonance imaging contrast agent
for noninvasive imaging of
dopamine
A version of this chapter has been published as [100].
2.1 Abstract
The development of molecular probes that allow in vivo imaging of neural signaling processes with
high temporal and spatial resolution remains challenging. Here we applied directed evolution tech-
niques to create magnetic resonance imaging (MRI) contrast agents sensitive to the neurotransmitter
dopamine. The sensors were derived from the heme domain of the bacterial cytochrome P450-BM3
(BM3h). Ligand binding to a site near BM3h’s paramagnetic heme iron led to a drop in MRI signal
enhancement and a shift in optical absorbance. Using an absorbance-based screen, we evolved the
specificity of BM3h away from its natural ligand and toward dopamine, producing sensors with dis-
sociation constants for dopamine of 3.3–8.9 µM. These molecules were used to image depolarization-
triggered neurotransmitter release from PC12 cells and in the brains of live animals. Our results
demonstrate the feasibility of molecular-level functional MRI using neural activity-dependent sen-
sors, and our protein engineering approach can be generalized to create probes for other targets.
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2.2 Introduction
MRI is a uniquely valuable tool for studying the brain because MRI scans are noninvasive and can
provide information at relatively high spatial resolution (< 100 µm) and temporal resolution (∼1 s)
from living specimens. Functional imaging (fMRI) of brain activity is possible with MRI methods
sensitive to cerebral hemodynamics [101]. The most common fMRI technique, blood-oxygen-level-
dependent (BOLD) fMRI, is based on oxygenation of hemoglobin, an endogenous oxygen-sensitive
MRI contrast agent present in the blood [102]. Although BOLD fMRI has had a tremendous
impact in neuroscience, the method provides only a slow and indirect readout of neural activity,
owing to the complexity of neurovascular coupling [103]. Considerably more precise measurements
of brain function would be possible with MRI sensors that were directly and rapidly responsive to
neurochemicals involved in the brain’s information processing [104].
The challenging process of developing sensors for next-generation neuroimaging could be greatly
accelerated using advanced molecular engineering techniques. Directed evolution is a molecular en-
gineering method that employs successive rounds of mutagenesis and selection to generate proteins
with novel functionality, starting from a molecule with some of the desired properties of the end prod-
uct [36]. This technique could be applied to evolve MRI sensors from proteins that are magnetically
active (for example, paramagnetic) and have tunable ligand-binding or catalytic properties.
The flavocytochrome P450-BM3 (BM3), a fatty acid hydroxylase from Bacillus megaterium,
contains a paramagnetic iron atom embedded in a solvent-accessible substrate-binding pocket, sug-
gesting that it could produce ligand-dependent MRI signal changes. BM3’s binding specificity is also
highly tunable, as demonstrated by previous efforts to identify novel enzymatic activities through
directed evolution of this protein [105, 98, 106, 80]. If BM3 variants could be engineered to act as
MRI sensors, they would be genetically encodable, an added advantage over synthetic molecular
imaging agents.
We sought to apply directed evolution of BM3 to develop MRI sensors for a key signaling molecule
in the brain, the neurotransmitter dopamine. To our knowledge, no MRI contrast agent for sensing
dopamine (or any other neurotransmitter) currently exists, but there is considerable interest in mea-
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suring dopamine-related activity by MRI [107]. Dopamine is of particular significance because of its
roles in learning, reward, and motor coordination [108], and because the dysfunction of dopaminergic
systems underlies addiction [109] and several neurodegenerative diseases [110]. Existing techniques
for measuring dopamine in vivo are either invasive point-measurement methods [111, 112, 113] or
positron emission tomography procedures [114] with low spatial and temporal resolution. MRI
could be used successfully for dopamine measurement if combined with an imaging agent capable
of responding quickly, reversibly and specifically to extracellular dopamine fluctuations from < 1
µM to tens of micromolar [115, 116]. To be comparable with established functional brain imaging
techniques, interaction of dopamine with the probe should also produce image signal changes on
the order of 1% or more in vivo [117]. Here we show that directed evolution of BM3 is capable of
producing dopamine sensors that largely meet these specifications.
2.3 Results
2.3.1 P450 BM3 reports ligand binding in MRI
To evolve dopamine probes for MRI, we focused on the heme domain of BM3 (BM3h), a 53 kDa
moiety that is catalytically inactive in the absence of the full protein’s reductase domain [118].
BM3h contains a single iron(III) atom (mixed spin 1/2 and 5/2) [119] bound to a hemin prosthetic
group and axially coordinated by residue Cys400 on the protein. In the absence of substrates, the
remaining coordination site is filled by a water molecule [120]. Interaction of the heme iron with
exchanging water molecules at this axial site promotes T1 relaxation in aqueous solutions [121] and
is therefore predicted to modulate MRI contrast. To determine the extent of this effect, we used
a spin echo pulse sequence in a 4.7 T MRI scanner to measure the proton relaxation rate as a
function of protein concentration in PBS; the slope of this relationship (T1 relaxivity, or r1) provides
a standard measure of the strength of a contrast agent. For BM3h in the absence of ligands, an
r1 value of 1.23 ± 0.07 mM−1s−1 was obtained. Addition of a saturating quantity of the natural
BM3 substrate, arachidonic acid (400 µM concentration), resulted in an r1 of 0.42± 0.05 mM−1s−1
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(Figure 2.1A). This ligand-induced decrease in relaxivity, probably arising from the displacement
of water molecules at the BM3h heme, enabled quantitative sensing of arachidonic acid using MRI
(Figure 2.1B) and suggested that BM3h could serve as a platform for molecular sensor engineering.
We next tested whether dopamine or related compounds could serve as unnatural ligands to
BM3h when applied at high enough concentrations. As measured by MRI, addition of 1 mM
dopamine to BM3h in fact induced a drop in r1 to 0.76± 0.03 mM−1s−1 (Figure 2.1A). Binding of
arachidonic acid is known to induce a change (blue shift) in BM3h’s optical absorbance spectrum
because of perturbation of the electronic environment of the heme chromophore [122]. To determine
whether the relaxation change induced by dopamine also reflects interaction with the BM3h heme,
we measured optical spectra of the protein in the presence and absence of 1 mM dopamine. The
interaction produced a small but clearly discernable red shift of λmax, from 419 to 422 nm (Figure
2.1C ), indicative of ligand coordination to the heme iron [122]. This suggests that dopamine (at
1 mM) directly replaces water as an axial metal ligand in the BM3h substrate-binding pocket and
that directed evolution of BM3h binding specificity could therefore improve the protein’s relative
affinity for dopamine. In addition to providing mechanistic insight, the correspondence between op-
tical and MRI measurements of ligand binding to BM3h implied that either modality could be used
to obtain quantitative binding parameters. We monitored the difference between absorption at two
wavelengths as a function of ligand concentration to determine binding isotherms for arachidonic
acid and dopamine (Figure 2.1D,E ). For BM3h, the apparent Kd for arachidonic acid was 6.8± 0.5
µM; the Kd for dopamine was 990± 110 µM. Goals for the production of BM3h-based MRI sensors
thus included decreasing the affinity for arachidonic acid, increasing the dopamine affinity by at
least two orders of magnitude and maintaining or enhancing the relaxivity changes observed upon
ligand binding.
2.3.2 Directed evolution of dopamine-responsive BM3h variants
To create an MRI sensor for dopamine using directed evolution, we developed a customized screening
methodology (Figure 2.2A). Results shown in Figure 2.1 suggested that either MRI-based or optical
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assays could be used to distinguish BM3h mutants with differing ligand affinities. We chose an
absorbance assay for our screen because lower protein concentrations (∼1 µM) could be used in
this format. Input to each round of screening consisted of a library of BM3h mutants, each with
an average of one to two amino acid substitutions, generated by error-prone PCR from the wild-
type (WT) gene or a previously selected mutant. We transformed DNA libraries into Escherichia
coli. We grew and induced approximately 900 randomly selected clones in microtiter plate format,
then prepared cleared lysates for optical titration with dopamine and arachidonic acid in a plate
reader. Titration data were analyzed to determine Kd values for both ligands. An average of 79% of
assayed mutants had sufficient protein levels (absorbance signal > 30% of parent) and clean enough
titration curves (R2 > 0.8) for Kd estimation. Mutant affinities appeared to be distributed randomly
about the dissociation constant measured for the corresponding parent protein, but we were able
to identify individual clones with desired affinity changes in each round (Figure 2.2B). From each
screen, we chose eight to ten mutants on the basis of their estimated Kds, purified them in bulk,
re-titrated them to obtain more accurate estimates of their dopamine and arachidonic acid affinities,
and examined them with MRI to ensure that robust ligand-induced changes in r1 could be detected.
On the basis of these assays, we chose as a parent for the next round of evolution the mutant showing
the best combination of relaxivity changes, improved dopamine affinity and decreased affinity for
arachidonic acid.
After carrying out the screening strategy over multiple rounds, we found a steady trend in
the distribution of Kd values toward greater affinity for dopamine and less affinity for arachidonic
acid (Figure 2.2B–D). Little change in binding cooperativity was observed, and changes in partial
saturation generally occurred over 100-fold ranges of dopamine concentrations. Five rounds of
evolution yielded a BM3h variant with eight mutations (Figure 2.2E ), four near the ligand-binding
pocket and four at distal surfaces of the protein. One residue (Ile263) was first mutated to threonine
(third round), then to alanine (fourth round). The clones selected from rounds 1, 3, and 5 had two
new mutations each. We did not determine the individual contributions of these mutations to the
observed changes in affinity. We introduced the mutation I366V by site-directed mutagenesis before
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the fifth round to enhance thermostability and tolerance of BM3h to further mutation [14, 30]; it
did not noticeably affect dopamine binding affinity.
The mutant proteins selected after the fourth and fifth rounds of evolution, denoted BM3h-8C8
and BM3h-B7, had optically determined dissociation constants of 8.9 ± 0.7 µM and 3.3 ± 0.1 µM,
respectively, for dopamine, and 750 ± 140 µM and 660 ± 80 µM, respectively, for arachidonic acid.
The T1 relaxivity of BM3h-8C8 was 1.1 ± 0.1 mM−1s−1 in the absence of ligand and 0.17 ± 0.03
mM−1s−1 in the presence of 400 µM dopamine (Figure 2.3A). For BM3h-B7, the corresponding r1
values were 0.96±0.13 mM−1s−1 and 0.14±0.04 mM−1s−1. Both sensor variants showed a dopamine
concentration-dependent decrease in T1-weighted MRI signal (up to 13% with 28.5 µM protein) that
could be fitted by binding isotherms with estimated Kd values of 4.9 ± 2.7 µM for BM3h-8C8 and
2.7± 2.9 µM for BM3h-B7 (Figure 2.3B,C ). For both BM3h variants, the stability, reversibility and
rate of dopamine binding were established using spectroscopic assays (Supplementary Figures 2.6
and 2.7).
We investigated the reporting specificities of BM3h-8C8 and BM3h-B7 for dopamine by measur-
ing MRI signal changes that resulted from incubation of 28.5 µM of each protein with 30 µM of either
dopamine or one of eight other neuroactive molecules: norepinephrine (a neurotransmitter formed
by catalytic hydroxylation of dopamine), 3,4-dihydroxy-L-phenylalanine (DOPA, the biosynthetic
precursor to dopamine), serotonin, glutamate, glycine, -aminobutyric acid (GABA), acetylcholine,
and arachidonic acid (Figure 2.3D). Of these potential ligands, only dopamine, norepinephrine, and
serotonin elicited substantial changes in the T1 relaxation rate (1/T1). For BM3h-8C8, the 1/T1
reductions produced by norepinephrine and serotonin were 0.0076± 0.0023 s−1 and 0.0041± 0.0020
s−1, respectively, compared to 0.0182± 0.0006 s−1 for dopamine; for BM3h-B7, norepinephrine and
serotonin induced 1/T1 decreases of 0.0112± 0.0024 s−1 and 0.0171± 0.0005 s−1, respectively, com-
pared to 0.0208 ± 0.0002 s−1 for dopamine. We measured the affinities of BM3h-based dopamine
sensors for these competitors spectroscopically (Figure 2.3D, inset). For BM3h-8C8, measured Kds
were 44 ± 3 µM and 80 ± 8 µM for norepinephrine and serotonin, respectively, and for BM3h-B7
the Kd values were 18.6 ± 0.4 µM and 11.8 ± 0.1 µM, respectively. Although both BM3h-8C8 and
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BM3h-B7 show substantially higher affinity for dopamine than for norepinephrine (fivefold and six-
fold, respectively) or for serotonin (ninefold and fourfold, respectively), the BM3h-8C8 variant is
more specific for sensing dopamine at concentrations above 10 µM. In settings where dopamine is
known to be the dominant neurotransmitter, BM3h-B7 may provide greater overall sensitivity.
The specificity data also provided a possible indication of the geometry of dopamine binding to
the evolved BM3h proteins. Only monoamines showed affinity for BM3h-8C8 and BM3h-B7, whereas
two catechols that lack primary amines, epinephrine and 3,4-dihydrophenylacetic acid, showed no
measurable affinity (data not shown). Combined with the spectral evidence that dopamine directly
coordinates the BM3h heme (Figure 2.1C ), the titration results therefore suggest that the dopamine
amine may serve as an axial ligand to the BM3h heme in the sensor-analyte complexes we examined.
2.3.3 BM3h-based sensors detect dopamine released from PC12 cells
We asked whether BM3h mutants produced by directed evolution could sense dopamine release in a
standard cellular model of dopaminergic function. We applied an established protocol [123] to test
the ability of our sensors to measure dopamine discharge from PC12 cells stimulated with extra-
cellular K+ (Figure 2.4A). Cells were cultured in serum-free medium supplemented with dopamine
to promote packaging of the neurotransmitter into vesicles. After pelleting and washing, we re-
suspended cells in a physiological buffer containing 32 µM BM3h-B7 and either 5.6 or 59.6 mM
K+ (cells in the low-K+ condition were osmotically balanced with Na+). T1-weighted MRI images
(spin echo TE/TR = 10/477 ms) obtained with BM3h-B7 showed a 4.0± 0.5% reduction in signal
intensity in the supernatant of K+-stimulated cells, compared with cells for which isotonic Na+
was used as control (Figure 2.4B). This corresponded to a 54 ± 4% decrease in sensor r1 (Figure
2.4C ). Given the dopamine dissociation constant of BM3h-B7 and its relaxivities under ligand-free
and dopamine-saturated conditions, and assuming negligible dilution of the sensor after mixing
with cells, we estimated supernatant dopamine concentrations of 60.3± 7.9 µM for stimulated cells
and 22.2± 1.1 µM for controls. These estimates were in reasonable agreement with an independent
quantification of dopamine release measured using an enzyme-linked immunosorbent assay (ELISA),
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which yielded concentrations of 54 ± 9 µM and 13 ± 2 µM for stimulated and control cells, respec-
tively (Figure 2.4D). We were also able to use BM3h-8C8 to image dopamine release from PC12
cells. Under experimental conditions similar to above, BM3h-8C8 had a 37± 2% reduction in r1 in
the supernatant of K+-stimulated cells relative to Na+ controls (Supplementary Figure 2.8).
2.3.4 Dopamine detection in the brain of living rats
As an initial test of the ability of BM3h-based sensors to measure dopamine concentrations in
intact animals, we injected BM3h-8C8 in the presence or absence of exogenous dopamine into the
brains of anesthetized rats. We chose this simple experimental protocol for validation of the sensor
because it guaranteed the presence of reproducible and unambiguous micromolar-level dopamine
concentrations, suitable for evoking robust responses from our sensors in vivo. We obtained T1-
weighted MRI scans (fast spin echo TE/TR 14/277 ms, 8.9 s per image) continuously during 0.5-
µl-min−1 paired infusions of 500 µM BM3h-8C8 with and without 500 µM dopamine, via cannulae
implanted stereotaxically into the left and right striatum. Dopamine-dependent contrast changes
were apparent in images obtained during and after the injection period (Figure 2.5A). We quantified
MRI changes across multiple trials in striatal regions of interest (ROIs) that were reliably (though
inhomogeneously) filled by convective spread of the contrast agent from the cannula tips (∼1.5 mm
radius). Consistent with results obtained in vitro, addition of dopamine dampened the observed MRI
intensity enhancement by approximately 50% (Figure 2.5B); the effect was significant (t-test, P =
0.003, n = 7). We performed the same paired infusion procedure with WT BM3h, which has very
low affinity for dopamine (Kd ∼ 1 mM). As expected, the time course of the MRI signal during and
after the WT BM3h injection period (Figure 2.5C ) was not significantly affected by the presence
or absence of dopamine (t-test, P = 0.8, n = 5), indicating that the dopamine-dependent signal
differences shown in Figure 2.5B require the presence of a micromolar-affinity dopamine sensor and
cannot be explained by physiological or biochemical effects of dopamine itself. Moreover, infusion
of 500 µM dopamine alone into the brain produced no noticeable signal changes in an equivalent
experiment (data not shown). Histological analysis showed minimal evidence of toxicity due to these
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procedures (Supplementary Figure 2.9). Using relaxivity values measured for BM3h-8C8 in vitro, we
estimated maximal concentrations of 89±19 µM BM3h-8C8 and 75±28 µM dopamine from the data
of Figure 2.5B, averaged across the striatal ROIs. The ability to quantify BM3h-8C8 concentration
on the basis of its T1 enhancement in the absence of elevated dopamine represents an advantage of
this sensor’s “turn-off” mechanism.
To test whether BM3h-8C8 could detect release of endogenous neurotransmitters in the rat brain,
we acquired MRI data during co-infusion of the dopamine sensor with elevated concentrations of
K+, a depolarizing chemical stimulus shown previously to release large amounts of dopamine into
the striatum [124, 125]. We chose K+ over pharmacological stimuli to obviate potential solubility- or
viscosity-related artifacts in the experimental paradigm. K+ itself had no effect on r1 of the BM3h
variants (data not shown). In the stimulation experiments, three 5-min blocks of high-K+ (153 mM)
infusion alternated with 10 min ‘rest’ periods during which we administered a low-K+ solution (3
mM, osmotically balanced with Na+). Both high- and low-K+ solutions were delivered at a rate of
0.2 µl min−1 and also contained 500 µM BM3h-8C8, ensuring that a relatively constant concentra-
tion of dopamine sensor was present throughout the procedure. We acquired T1-weighted MRI scans
continuously as for the exogenous dopamine infusion experiments. To control for effects unrelated to
neurotransmitter sensing by the contrast agent (potentially including K+-induced edema or hemo-
dynamic responses incompletely suppressed by the T1-weighted spin echo pulse sequence), we paired
each striatal injection of BM3h-8C8 with an injection of WT BM3h into the opposite hemisphere,
following the same blocked K+ stimulation paradigm for both injections. As in conventional ‘block
design’ fMRI, we performed a t-test analysis to evaluate the correspondence of each voxel’s inten-
sity time course with the alternating periods of low and high K+. We determined an appropriate
temporal shift for the stimulus-related analysis windows with respect to infusion buffer switches by
observing the time courses of similarly switched mock infusions into 0.6% agarose phantoms [126]
and by comparing these with statistical results as a function of offset (Supplementary Figure 2.10
and Supporting Material). As additional controls for MRI effects unrelated to dopamine sensing,
we examined MRI signal change in response to K+ stimulation and again in response to dopamine
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infusion, both in the absence of contrast agents (data not shown). We also continuously monitored
blood oxygen levels and heart rate. In no case were stimulus-associated changes observed.
Figure 2.5D shows the distribution of voxels with significant (t-test, P < 0.01) MRI signal
decreases in response to K+ stimulation in a single rat. We performed a group analysis by combining
data from all subjects (n = 6) over geometrically defined ROIs centered around the injection cannula
tips in each animal. In three slices spanning the infusion site, seven voxels within 0.75 mm of the
BM3h-8C8 injection cannula, but only one voxel near the WT cannula, showed strong correlation
(P < 0.01) with the stimulus. We mapped mean signal decreases over 2.7-mm-diameter ROIs
corresponding to the BM3h-8C8 and WT BM3h injection sites in the group analysis (Figure 2.5E ).
Again, dopamine sensor-dependent responses were apparent. The signal difference between low- and
high-K+ periods averaged across the entire BM3h-8C8 ROI (all voxels within a 2.7-mm-diameter
by 3-mm-long cylinder, regardless of modulation by K+) was 0.07%, whereas the signal difference
averaged across the control ROI was 0.02% (Figure 2.5F ). The high- versus low-K+ signal difference
observed near the BM3h-8C8 infusion site was significant (t-test, P = 0.0008) and consistent with
the expected suppression of MRI signal by dopamine release under high-K+ conditions.
The mean time course of all stimulus-correlated voxels (P < 0.05) showing K+-induced MRI
signal changes near the BM3h-8C8 injection site, averaged over animals, is shown in Figure 2.5G.
Discernable signal decreases of up to 3% were produced during each K+ stimulation block. The
first K+ block evoked the largest response (presumably because of partial dopamine depletion over
subsequent blocks [116]) and elicited a clear spatiotemporal pattern of mean MRI signal change from
baseline over the course of the stimulation period (Figure 2.5G, top panels).
2.4 Discussion
These results demonstrate the feasibility of developing molecular-level fMRI sensors and serve as
a proof of principle that BM3h-based probes can be used to monitor dopamine signaling processes
in vivo. With the experimental conditions and estimated sensor concentrations (34 ± 4 µM) used
for our K+ stimulation experiments, MRI signal changes of 3% would be evoked by the rewarding
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brain stimuli reported in previous studies to release large amounts of dopamine [115, 116]. This
amplitude is reasonably large by functional imaging standards, and it could be used in the near
term to map phasic dopamine release at high resolution across the striatum, or more generally
to study mesolimbic dopamine dynamics in animal models of reward processing and neurological
conditions that can be probed with strong stimuli.
Sensitivity gains will be possible using repeated stimulation and statistical analysis techniques,
as in conventional fMRI, and by optimizing the imaging approach itself. For instance, higher-field
scanners and faster alternatives to the T1-weighted spin echo pulse sequences we used here may offer
improved signal-to-noise ratios. Directed evolution or rational modification of BM3h variants for
substantially higher relaxivity is possible as well (unpublished data). Sensors with higher relaxivity
will produce larger MRI signal changes, and could have the added benefit of reducing the potential
for dopamine buffering, because they may be used at lower concentrations in vivo: with 35 µM
sensor and 35 µM total dopamine present, for example, ∼60% of the dopamine would be bound to
the sensor, but with 15 µM sensor present, only ∼30% dopamine would be sequestered. Protein
engineering techniques could also be used to improve the dopamine affinity and specificity of the
first-generation sensors described here.
Our method for producing dopamine sensors represents a general paradigm for the development
of molecular probes for MRI. Sensors may be evolved for targets inside or outside the brain; the
diversity of potential targets is exemplified by the contrast between WT BM3h, which produces
MRI signal changes in response to long-chain fatty acids, and BM3h-8C8 and BM3h-B7, which
respond to a catecholamine. Contrast agents engineered to detect dopamine and other signaling
molecules in the brain will permit functional neuroimaging based on direct detection of neuronal
events rather than hemodynamic changes. Exogenous delivery of macromolecules such as BM3h to
large regions of animal brains should be possible using a variety of techniques [127]. Because BM3h
is a protein, it might also be possible to deliver variants via expression from transfected cells in
vivo or in transgenic subjects. Preliminary evidence that BM3h can be expressed to 1% protein
content in mammalian cells supports the feasibility of this approach (Supplementary Material).
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Because of their small size, BM3h-based dopamine sensors might sample synaptic dopamine better
than voltammetry or microdialysis probes, and with appropriate targeting could potentially become
synapse specific. Dopamine sensor-dependent MRI would offer a combination of spatial coverage
and precision inaccessible to other methods and uniquely suited to studies of dopaminergic function
in systems neuroscience research.
2.5 Methods
2.5.1 Animal care
We performed all experiments involving vertebrate animals with approval of the Massachusetts
Institute of Technology Committee on Animal Care.
2.5.2 Library construction
We constructed BM3h mutant libraries in accordance with a previously published protocol [98].
The starting parent for evolution was the WT heme domain of BM3 with a C-terminal hexahis-
tidine tag, housed in the pCWori vector [128]. We produced mutant libraries through error-prone
PCR using the primers 5’-GAAACAGGATCCATCGATGCTTAGGAGGTCAT-3’ (forward) and
5’-GCTCATGTTTGACAGCTTATCATCG-3’ (reverse) and Taq polymerase (AmpliTaq, Applied
Biosystems) with 25 µM MnCl2, producing ∼1-2 mutations per gene. Between the fourth and fifth
rounds of evolution, we introduced the mutation I366V into BM3h-8C8 via overlap extension PCR
to improve protein thermostability [30].
2.5.3 Protein expression and high-throughput screening
We inoculated mutant colonies into deep-well 96-well plates containing 0.4 ml Luria broth (LB)
medium and grew them overnight. On each plate, we included the parent clone and up to three
previous parents in triplicate. We then transferred 0.1 ml of each culture to new plates containing
1.2 ml fresh terrific broth (TB) medium per well, supplemented with 100 µg ml−1 ampicillin, 0.2
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mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and 0.5 mM δ-aminolevulinic acid (ALA). We
stored remaining LB cultures with glycerol at 80 ◦C. After 20–30 hours of protein expression at
30 ◦C, we pelleted cultures and lysed the pellets in 0.65 ml PBS containing 0.75 mg ml−1 hen egg
lysozyme (Sigma-Aldrich) and 5 µg ml−1 DNase I (Sigma-Aldrich). We recorded absorbance spectra
of 200 µl of cleared lysate from each well in a multiwell plate reader (Spectramax Plus, Molecular
Devices) before and after addition of successively more concentrated dopamine or arachidonic acid.
We analyzed the resulting absorbance spectra in MATLAB (Mathworks) using a custom routine
that calculated the absorbance difference spectra for each acquisition relative to ligand-free lysate,
computed the difference between maximum and minimum of each difference spectrum, plotted each
value as a function of ligand concentration and, for each well, fitted a non-ligand-depleting bimolec-
ular association function to estimate the corresponding Kd. We subsequently compared mutant
Kd values to those of the parents within each plate and chose eight to ten mutants showing the
greatest decrease in Kd for dopamine and/or the greatest increase in Kd for arachidonic acid for
bulk expression and analysis.
2.5.4 Bulk expression and titrations
To produce selected proteins in bulk, we began by inoculating frozen LB cultures of candidate mu-
tants into 30 ml TB medium containing 100 µg ml−1 ampicillin. We induced the cultures at log
phase with 0.6 mM IPTG, supplemented them with 0.5 mM ALA and 50 µg ml−1 thiamine, and
shook them for an additional 20–25 hours to express protein. We then lysed pelleted cells with Bug-
Buster and Lysonase (EMD Chemicals) and purified BM3h mutants overNi-NTA agarose (Qiagen).
We exchanged buffer to PBS over PD-10 desalting columns (GE Healthcare), and measured pro-
tein concentration using a carbon monoxide binding assay [129]. To characterize ligand affinities of
the purified variants, we titrated protein samples with dopamine, arachidonic acid, serotonin, nore-
pinephrine, pyrocatechol, 3,4-dihydroxy-L-phenylalanine (DOPA), 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), 3-methoxytyramine (3MT), acetylcholine, glutamate, glycine,
GABA, and epinephrine (all from Sigma Aldrich) and analyzed the results using Matlab as described
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above. We performed all measurements at room temperature (∼ 21 ◦C). 3MT had a Kd of 73± 13
µM for BM3h-B7 and 183 ± 28 µM for BM3h-8C8. HVA and pyrocatechol showed no measurable
affinity.
2.5.5 In vitro magnetic resonance imaging
To assess magnetic relaxation behavior of the proteins, we arrayed BM3h samples (60–100 µl) into
microtiter plates and placed them in a 40-cm-bore Bruker Avance 4.7 T MRI scanner, equipped with
a 10-cm-inner-diameter birdcage resonator radiofrequency coil and 26 G cm−1 triple-axis gradients.
We filled unused wells of the microtiter plates with PBS and performed imaging at ∼21 ◦C on a
2 mm slice through the sample. We used a T1-weighted spin echo pulse sequence; echo time (TE)
was 10 ms, and repetition times (TR) were 73, 116, 186, 298, 477, 763 ms, 1.221, 1.953, 3.125
and 5.000 s. Data matrices consisted of 512 × 128 points, zero-filled to 1024 × 512 points, where
the second dimension corresponds to the phase-encoding direction; the field of view (FOV) was
16× 8 cm. We reconstructed and analyzed images using custom routines running in MATLAB and
adjusted contrast to optimize MRI images presented in the figures. We calculated relaxation rates
by exponential fitting to the image data, using an equation of the form I = k[1 − exp(TR/T1)],
where I was the observed MRI signal intensity and k was a constant of proportionality. We then
determined values of r1 by linear fitting to a plot of R1 against protein concentration for six to
eight BM3h concentrations in the range from 0 to 240 mM. We also performed low-field relaxivity
measurements using benchtop spectrometers operating at 21 ◦C with proton resonance frequencies
of 20 MHz and 60 MHz (Bruker Minispec NMS120 and mq60). Samples of 150 µL containing 50–100
µM BM3h-8C8 in PBS in the absence or presence of 500 µM dopamine yielded 20 MHz relaxivity
measurements of 1.0 or 0.25 mM−1 s−1, respectively, and 60 MHz relaxivities of 1.1 or 0.23 mM−1
s−1, respectively.
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2.5.6 Dopamine release from PC12 cells
We grew PC12 cells in suspension in F-12K medium supplemented with 15% (vol/vol) horse serum
and 2.5% (vol/vol) FBS (ATCC). In preparation for dopamine release experiments, we incubated
50 ml cell cultures for 1 h in medium supplemented with 1 mM dopamine and 1 mM ascorbic acid,
pelleted the cells and washed them twice with Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM
NaHCO3, 2.3 mM CaCl2, 5.6 mM D-glucose, and 5 mM HEPES pH 7.4). To Locke’s buffer missing
54 mM NaCl and containing or not containing the sensor, we added a 1:50 dilution of 2.7 M KCl
(stimulus) or NaCl (control). We resuspended the washed PC12 cell pellets in 200 µl of either K+-
or Na+-supplemented buffer, with or without sensor. After 30–60 min incubation at ∼21 ◦C, we
pelleted cells and imaged the supernatant in an MRI scanner as described above. We estimated
dopamine release by calculating sensor saturation level from observed r1, then solving the quadratic
equation describing bimolecular equilibrium binding with a known Kd, and assuming 32 µM of
sensor for ligand concentration. We made independent measurements of dopamine release using the
Dopamine EIA Kit (LDN).
2.5.7 Brain injection of sensors with exogenous dopamine
For injection experiments testing the effect of exogenous dopamine on BM3h-8C8 and WT BM3h
(Figure 2.5A–C ), we anesthetized adult male Lewis rats with 1–2% isoflurane. We stereotaxically
inserted plastic guide cannulae (Plastics One) bilaterally into the striatum and secured them in place
with dental cement (coordinates with respect to bregma: +0.7 mm anterior, 3 mm lateral, 6 mm
below the surface of the skull). We connected tubing filled with silicone oil to an MRI-compatible
dual channel syringe pump (Harvard Apparatus), attached it to internal cannulae and back-filled the
cannulae with contrast agent solution, 500 µM BM3h-8C8 or WT BM3h, with or without equimolar
dopamine (chemicals from Sigma-Aldrich). We ran the pump in infusion mode for a few seconds
to ensure that no air entered the system and then lowered the internal cannulae (connected to the
pump) into the implanted guide cannulae and fixed them in place with dental cement. After the
implantation was complete, we transferred the animal to a plastic positioning device (Ekam Imaging)
39
for imaging and placed it into a 4.7-T Bruker Avance scanner. We acquired fast spin echo (FSE)
MRI scans (TE/TR 14/277 ms, 8.9 s per scan, 0.3×0.3×1.0 mm resolution, 3.8×3.8 cm FOV, data
matrix 128× 128) before infusion (seven scans) and continuously during and after bilateral infusion
of paired solutions, each injected for 20 min at 0.5 µl min−1. We monitored heart rate continuously
during the infusions using a Nonin Medical 8600V pulse oximeter equipped with a nonmagnetic
sensor. We digitized raw oximetry readings using a National Instruments USB-6008 interface and
converted them to heart rate using a MATLAB code. Values were stable at around 350 beats per
minute ± 40 (s.d.).
We analyzed MRI data from these experiments using custom routines running in MATLAB.
We detrended image signal time courses, converted them to percent change with respect to the
preinjection baseline and averaged them over striatal ROIs. ROIs were chosen to approximate the
maximal volumes reliably filled with the contrast agent, and were defined by a five-voxel in-plane
radius (2.7 mm diameter) around the cannula tips over three image slices centered rostrocaudally
around the implantation position, excluding voxels with notable signal dropout due to the cannulae
themselves. We produced data for group analyses by combining data from ROIs defined separately
with respect to the injection cannulae tips in each individual. We computed maximal MRI signal
changes and signal change maps by averaging the image intensity at the end of the injection period
(scans 121–140) and subtracting and normalizing it to the pre-injection intensity (scans 1–7).
2.5.8 Protein and dopamine quantification based on in vivo imaging data
We estimated absolute concentrations of contrast agent and dopamine under the assumptions that
minimal endogenous dopamine was present, that the relaxivity and dopamine affinity of BM3h
variants were the same in vivo and in vitro, and that the MRI acquisition procedure satisfied a
strong T1-weighting requirement, where TR << T1. Under these assumptions, the fractional MRI
signal change ∆I/I0 is approximately equal to ∆R1/R10, the fractional change in R1 (equal to
1/T1). R10 is the basal value of R1, measured as 0.55 ± 0.01 s−1 from curve fitting to multiple
FSE images obtained with different TR values. We estimated the maximal total concentration of
40
BM3h-8C8 by determining the corresponding ∆R1 averaged over multiple injections of BM3h-8C8 in
the absence of dopamine and dividing it by the relaxivity of the unliganded protein. We determined
total dopamine concentration from the value of ∆R1 observed during injection of BM3h-8C8 plus
dopamine, the relaxivities of liganded and unliganded BM3h-8C8, the previously determined BM3h-
8C8 concentration and the mass action relationships governing binding of the sensor to dopamine. In
in vitro measurements, BM3h-8C8 had a T2 relaxivity of 4 mM
−1 s−1; addition of 1 mM dopamine
did not noticeably perturb this value significantly, suggesting that T2 effects in conjunction with
appropriate imaging methods might be able to provide a basis for protein quantification similar to
the approach we describe here.
2.5.9 Histological analysis
After MRI contrast agent injection experiments using the paradigm described above, we placed
rats under terminal anesthesia with ketamine and xylazine and transcardially perfused them with
phosphate buffer containing heparin (Hospira) and then with 4% wt/vol paraformaldehyde (Sigma-
Aldrich). We removed brains and obtained coronal cryosections of 10 µm thickness at 100 µm
intervals across a range extending ∼1 mm anterior and posterior to the injection cannula insertion
site. We used standard protocols for hematoxylin and eosin staining. Terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed using the DeadEnd
Colorimetric TUNEL system from Promega with visualization enhanced by the DAB Substrate Kit
from Vector Laboratories. Histological procedures were implemented by Wax-it Histology Services.
2.5.10 In vivo potassium stimulation experiments
For in vivo K+ stimulation experiments (Figure 2.5D–G), we used isoflurane-anesthetized male
Lewis rats. We fitted internal cannulae with Y-connectors and positioned them through bilateral
guide cannulae at coordinates 0.8 mm anterior to bregma, 2.8 mm lateral to the midline, and 7.8
mm below the skull surface. Each two-channel cannula delivered a given BM3h variant (BM3h-8C8
or WT, paired on opposite hemispheres of the brain; sides were randomized). On each two-channel
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injection cannula, we loaded one arm with protein in standard artificial cerebrospinal fluid (aCSF,
containing 150 mM Na+ and 3 mM K+) and the other arm with protein in high-K+ modified
aCSF containing no Na+ and 153 mM K+. Two infusion pumps (Harvard Apparatus) drove the
infusions; one pump controlled the standard aCSF (low-K+) infusions on both BM3h-8C8 and WT
control sides, and the other pump controlled high-K+ infusions on both sides. We programmed the
two pumps and synchronized them with the MRI experiment so as to acquire a preinfusion image
baseline for 2 min, followed by continuous scanning over three stimulation cycles consisting of 10
min low K+ alternating with 5 min high K+, followed by a further 10 min of low K+, followed by up
to 30 min of post-injection signal acquisition. During these experiments, we continuously recorded
heart rate and found it to be 355 beats per minute ± 45 (s.d.); blood oxygen saturation levels were
94.1 ± 5.8%.
We acquired T1-weighted multislice MRI scan series as for the dopamine injection experiments
described above. We imported raw data into MATLAB, processed them with spatial smoothing over
nearest neighbors (in-plane) and converted them to percent signal change with respect to a fitted
third-order polynomial baseline. Scans from the initial protein-only injection period (< 15 min)
were excluded from the analysis. To statistically analyze data acquired during the three cycles of
K+ stimulation, we used a procedure analogous to classical fMRI methods, by performing a t-test
on intensity values associated with high and low K+ conditions. We considered voxels showing
lower signal during the 5-minute intervals corresponding to K+ stimulation to be consistent with
the expected effect of K+-evoked dopamine release on MRI signal in the presence of BM3h-8C8. We
estimated that the delay between infusion pump switching and actual changes to K+ concentration
in the brain was roughly 8–9 min. We derived this estimate by recording the time required for
spreading of Trypan blue to a radius of 0.75 mm (comparable to ROIs used for most of the analyses
presented) from an injection cannula embedded in 0.6% agarose, in a switched injection paradigm
equivalent to the K+ stimulation paradigm applied in vivo. We chose a delay of 9 min for analyses
presented in the text, but delays ranging from 7 to 12 min produced qualitatively similar statistical
results, all with elevated numbers of voxels near the BM3h-8C8 infusion site showing the expected
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MRI signal decrease upon K+ stimulation and far fewer (if any) voxels near the WT BM3h control
cannula showing significant (P < 0.01) effects (Supplementary Figure 2.10). We performed ROI-wide
computations on cylindrical regions of 1.5 or 2.7 mm diameter in-plane extending over three (1 mm
thick) image slices, centered about the BM3h-8C8 and WT BM3h infusion cannula tips, excluding
from the calculations voxels showing substantial signal dropout due to the cannulae themselves. We
performed group analyses by combining data from ROIs defined separately with respect to injection
cannulae in each animal, without further anatomical coregistration.
2.6 Supplementary Material
2.6.1 DA binding to BM3h-B7 and BM3h-8C8 is stable and reversible
The stability of dopamine (DA) binding to BM3h-B7 and BM3h-8C8 was tested by incubating each
protein with various amounts of DA at room temperature and measuring the absorbance difference
between 430 nm and 410 nm over two hours (Supplementary Figure 2.6). During this time, a decline
of less than 5% was observed when 1 µM sensor was incubated in the presence of excess DA (800
µM). Optical changes were greater when sensor was incubated with subsaturating concentrations
of DA (up to 22% signal change for 1.3 µM DA incubated with BM3h-B7), consistent with the
predicted effects of DA oxidation (known to take place under ambient conditions) on the partial
saturation of the sensor. To test the reversibility of DA binding to BM3h-B7 and BM3h-8C8, we
acquired absorbance spectra of the proteins alone and with 400 µM DA before and after filtering the
solutions through a 30 kDa cutoff centrifugal filter. Successive steps of filtering and resuspension
restored the original, ligand-free spectrum (Supplementary Figure 2.7). Rate constants for binding
and unbinding of DA to BM3h-8C8 were estimated to be 3×103 M−1s−1 and 0.02 s−1, respectively,
at room temperature in phosphate buffered saline (PBS). Association was measured by rapid 1:1
mixing of protein (4.8 µM) and DA solutions (0.6–2.5 mM), followed by absorbance spectroscopy
in a Hi-Tech KinetAsyst SF-61DX2 stopped-flow spectrometer (TgK Scientific, Wiltshire, UK).
Dissociation was measured by fast 1:100 dilution of a solution containing 100 µM BM3h-8C8 and
43
50 µM DA, followed by absorbance recording in a Spectramax M2e spectrophotometer (Molecular
Devices, Sunnyvale, CA).
2.6.2 Thermostabilization of BM3h-8C8
Mutations in the amino acid sequence of BM3h have been shown to reduce the proteins thermosta-
bility. This was observed during directed evolution of BM3h: the melting temperature (Tm, the
midpoint temperature for thermal denaturation after 10 min) of WT BM3h was approximately 58
◦C, while the Tm for BM3h-8C8 was approximately 48 ◦C. While this change did not significantly
affect the proteins stability in physiologic buffer at room temperature, it did apparently reduce the
yield of our bulk purification procedure. To improve thermostability of BM3h-8C8 before performing
the fifth round of evolution, we introduced the mutation I366V, which has been shown previously
to improve stability [14]. For BM3h-8C8 this improvement corresponded to a Tm increase by ap-
proximately 4 ◦C.
2.6.3 Histological analysis of injected rat brains
Histological analysis was performed on some of the experimental animals, following injection with
contrast agents and MRI scanning (Supplementary Figure 2.9). Brains were extracted, and frozen
sections were obtained from regions near the cannula placement sites. Hematoxylin and eosin (H&E)
staining was performed to evaluate tissue architecture, and terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) staining was performed to assay cell death in brain
regions near the injection sites. Some mechanical disruption occurred in areas immediately sur-
rounding the cannula implantation tracts, but the tissue appeared normal in other respects. The
tissue was intact in brain regions that did not include the cannula tracts. To obtain quantitative
information about cell death near the injection site, TUNEL positive and negative nuclei were tallied
in a region of 0.5 mm × 0.5 mm near the cannula tip placement site in a representative histological
image; this site had been administered an injection solution containing 500 µM BM3h-8C8 and 500
µM DA. Fewer than 4% of nuclei appeared to be TUNEL positive, indicating that widespread cell
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death was not induced by introduction of the agents used in our experiments.
2.6.4 BM3h expression in mammalian cells
As a preliminary test of the feasibility of applying BM3h-based sensors as genetically encoded re-
porters in mammalian cells and animals, we created mammalian codon-optimized versions of the
BM3h and BM3h-8C8 genes using Gene Designer software (DNA2.0, Menlo Park, CA). The result-
ing sequences were synthesized by Blue Heron (Bothell, WA), cloned into a PCMV-Sport vector
(Invitrogen, Carlesbad, CA), and transfected into the HEK293 cell line adapted for the Invitrogen
Freestyle293 expression system. One day after transfection, cells were supplemented with 0–40 µM
hemin, to ensure an adequate supply of heme for expression and folding of BM3h. Cells were lysed
after four days of expression. Proteins were purified from lysates by nickel affinity chromatogra-
phy and analyzed by optical spectroscopy. Spectra of mammalian cell-expressed and recombinant
bacterial BM3h were virtually identical, indicating correct folding of the proteins. Absolute BM3h
expression levels were measured by performing CO assays on clarified HEK293 lysates, and the re-
sults were compared with BCA assay (Pierce, Rockford, IL) results indicating the total amount of
protein present. BM3h accounted for 0.4% to 1.9% of total cell protein depending on the level of
hemin supplementation during growth. Assuming a typical protein density of 150 mg/mL in living
tissue, 1% of total protein would correspond to a tissue concentration of 25 µM. This figure indicates
cytosolic expression levels, but robust expression of secreted BM3h, appropriate for extracellular DA
sensing, should also be feasible. High level expression of secreted proteins from mammalian cells
has been described in the literature. One study reported yields of 5 mg/L over a two-hour period
from monolayer cultures containing approximately 105 cells per 1.5 mL well [130], a figure likely
to constitute well over 10% of total protein in the samples, and therefore significantly greater than
the intracellular yields we obtained from BM3h expression in HEK293 cells. In mice, comparably
high expression levels of several mg/L in serum of a secreted enzymatic reporter protein have been
observed following adenoviral infection [131] or genetically-modified xenograft implantation [132].
Another point of reference related to attainable secreted protein expression levels is the protein con-
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tent of the brains extracellular space, which has been estimated at 1% by weight [133], equivalent
to 200 µM of proteins averaging 50 kD.
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2.7 Figures
Figure 2.1: Ligand binding to the BM3 heme domain changes MRI contrast and optical absorption
in a concentration-dependent manner. (A) T1 relaxivity (r1) of BM3h in PBS solution and in the
presence of 400 µM arachidonic acid (AA) or 1 mM dopamine (DA); inset shows T1-weighted spin
echo MRI image intensity (TE/TR = 10/477 ms) of microtiter plate wells containing 240 µM BM3h
in PBS alone (left) or in the presence of 400 µM arachidonic acid (middle) or 1 mM dopamine (right).
(B) T1 relaxation rates (1/T1) measured from solutions of 28.5 µM BM3h incubated with 0–250 µM
arachidonic acid. (C ) Optical absorbance spectra of 1 µM BM3h measured alone (blue) and after
addition of 400 µM arachidonic acid (gray) or 1 mM dopamine (orange). OD, optical density.
(D) Difference spectra showing the change in BM3h absorbance as a function of wavelength upon
addition of 400 µM arachidonic acid (gray) or 1 mM dopamine (orange). (E ) Normalized titration
curves showing binding of BM3h to arachidonic acid (gray) or dopamine (orange). We computed
the optical signals used for titration analysis by subtracting the minimum from the maximum of
difference spectra (arrowheads in D) under each set of conditions. Error bars in A, B, and E reflect
s.e.m. of three independent measurements (errors in E were smaller than the symbols).
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Figure 2.2
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Figure 2.2: Screen-based isolation of BM3h mutants with enhanced dopamine affinity. (A) Schematic
of the directed evolution approach, including (left to right) generation of a mutant DNA library,
transformation into E. coli and growth in multiwell plate format, spectroscopic analysis of each
mutant’s ligand binding affinities, and detailed MRI and optical characterization of selected mutant
proteins. (B) Histograms of mutant dopamine dissociation constants determined during each round
of directed evolution, comparing each mutant protein’s relative dopamine affinity (measured in
plate format) to the Kd of the parent protein (measured in bulk). Kd distributions for screening
rounds 1 (black), 2 (green), 3 (red), 4 (cyan), and 5 (purple) are labeled with numbers in circles.
Color-coded arrowheads indicate the measured Kds of parent proteins used to create the library
of mutants at each round; yellow arrowhead indicates the Kd of the mutant protein selected after
round 5. (C ) Dissociation constants for dopamine (DA; orange) and arachidonic acid (AA; gray)
for WT BM3h and mutant BM3h variants isolated at each round of screening; progressive increases
in dopamine affinity and attenuation of arachidonic acid affinity are evident. Colored arrowheads
indicate correspondence with data in B. Error bars denote s.e.m. of three independent measurements.
(D) Titration analysis of dopamine binding to WT BM3h and to proteins selected after each round
of directed evolution (colored as in B). Mutant proteins identified by rounds 4 (8C8) and 5 (B7)
were considered to be end products of the screening procedure. (E ) X-ray crystal structure [134] of
WT BM3h (gray; heme group shown in orange) bound to palmitoleic acid (black), indicating the
locations of amino acid substitutions accumulated during directed evolution of enhanced dopamine
binding affinity. Each mutation’s location is marked with a blue sphere and a label color-coded
according to the parent protein in which the substitution was first identified (see legend for B).
The previously characterized I366V mutation (asterisk) was incorporated between screening rounds
4 and 5 to improve the thermostability of the engineered proteins.
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Figure 2.3: Selected sensor proteins produce strong and specific MRI signal changes in response to
dopamine. (A) Relaxivity values measured from BM3h-B7 (yellow bars) and BM3h-8C8 (purple
bars) in PBS alone or in the presence of 400 µM dopamine (DA). Inset, T1-weighted MRI signal
(TE/TR = 10/477 ms) obtained from 195 µM BM3h-B7 or BM3h-8C8, each incubated in microtiter
plate wells with or without 400 µM dopamine (wells ordered left to right as in the bar graph). (B)
MRI image showing signal amplitudes measured from wells containing 28.5 µM WT BM3h, BM3h-
8C8 or BM3h-B7, each incubated with increasing dopamine concentrations (0–63 µM, left to right).
The image was obtained using a T1-weighted pulse sequence (TE/TR = 10/477 ms). (C ) Relaxation
rates (1/T1 values) measured from solutions of 28.5 µM WT BM3h (black), BM3h-B7 (yellow), or
BM3h-8C8 (purple), as a function of total dopamine concentration. Curves were fit using a ligand-
depleting bimolecular association model. (D) Changes in 1/T1 relative to ligand-free protein for 28.5
µM BM3h-B7 (yellow) or BM3h-8C8 (purple) incubated with 30 µM dopamine, serotonin (5HT),
norepinephrine (NE), DOPA, arachidonic acid (AA), acetylcholine (ACh), GABA, glutamate, or
glycine. Inset, spectroscopically determined affinities (Ka = 1/Kd) of BM3h-B7 and BM3h-8C8 for
dopamine, serotonin, and norepinephrine. Error bars in panels A, C, and D denote s.e.m. of three
independent measurements.
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Figure 2.4: BM3h-based sensors measure dopamine release in cell culture. (A) PC12 cells depolarized
by addition of 54 mM K+ were stimulated to release dopamine (DA) into supernatants containing a
BM3h-based sensor; cells did not release dopamine after addition of 54 mM Na+. (B) T1-weighted
spin echo MRI signal amplitudes (TE/TR = 10/477 ms) measured from the supernatants of PC12
cells incubated with 32 µM BM3h-B7 in the presence of K+ (stimulus) or Na+ (control). Inset, MRI
image of microtiter wells under corresponding conditions. (C ) Relaxation rates measured from the
samples in B, minus the relaxation rate of buffer not containing BM3h-based sensors. Given the
approximate concentration of BM3h variants in these samples, the ∆(1/T1) values presented here
can be converted to apparent relaxivities of 0.23 and 0.50 mM−1 s−1 in K+ and Na+ incubation con-
ditions, respectively. (D) Data from C were used to estimate the concentrations of dopamine present
in samples treated with K+ and Na+ (dark bars). We independently measured the concentrations
of dopamine under equivalent conditions using ELISA (light bars).
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Figure 2.5
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Figure 2.5: BM3h-8C8 reports dopamine in injected rat brains. (A) Top, coronal MRI image (0.7
mm anterior to bregma, averaged over the injection period) from a single rat injected with 500
µM BM3h-8C8 in the presence (orange dashed circle) or absence (blue dashed circle) of equimolar
dopamine; the image contrast was linearly adjusted for display. MRI hyperintensity is noticeable
near the tip of the dopamine-free cannula. The circles indicate approximate ROIs (∼1.5 mm around
cannula tips) over which image intensity was averaged for quantitative analyses. Bottom, map of
percent signal change (%∆) for the same animal, computed by comparing pre- and post-injection
MRI signal. Areas corresponding to both high- and low-dopamine co-injections (+DA and DA) are
delineated by apparent signal changes, but the strong difference between the two conditions is clear.
(B) Time courses of relative signal change observed during injection of BM3h-8C8 DA (blue) or
+DA (orange), averaged over multiple animals (n = 7) in ROIs denoted in A. Gray shading denotes
the 20 min injection period. (C ) Corresponding time courses of a control injection in which WT
BM3h was introduced instead of the dopamine sensor (n = 5). (D) Statistical parametric map of
t-test significance values (color scale) for correlation of MRI intensity with low- and high-K+ condi-
tions in an individual rat, overlaid on a corresponding T1-weighted coronal slice (grayscale) showing
injection cannulae used for BM3h-8C8 infusion (left, purple dashed circle) and WT BM3h control
infusion (right, black dashed circle). (E ) Maps of percent signal difference (SD) between high- and
low-K+ conditions observed in 2.7-mm-diameter ROIs centered around BM3h-8C8 sensor (left) and
WT BM3h control (right) injection sites, after spatial coregistration and averaging across multiple
animals (n = 6); ROIs correspond approximately to the color-coded circles in d. Voxels outlined
in green are those that showed the most significant correlation with the K+ stimulus regressor in
the group analysis (Student’s t-test, P < 0.01); these generally showed ∼1% mean signal change.
Gray cross-hatching indicates approximate locations of the infusion cannulae. (F ) Mean MRI signal
change from baseline observed during high-K+ (dark bars) and low-K+ (light bars) periods in ROIs
centered around infusion sites for BM3h-8C8 (purple) and WT BM3h (gray) proteins. ROIs were
cylinders 2.7 mm in diameter and extending over 3-mm-thick slices registered around the infusion
sites; signal was averaged in unbiased fashion over all voxels, regardless of correlation with the stim-
ulus. The signal difference in the presence of BM3h-8C8 was statistically significant (P = 0.0008,
asterisk). (G) Graph shows the mean time course of MRI signal in voxels within the BM3h-8C8-
infused ROI and identified as correlated (P < 0.05) with the stimulus, averaged over animals and
binned over 1.5 min intervals (shaded area denotes s.e.m., n = 6; individual traces are shown in
Supplementary Figure 2.11). Gray vertical bars denote periods associated with highest K+ stimula-
tion, accounting for delays due to convective spreading of K+ from the cannulae tips and the dead
time of the injection apparatus. Arrowheads indicate the timing of pump switches associated with
transitions from low to high (up) and from high to low (down) K+ infusion conditions. Panels above
the graph depict ‘snapshots’ of signal change spaced throughout the first K+ stimulation cycle, as
indicated by the dotted lines. The ROI corresponds to the left side of E, and the color scale denotes
0% (black) to 3% (yellow) signal change from baseline at each voxel and time.
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Supplementary Figure 2.6: Stability of BM3h complexes. Optical signatures of DA binding to
BM3h-B7 (A) and BM3h-8C8 (B) are stable over two hours. Absorbance at 430 nm minus 410 nm
collected over 2 hours for 1 µM sensor incubated in the presence of 0-800 µM DA (labels in color).
Supplementary Figure 2.7: DA binding to BM3h-B7 and BM3h-8C8 is reversible. (A) Absorbance
spectra of 1 µM BM3h-B7 alone (blue) or incubated with 400 µM DA (green) before filtering (top),
and after filtering twice (middle) or three times (bottom) through a 30 kDa cutoff filter. (B) Ratios
of absorbance at 430 nm to 410 nm corresponding to the DA-free (white bars) and DA-incubated
(gray bars) spectra in A. Panels C and D display equivalent data for sensor variant BM3h-8C8.
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Supplementary Figure 2.8: BM3h-8C8 reports DA release from PC12 cells. Plots of signal change
(A) and ∆(1/T1) (B) are analogous to Figure 2.4, and were obtained using identical experimental
procedures.
Supplementary Figure 2.9: Histological data from a rat injected with 500 µM BM3h-8C8 and 500 µM
DA. Panel A shows a comparison of MRI and hematoxylin and eosin (H&E) stained brain hemi-slices,
taken from near the injection site (∼1 mm anterior to the cannula position). The pseudocolored
MRI image (left) maps the percent change in MRI signal (relative to preinjection baseline) observed
in this animal; the color scale (left edge) ranges from -25% to +25%. The superimposed yellow brain
atlas diagram [135] demonstrates that the region of greatest signal change following this injection
falls within the caudate nucleus of the striatum. The right side of panel A shows a corresponding
H&E section from the same animal (scale bar = 2 mm) (H&E and MRI data are shown as mirror
images, to facilitate comparison). A closeup view (20x) of the H&E stained section in the region
of greatest contrast agent accumulation shows normal cellular staining (B). The scale bar denotes
100 µm, and the field of view shown in B corresponds to the small rectangle in the right half of
panel A. TUNEL staining was performed to assay cell viability in the injected ROI (C ). Over 95%
of visualized nuclei were judged to be TUNEL negative, indicating the overall health of the tissue.
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Supplementary Figure 2.10: Statistical analysis of K+ stimulation data with variable delay between
infusion switching and estimated periods of high and low K+ in the brain. Data acquired during
three cycles of potassium stimulation were analyzed over a range of delays, and the number of voxels
showing significant (t-test p < 0.01) signal decreases during modeled periods of high K+ was tallied
in 0.75 mm radius ROIs extending over three 1 mm slices around the BM3h-8C8 (purple) and WT
BM3h control (black) infusion sites. The plot shows the average (solid line) and standard error
(shading) across the six individual animals that contributed to the analysis. The horizontal scale
spans a range from the dead time of the injection cannulae (4 min.) to the duration of an entire
stimulus cycle (15 min.). The vertical dotted line specifies the delay (9 min.) used to generate
figures and data cited in the main text.
Supplementary Figure 2.11: Time courses of MRI signal in the six individual animals contributing
to the average in Figure 2.5G. For each animal (represented by different line styles), signal was
averaged over all voxels within ROIs of 2.7 mm diameter and three 1 mm slice thickness around
BM3h-8C8 infusion sites, and determined to be correlated (p < 0.05) with K+ stimulation blocks.
As in Figure 2.5G, gray vertical bars denote periods associated with highest K+ stimulation, and
arrowheads label timing of pump switches associated with transitions from low to high (up) and
high to low (down) K+ infusion conditions.
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Chapter 3
SCHEMA-designed chimeras of
Human Arginase I and II reveal
sequence elements important to
stability and catalysis
3.1 Abstract
Arginases catalyze the divalent cation-dependent hydrolysis of L-arginine to urea and L-ornithine.
The divalent metal cluster of arginase is not only integral to catalysis, but also contributes to the
stability of the enzyme. There is much interest in using arginase as a therapeutic anti-neogenic
agent against L-arginine auxotrophic tumors and in enzyme replacement therapy for treating hyper-
argininemia. Both therapeutic applications require enzymes with sufficient stability under physio-
logical conditions. Using SCHEMA structure-guided recombination, we designed and synthesized a
diverse set of active chimeric arginases that are composed of sequence fragments from the two human
isozymes Arginase I and II. Within this data set, linear regression was used to identify the sequence
elements that contribute to an arginase’s long-term stability under physiological conditions. Our
data revealed: (i) a striking correlation between an arginase’s isoelectric point and its long-term
stability and (ii) a moderate correlation between an arginase’s metal affinity and catalytic efficiency.
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3.2 Introduction
Humans produce two arginase isozymes (EC 3.5.3.1) that catalyze the hydrolysis of L-arginine (L-
Arg) to urea and L-ornithine (L-Orn). The Arginase I (hArgI) gene is located on chromosome 6
(6q.23), is highly expressed in the cytosol of hepatocytes, and functions in nitrogen removal as the
final step of the urea cycle. The Arginase II (hArgII) gene is found on chromosome 14 (14q.24.1).
Arginase II is mitochondrially located in tissues such as kidney, brain, and skeletal muscle, where it
is thought to provide a supply of L-Orn for proline and polyamine biosynthesis [136]. Both enzymes,
which share 61% sequence identity, adopt a homo-trimeric structure composed of an α/β fold of a
parallel eight-stranded β-sheet surrounded by several helices. These enzymes contain a di-nuclear
metal cluster that generates a hydroxide for nucleophilic attack on the guanidinium carbon of L-
arginine [137, 138]. In eukaryotes and most prokaryotes, the native metal cofactor in arginase is
Mn2+.
There is significant interest in applying arginases as cancer chemotherapeutic agents. A number
of high morbidity tumors such as hepatocellular carcinomas (HCC), melanomas, renal cell, and
prostate carcinomas [139, 140, 141] are deficient in the urea cycle enzyme, argininosuccinate synthase
(ASS), and thus are sensitive to L-arginine (L-Arg) depletion. Non-malignant cells typically enter
into quiescence (G0) when deprived of L-Arg and remain viable for several weeks. However, ASS-
deficient tumor cells experience cell cycle defects that lead to the re-initiation of DNA synthesis even
though protein synthesis is inhibited, in turn resulting in major imbalances that lead to rapid cell
death [142, 143]. The selective toxicity of L-Arg depletion for HCC, melanoma and other urea-cycle
enzyme deficient cancer cells has been extensively demonstrated in vitro, in xenograft animal models
and in clinical trials [139, 144, 142, 140]. Arginase has also been explored as an enzyme replacement
therapy to treat hyperargininemia. Although rare, autosomal recessive errors in hArgI can result in
hyperargininemia, which clinically presents with hyperammonemia, spasticity, seizures, and failure
to thrive [145]. Dietary management in combination with oral phenylbutyrate is often successful in
controlling hyperammonemia, but the underlying hyperargininemia can persist, which can result in
L-arginine-associated neurotoxicity [146]. Red blood cell replacement, which provides supplemental
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hArgI, has shown promise in treating hyperargininemia as evidenced by reduced serum L-Arg levels
and improved clinical outcomes [147, 148].
To function as a therapeutic, arginase must efficiently degrade L-Arg under physiological con-
ditions (∼100 µM L-Arg, 37 ◦C, and pH 7.4) and not produce adverse immunological responses.
For these reasons, the human arginase isozymes are logical starting points for the development of
a therapeutic enzyme. Unfortunately, both hArgI and hArgII display low enzymatic activity at
physiological pH and are rapidly inactivated in blood serum, with half-lives of only a few hours.
We recently reported that Co2+-substituted hArgI (Co-hArgI) displays a dramatically reduced Km
for L-Arg relative to the native Mn+2-containing enzyme, which leads to a twelvefold increase in
kcat/Km. More importantly, Co-hArgI is significantly more stable in blood serum, with an inacti-
vation half-life of over 30 hours [149]. With these enhanced properties, Co-hArgI displays potent
tumor cytoxicity against numerous cancer cell lines in vitro, and inhibits the growth of HCC and
pancreatic carcinomas in mouse xenograft models [149, 150].
Here, we designed a highly informative set of engineered arginases and used this set of sequences
to study the biophysical properties of arginase enzymes. We start by designing a SCHEMA structure-
guided recombination library of arginase chimeras composed of sequence fragments from the human
arginases hArgI and hArgII. Past SCHEMA libraries have contained a large number of functional
and diverse sequences [80, 151], providing ideal data sets for investigating the properties of sequences
within a protein family. Next, we select a maximally informative subset of the arginase SCHEMA
library using a novel active learning algorithm which identifies sequences that are both functional and
highly informative. This diverse set of engineered arginases is used to study the long-term stability
and catalytic efficiency of arginases under physiological conditions. From this investigation, we
propose a mechanism of arginase inactivation and suggest future strategies for engineering arginases
with exceptional long-term stability.
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3.3 Materials and Methods
3.3.1 Active learning algorithm
The active learning algorithm consists of a two-step experimental design. The first step involves
finding an informative set of chimeras for a logistic regression model of functional status, that is
whether a chimeric sequence is folded and has arginase activity. Here, we would like to find the set
of sequences S which maximize the mutual information between the chosen set of chimeras and the
remainder of the library
I(S;L\S) = H(L\S)−H(L\S|S), (3.1)
where H(L\S) is the Shannon entropy of library L excluding the chimeras in subset S and H(L\S|S)
is the entropy of the same sequences after the chimeras in S have been observed. We approximate
the intractable entropy of the Bayesian logistic regression model by replacing the logistic response
with a Gaussian likelihood. Gaussian mutual information is a submodular set function [152] and
therefore can be maximized efficiently using a greedy approximation algorithm [153]. The functional
status of the resulting sequences was then used to train a Bayesian logistic regression model, which
can predict the probability a chimera will function for all sequences in the library.
The second step of the algorithm consists of finding a highly informative set of functional chimeric
arginases. Here, we want to find the set of chimeras S which maximize the expected value of the
mutual information
E[I(S;L\S)] =
∑
A∈P(S)
I(A;L\A) ∏
c∈A
pC
∏
c∈(S\A)
1− pC
 , (3.2)
where the sum is over all subsets A in the power set of S, and pc is the predicted probability
of being functional for chimera c from the logistic regression model. This objective is chosen to
simultaneously find sequences that are informative and have a high probability of being functional.
Since submodular functions are closed under positive linear combinations, the expected value of the
Gaussian mutual information is also submodular and therefore greedy maximization provides strong
60
performance guarantees. The covariance between sequences was calculated using the chimera-block
coding scheme described in the regression analysis section (below). All experimental designs were
performed with the Submodular Function Optimization Matlab Toolbox [154].
3.3.2 Gene synthesis and cloning
Genes encoding the SCHEMA designed arginase chimeras were synthesized from oligonucleotides as
described previously [155]. In brief, long DNA oligonucleotides (99 bases) were synthesized in-house
and assembled into two 560-base pair fragments using inside-out PCR. These primary fragments
were combined without purification in a secondary overlap-extension reaction that formed the final
desired 1086-base pair product. Custom software directed the assembly schemes and the efficient
re-use of oligonucleotides across multiple related sequences. 32-base-pair overlaps were designed
between adjacent oligonucleotides and a 35-base-pair overlap was designed between the two primary
fragments. Genes were synthesized with an N-terminal 6x His tag followed by a tobacco etch virus
protease cleavage site and NcoI and EcoRI restriction sites as described previously [149]. These genes
were cloned into a pET28a expression vector and the sequences were verified using DNA sequencing.
3.3.3 Expression and Purification
E. coli BL21(DE3) cells expressing arginase variants were grown at 37 ◦C in minimal media to
an OD600 of 0.8–1. Cells were collected by centrifugation, re-suspended in fresh minimal media
containing 0.5 mM IPTG and 100 µM MnSO4, and incubated for an additional 8–12 hours at 37
◦C with shaking. After protein expression, cells were collected by centrifugation, lysed by a French
pressure cell, and centrifuged at 14,000 g for 20 min at 4 ◦C. The clarified lysate was applied to a
nickel IMAC column, washed with 10–20 column volumes of IMAC buffer and the purified arginases
were eluted with IMAC elution buffer (50 mM NaPO4, 250 mM imidazole, 300 mM NaCl, pH 8).
The purified arginases were buffer exchanged several times into PBS, 10 % glycerol, pH 7.4 using a
10,000 MWCO centrifugal filter device (Amicon). Aliquots of purified arginase variants were then
flash frozen in liquid nitrogen and stored at -80 ◦C.
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3.3.4 Enzyme Kinetics
Michaelis-Menten kinetics for L-Arg hydrolysis were determined in 100 mM HEPES buffer at 37 ◦C,
pH 7.4 as previously described [149].
3.3.5 Long-term stability
The long-term stability of the arginase chimeras was measured in 100 mM HEPES buffer, pH 7.4
at 37 ◦C, with or without 500 mM NaCl. Proteins were diluted to 2 µM with 100 mM HEPES, pH
7.4 and placed at 37 ◦C. Aliquots of 30 – 50 µL were taken at different time points (typically t =
0, 0.5, 3, 24, 48, and 72 hours). The activity at each time point was immediately measured using 1
mM L-Arg, as described previously [149]. The data were plotted as percent activity as a function
of time, and the area under this inactivation curve (AUC) was calculated using Kaleidagraph.
3.3.6 Thermal stability
Arginase variants (20–40 µM) in PBS, pH 7.4 with or without EDTA (10 mM final concentration)
were incubated in 96-well low-profile PCR plates (Fisher Scientific, Rockford, IL) on ice for 30
minutes. SYPRO orange dye (Sigma Aldrich) was added into each well immediately before placing
the plate in an RT (reverse transcription)-PCR machine (LightCycler 480, Roche). The temperature
dependence of protein unfolding was measured from 20–95 ◦C, and all chimeric arginases unfolded
in a single cooperative transition. The thermal transition midpoint (Tm) was determined by fitting
the unfolding curves to a modified logistic equation. All measurements were performed in at least
duplicate.
3.3.7 Regression analysis
For both regression models, the independent variable corresponds to the sequence of chimeric
arginases and is represented with a binary vector x, where xi indicates the parent identity at block
i. Since we have limited data, we use Bayesian parameter estimation, which outperforms maximum
likelihood estimation on small data sets.
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A chimera’s binary functional status was modeled with a Bayesian logistic regression model,
which contains a Bernoulli likelihood function and a zero-mean, isotropic Gaussian prior on coef-
ficients [156]. The resulting posterior distribution was approximated using Laplace’s method and
prior variance was estimated from the data by maximizing the marginal likelihood function. Using
Newton’s method, we found the maximum a posteriori (MAP) estimates for each chimera block’s
contribution to functionality. A chimera’s probability of being functional was estimated by applying
these MAP parameter estimates to the logistic model.
The logarithm of a chimera’s long-term stability (AUC) was modeled with a Bayesian linear
regression model, which consists of a Gaussian likelihood function with a zero-mean, isotropic Gaus-
sian prior on coefficients [156]. The measurement noise and prior variance were estimated from the
data by maximizing the marginal likelihood function. With these hyperparameters, MAP estimates
for each block’s contribution to long-term chimera stability were found in closed-form.
3.4 Results
3.4.1 SCHEMA library design
Human Arginase I (hArgI) and human Arginase II (hArgII) were chosen to be the parent sequences
for the recombination library. These human isozymes, which share 61% sequence identity, were
chosen in order to minimize the immunogenicity of the resulting chimeras, as required for therapeutic
applications. The combinatorial library was chosen to have seven recombination sites (eight sequence
blocks), resulting in a total of 256 (28) chimeric arginases. The SCHEMA disruption of a chimeric
protein is based on a residue-residue contact map representation of a protein structure [73]. The
trimeric structure of hArgII (PDB ID: 1PQ3) was used to prepare this contact map, which included
both intra- and inter-subunit contacts. The RASPP algorithm was used to identify libraries that
minimized the average SCHEMA disruption at various levels of mutation [157], and we selected a
library that balanced deleterious interactions with sequence diversity. Based on the modest average
SCHEMA disruption (〈E〉 = 16) and results from past libraries, we expected approximately half
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the chimeras within this library to be functional arginases. The sequences within this library were
diverse: on average chimeras differed by 60 mutations (as low as 6 and as high as 120). These
chimeras were also novel: the average mutational distance from the parental arginase sequences is
40.3.
The chimera blocks chosen for the arginase recombination library are illustrated in Figure 3.1.
The arginase superfamily is characterized by a trimeric quaternary structure composed of 3-layer
(αβα) sandwich subunits. Residues within chimera blocks 5, 6, and 8 form the trimer interface,
and in each subunit’s central parallel β-sheet seven of eight strands come from different blocks.
Substrate recognition is achieved by several loops that flank the active site in addition to numerous
water-mediated hydrogen bonds [158]. Within the library, each of these ‘specificity’ loops is located
in different blocks. The residues that coordinate the catalytic binuclear manganese cluster are
conserved in the parents, but the surrounding, second-shell residues come from chimera blocks 3, 4,
7, and 8. When these sequence fragments are shuffled within the library, new residue combinations
will possibly contribute to the diversification of multiple arginase properties.
3.4.2 Generation of an informative set of chimeric arginases
Studying sequence-function relationships within recombination libraries using randomly selected
chimeras requires constructing and characterizing a large number of sequences [86]. Systematically
chosen chimera sets are more effective than randomly chosen ones, but still lack efficiency due to the
significant proportion of nonfunctional sequences which provide little information about sequence
properties [151]. Nonfunctional sequences can be avoided by one-factor-at-a-time experimental de-
signs, which avoid disruptive interactions, but these designs result in highly skewed data sets [159].
Here, we present a two-step active learning algorithm that efficiently identifies an informative set
of functional chimeras by first training a functional status classifier and then using this classifier to
guide an experimental design.
The first step of the algorithm involves finding an informative set of chimeras for a logistic
regression functional status model. Here, we chose a set of eight chimeras that maximized the mutual
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information between the chosen set and the remainder of the library (see Methods). These eight
chimeras were synthesized and expressed (see Methods). As expected, only half produced functional
arginases. With this functional status information, we trained a Bayesian logistic regression model
to predict the probability a chimera will function for all sequences within the library.
The second step of the algorithm consists of finding a highly informative set of functional chimeric
arginases. With the predictions from the logistic regression model, we can select sequences that
maximize the expected value of the mutual information between the chosen set and the remainder
of the library (see Methods). This objective was chosen to simultaneously find sequences that are
both informative and have a high probability of being functional. We selected a set of four chimeras
that maximized the expected value of the mutual information. These sequences were synthesized,
expressed, and all yielded functional enzymes.
Our final data set (Table 3.1) consists of a highly informative set of 13 functional arginases (2
parents and 11 chimeras). Within this set of sequences, each parent at each block was typically
observed multiple times, and 103 of the 112 possible block pairs are observed. Some blocks, such
as block 4 parent 1, were under-represented because they contributed to loss of function and were
therefore avoided in the second step of the sequence selection algorithm. Most importantly, the
set comprised a full-rank parameter covariance matrix, allowing for accurate parameter estimation
with linear regression. In the following section we use chimera-block linear regression to explore
sequence-function relationships within the arginase library.
3.4.3 Regression model for long-term stability
Many of the chimeric arginases exhibited a biphasic loss of activity with time, which can be attributed
to kinetic differences between the two metal-binding sites [149, 160]. To account for all enzymatically
active forms of the arginases, we quantify the long-term stability as the area under the normalized
inactivation curve (AUC). The long-term stability of all ten enzymes within the designed set of
sequences was measured (see Methods) and is presented in Table 3.1. A Bayesian linear regression
model was used to relate sequence fragments to the experimentally measured AUC (see Methods).
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This model fits the experimental data well (r = 0.97) as seen in Figure 3.2A. The block regression
parameters are given in Table 3.2. To validate the linear regression model, we designed two additional
chimeric arginases (SCHEMA O and P) that were predicted to have enhanced long-term stability.
These sequences were synthesized and characterized. The regression model showed good predictive
ability (Figure 3.2A) and both sequences are more stable than 80% of the other chimeric arginases.
From the regression analysis, the most stabilizing sequence element is block 3, where substituting
parent 1 for parent 2 is estimated to increase a chimera’sAUC by 66%. Closer inspection of the amino
acid sequences of this important chimera block revealed an abundance of charged residues, which led
us to consider how a chimera’s isoelectric point may contribute to long-term stability. The chimera’s
estimated isoelectric point [161, 162] shows a striking negative correlation (r = −0.90, p < 0.001)
with AUC, Figure 3.2B. Here, chimeras with greatest net charge under the assay conditions (pH
7.4 and 37 ◦C) were the most stable while those closer to their isoelectric point exhibited faster
inactivation.
3.4.4 Factors contributing to arginase inactivation
Using our diverse set of chimeric arginases, we explored how additional factors, besides isoelectric
point, contribute to arginase inactivation under physiological conditions. The melting temperature
for all sequences was measured (see Methods) and is shown in Table 3.1. These melting temperatures
show no significant correlation with long-term stability (r = −0.05, p = 0.87). This suggests
that arginase inactivation is minimally influenced by thermodynamic stability since the melting
temperature of a protein is closely related to its Gibbs free energy of unfolding [163].
In another set of experiments, we measured the long-term stability of the chimeric arginases in
the presence of excess manganese (500 µM MnCl2) (Table 3.1). Surprisingly, this excess manganese
typically increases a chimera’s long-term stability more than twofold, indicating that arginases inac-
tivate significantly more slowly under these conditions. This suggests that the manganese-free form
of arginase is irreversibly inactivated, or on route to irreversibly inactivated states (see Discussion).
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3.4.5 Correlation of relative metal affinity and catalytic efficiency
For all chimeric arginases, we performed Michaelis-Menten kinetic measurements (see Methods) and
estimated their catalytic efficiency (kcat/Km) (Table 3.1). From these data, we found a compelling
correlation between an arginase’s relative metal affinity and its catalytic efficiency (r = 0.82 and
p = 0.015), where enzymes with low metal affinity tend to have the greatest catalytic efficiency
for L-Arg hydrolysis (Figure 3.3). Here, we estimate the relative metal affinity of arginases as the
difference between the long-term stability in the presence of excess manganese (AUCMn) and the
long-term stability at physiological conditions (AUC). Arginases with a high affinity for metal
will have a small difference (AUCMn − AUC) because excess manganese has little affect on their
inactivation rate. A similar correlation has been observed within a set of Cu2+ complexes [164]. In
this study, the authors found the stability of a Cu2+ complex to be inversely related to its rate of
glycine methyl ester hydrolysis, indicating that more stable complexes lower the Lewis acidity of
the Cu2+ ion. Likewise, arginases that bind Mn2+ more tightly may have reduced Lewis acidity in
coordinating substrate or water ligands, and therefore diminished catalytic efficiency.
3.5 Discussion
The combination of structure-guided SCHEMA recombination and an efficient active learning pro-
cedure has generated a highly informative set of chimeric arginases. The high level of sequence
diversity within this set of sequences translates into functional diversity: many of the measured
properties are outside the range displayed by the two parents (Table 3.1). Site-directed recombina-
tion libraries provide unique data sets for studying sequence-function relationships, offering distinct
advantages over sets of point mutants or naturally existing proteins. The effects of point mutations
are frequently too small to resolve experimentally, and the large numbers of neutral mutations in
naturally existing proteins make it difficult to pinpoint the basis of functional differences. In con-
trast, libraries of chimeric proteins contain an intermediate level of sequence diversity and mutational
changes are observed in multiple sequence backgrounds. Additionally, the additive structure of the
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recombinational landscape allows linear regression models to efficiently identify sequence features of
interest.
Within this data set, a linear regression model helped identify the strong negative relationship
between a chimeric arginase’s isoelectric point and its long-term stability (r = −0.90, p < 0.001).
Recombination of hArgI and hArgII (pI = 6.8 and 5.7, respectively) generated a set of functional
chimeras with isoelectric points ranging from 5.5 to 7.5. Since the long-term stability experiments
were performed at physiological pH (7.4), chimeras with the greatest net charge (low pI) displayed
the greatest stability. This relationship between a protein’s net charge and its stability has been
observed numerous times. A large survey across multiple protein families found many proteins to
be less stable near their isoelectric point [165]. Similarly, engineered ribonuclease variants show
decreased solubility and increased aggregation near their isoelectric point [166, 167]. Our proposed
mechanism of arginase inactivation at physiological conditions is depicted in Figure 3.4. Based on
the correlation between a chimera’s isoelectric point and long-term stability (Figure 3.2B) and the
frequently observed aggregation during purification and characterization (not shown), we believe
that the irreversible loss of catalytically active arginase at physiological conditions is dominated by
protein aggregation, rather than thermodynamic stability. More negatively charged arginases resist
the tendency to aggregate by electrostatic repulsion, providing longer enzyme lifetimes. Additionally,
we find the rate of this aggregation process to be strongly metal-dependent: excess manganese
typically increases the long-term stability more than twofold. This suggests the metal-free arginases
are more prone to aggregation and therefore are the primary route to inactivation. Based on this
mechanism of inactivation, future arginase engineering efforts should be focused on increasing metal
affinity and preventing aggregation. However, increasing an arginase’s metal affinity may come at
the cost of reduced catalytic efficiency as described above (Figure 3.3). ‘Supercharging’ proteins
by replacing numerous surface residues with charged residues [168], is an engineering method for
preventing aggregation and may provide a simple strategy for designing arginases with exceptional
long-term serum stability.
Hyperargininemia patients have elevated serum L-Arg levels that range from 600–900 µM [169], in
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contrast to normal reference values of 50–150 µM [170]. Arginase replacement therapy is a potential
treatment modality for patients suffering from the neurotoxicities associated with hArgI deficiencies.
Since hArgI has been under investigation as an antineoplastic agent, its serum retention time has
been pharmacologically optimized via PEGylation, resulting in dose dependent L-Arg depletion in
rats for up to days at a time [171]. However, the desired kinetic parameters for treating cancer
(very low L-Arg) are different than those required for treating hyperargininemia patients, where the
goal is long-term reduction of L-Arg to non-pathological levels. For hyperargininemia treatment, the
most crucial pharmacological parameter is an arginase’s long-term serum stability, which determines
the patient’s dosage intervals. The SCHEMA K variant, identified in this study, has a stable linear
decay rate of only 1% per hour when loaded with Mn2+, which is ideal for introducing long-term
basal arginase activity. A simple model suggests that a single dose of SCHEMA K could maintain
L-Arg levels in hyperargininemia patients within the normal range for five days longer than a single
dose of the hyperactive (but less stable) Co2+-loaded hArgI.
The ability to design enzymes that are customized to specific reaction conditions is of significant
interest to biomedical science. SCHEMA recombination provides a diverse sampling of the protein
fitness landscape, revealing features that cannot be observed by traditional biochemical methods.
These data sets provide a unique opportunity to explore the relationships between protein sequence
and protein function, providing principles that can be used to engineer highly-optimized protein
sequences.
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3.6 Figures and Tables
Figure 3.1: Arginase chimera library block boundaries. (A) Arginase three-dimensional structure
with SCHEMA blocks represented by different colors. The trimer interface is shown as a transparent
surface. (B) Contact map displaying residue-residue contacts that could be broken upon recombina-
tion. The colored squares correspond to the block divisions of the library. (C ) Secondary structure
diagram showing the chimera library block divisions.
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Figure 3.2: Arginase long-term stability. (A) Bayesian linear regression model for AUC. Green
and blue circles correspond to the parents and chimeras (respectively) within the initial data set
(r = 0.97 and p < 0.001). Red stars represent the model’s predictions on the validation set. (B)
Correlation between isoelectric point and AUC (r = −0.90 and p < 0.001).
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Figure 3.3: Correlation between relative metal affinity (AUCMn − AUC) and catalytic efficiency
(kcat/Km), r = 0.81 and p = 0.015.
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Figure 3.4: Schematic of potential arginase inactivation mechanisms. A) Loss of first equivalent
of bound metal and decrease of some activity, B) loss of second equivalent of bound metal and
loss of all activity, C) equilibrium between folded and unfolded states, D) irreversible precipita-
tion/aggregation.
Chimera
Name Blocks AUC AUCMn Tm
◦C kcat/Km mM−1s−1
hArgI 11111111 2929 5326 81.0 130± 20
hArgII 22222222 4042 80.6 114± 18
SCHEMA A* 11112122
SCHEMA B 12122211 3664 2927 81.2 19± 7
SCHEMA C 11221221 3872 5838 68.1 53± 10
SCHEMA D* 12211212
SCHEMA E* 21121221
SCHEMA F* 21212211
SCHEMA G* 22111221
SCHEMA H 22221111 3089 4109 68.5 31± 7
SCHEMA I 11122222 994 5890 82.5 138± 19
SCHEMA J 21122121 1654 67.5 27± 11
SCHEMA K 11222112 4710 6188 70.7 42± 8
SCHEMA L 22121121 1311 3408 78.9 23± 10
SCHEMA M 21222111 2828 70.5 19± 7
SCHEMA N 21121111 1417 74.3 39± 10
SCHEMA O 12122122 4005 71.2 45± 11
SCHEMA P 12222112 3901 70.6 36± 5
Table 3.1: Chimeric arginase data. SCHEMA A-N comprise the designed set of highly informa-
tive sequences, and SCHEMA O and P are the sequences used to validate the regression model.
Asterisked sequences had no detectable protein expression.
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parameter
name log(AUC)
Reference 7.96
Block 1 -0.27
Block 2 0.12
Block 3 0.50
Block 4 -0.38
Block 5 0.19
Block 6 0.31
Block 7 -0.14
Block 8 0.18
Table 3.2: Parameters for the arginase long-term stability regression model. The parameters repre-
sent the effect of substituting parent 2 for parent 1 at a given block on the logarithm of the AUC.
The most significant substitution occurs at block 3, which is shown in bold.
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Chapter 4
Random field model of the protein
recombinational landscape
4.1 Abstract
Intragenic recombination events contribute to the evolution of natural genomes, yet it is unclear what
advantage this molecular diversification mechanism provides over mutation. Experimental results
from libraries of proteins made by recombination have revealed the extreme tolerance of proteins
to recombination with homologous sequences and that sequence fragments make largely additive
contributions to a protein’s biophysical properties. Here, we develop a random field model to describe
the statistical features of the subset of protein space accessible by recombination, which we refer
to as the recombinational landscape. This model shows quantitative agreement with experimental
results compiled from nine recombination libraries. We use the random field model to understand the
origin of a protein’s tolerance to recombination and the additive effects of sequence fragments. The
results reveal a recombinational landscape that is enriched in functional sequences, with properties
dominated by a large-scale additive structure. Intragenic recombination explores a unique subset of
sequence space that may promote rapid molecular adaptation.
4.2 Introduction
The ubiquity of sex and recombination suggests these mechanisms must play a significant role in
evolution, yet their benefit is still highly debated [172, 173]. Intragenic recombination events generate
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chimeric proteins, which are believed to make important contributions to allelic diversity in natural
populations [174, 175, 176, 177]. In the laboratory, the benefits of intragenic recombination of
homologous proteins have been clear: it provides a powerful method for engineering new proteins
that are functionally diverse while still having a high probability of functioning [75, 178]. The
resulting chimeric proteins have been useful for understanding protein thermostability [179, 151],
divergence of enzymatic function [180], and cellular signaling responses [181], shedding light on how
these properties may evolve in Nature and how best to engineer them in the laboratory.
Previously, we have developed techniques for the design, construction, and characterization of
large libraries of chimeric proteins [73, 157, 182]. Briefly, libraries are designed (crossover sites are
selected) to minimize the number of novel residue contacts generated upon recombination (SCHEMA
disruption), which tend to be deleterious to protein function. To date, the Arnold lab has tested
nine such site-directed recombination libraries: a library of chimeric bacterial β-lactamases (βlac13
and βlac), bacterial cytochrome P450s (P450), bacterial family 9 cellulases (Cel9), fungal family
5 cellulases (Cel5), bacterial family 48 cellulases (Cel48), fungal class I cellobiohydrolases (CBHI),
fungal class II cellobiohydrolases (CBHII), and human arginases (Arg) (Table 4.1). Each library,
which typically consists of thousands of new sequences, provides a glimpse of the protein fitness
landscape and can reveal important aspects of its structure. Here, we refer to the subset of the
protein fitness landscape that is accessible by recombination as the recombinational landscape.
These recombination libraries have highlighted the enrichment of functional sequences within
the recombinational landscape: most libraries contain a significant proportion (∼20–50%) of func-
tional sequences. For comparison, random mutation libraries with the same number of mutations
are estimated to contain 10–20 orders of magnitude fewer functional sequences [37, 36, 43]. The
accumulation of random mutations decreases the probability of functional sequences exponentially,
whereas mutations generated by recombination always move towards other functional sequences
and are therefore significantly more conservative [56]. For this reason, intragenic recombination
effectively explores a functional ridge through the mostly nonfunctional protein sequence space.
These libraries have also revealed significant variation in thermostability [86, 151] and other
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properties [85] within the recombinational landscape. We have observed that a majority of this
variation can be explained by additive effects [86, 151, 159]. This additivity has been used to
efficiently engineer highly-optimized chimeric proteins for a variety of applications. The additive
structure, or lack of epistasis, within the recombinational landscape may contribute to the ability of
intragenic recombination to traverse the protein fitness landscape.
We would like to understand the features of the recombinational landscape that contribute to
its extreme enrichment in functional sequences and its additive structure. Since the details of the
true protein recombinational landscape are unknown, we develop a random field model which cap-
tures its statistical properties. Random field models are effective at describing statistical features
of uncertain, spatially-organized functions, with applications ranging from geostatistics to image
analysis [183, 184, 185]. This versatile class of models has also been used to describe fitness land-
scapes [186], the best known example being Kauffman’s NK-model [187]. Our random field model
for the recombinational landscape is based on a physics-inspired energy function and parametrized
with experimental data. Using this model, we derive approximations for the expected value of the
proportion of functional sequences within a recombination library and the degree of landscape addi-
tivity, and relate these quantities back to experimental observations. We discuss how the structure
of the recombinational landscape may contribute to the utility of intragenic recombination as a
evolutionary mechanism and the implications for the design of future recombination libraries.
4.3 Results
4.3.1 Random field model for the protein recombinational landscape
Consider a pairwise, residue-level energy function to describe the large number of intramolecular
interactions that stabilize protein structures. These simplified contact potentials have been used
in the past for protein folding simulations and structure prediction [188, 189, 190]. Assuming a
fixed structure (set of contacts), the energy of any sequence can be determined from the sum of
energy terms associated with the sequence’s specific residue combinations at every pair of contacting
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residues. For chimeric proteins we distinguish between two types of contacts: parental (P) contacts,
which are residue pairs observed in at least one of the parents, and novel (N) contacts, which are
not. With this model, the energy of any chimeric protein c is given by
Ec =
∑
i
aic,P ε
i
P +
∑
i
aic,N ε
i
N , (4.1)
where εiP is the energy term associated with parental contact i, ε
i
N is the energy term associated
with novel contact i, and aic,P and a
i
c,N are binary variables which indicate the specific residue pairs
for each contact i in chimeric protein c. Since the specific values of εiP and ε
i
N are unknown, we
define the independent and identically distributed random numbers Pi and Ni, distributed with
means and variances
Pi ∼ µP , σ2P (4.2)
Ni ∼ µN , σ2N . (4.3)
Substituting these random variables into equation 4.1 defines a random energy function associated
with any chimeric protein c
Ec =
∑
i
aic,P Pi +
∑
i
aic,N Ni. (4.4)
This random energy function is defined over the parental subspace Sp, the set of all sequences that
can be generated by recombining the parent sequences, which specifies the random field
{Ec : c ∈ Sp}. (4.5)
The expected value of the random field at chimeric protein c is
E[Ec] = µP
∑
i
aic,P + µN
∑
i
aic,N , (4.6)
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and the covariance between any two sequences is
Cov[Ec1, Ec2] = σ2P
∑
i
aic1,P a
i
c2,P + σ
2
N
∑
i
aic1,N a
i
c2,N . (4.7)
This random field model provides a statistical description of the recombinational landscape. Most
importantly, the covariance structure captures our intuitive notion of protein similarity: proteins
with similar sequences have similar structures and therefore similar properties.
To parametrize the random field model, we must determine the mean energy µP and variance
σ2P of parental contacts and the equivalent parameters µN and σ
2
N for novel contacts. Using a large
binary functional status data set from the cytochrome P450 recombination library [80], these four
parameters were estimated by maximizing a marginalized likelihood function (see Methods). If we
assume the functional status data depends on a sequence’s Gibbs free energy difference from the
nonfunctional state, these estimated parameters can be interpreted as Gibbs free energy differences
(in arbitrary units), see Supplementary Material. As expected, parental contacts are slightly stabi-
lizing (µP = -0.66 AU), novel contacts are significantly destabilizing (µN = 52.06 AU), and both
classes of contacts show significant variation relative to their means (σP = 51.94 AU and σN =
58.33 AU). Estimating these parameters on recombination data from other protein families yields
qualitatively similar results (Supplementary Material). This is not surprising considering that most
proteins are marginally stable [33] and mutations (novel contacts) tend to be deleterious to protein
function [37, 36, 43]. In the following sections, this parametrized random field model is used to
interpret experimental observations from protein recombination libraries.
4.3.2 Effect of homologous substitutions on protein function
Previously, we compared the effects of random versus homologous amino acid substitutions [56].
Whereas the fraction of functional sequences declines exponentially with increasing random muta-
tions [37, 36], that fraction varies log-parabolically with the number of substitutions taken from
another functional parent. For two parents, the log-parabolic behavior appears because accumulat-
ing homologous substitutions must eventually convert one functional parent sequence into another
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functional parent sequence. Random mutagenesis carried out on β-lactamase measured a probability
that a single random mutation will preserve function (neutrality) of ∼0.54, whereas recombination
experiments on the same enzyme indicated the probability a homologous substitution will preserve
function (recombinational tolerance) is ∼0.79 [56]. Considering the relatively high recombinational
tolerance and the log-parabolic dependence, homologous substitutions are significantly more conser-
vative than random mutations. Here, we evaluate the effects of homologous substitutions using the
random field model and compare the results to our previous analysis.
Analyzing the two-parent, thirteen-crossover β-lactamase library (βlac13) [191], the probability
of functioning for each chimera was estimated by evaluating the logistic function at the expected
value of the random field. These probabilities were averaged within 15 groups binned by the number
of homologous substitutions. The same analysis was also performed on simulated random substitu-
tions, where a novel contact was any residue pair not seen in the two β-lactamase parents. After
reanalyzing the chimeric β-lactamase data to account for library construction errors (see Methods),
the random field model shows excellent agreement with the experimental substitutions generated
by recombination and randomly (Figure 4.1A). As observed previously, the fraction of functional
sequences shows a steep exponential decline with random mutations, while functionality displays a
log-parabolic dependence with homologous substitutions.
With the random field model, we can now explore the influence of recombination parameters such
as parent sequence identity and the number of sequence crossovers on the shape of the recombination
curve shown in Figure 4.1A. As parent sequence identity decreases, the curve stretches to a higher
level of mutation and to a lower fraction functional (Figure 4.1B), as was shown previously using
lattice protein simulations [56]. As the number of sequence crossovers decreases, the log-parabolic
curve shifts towards a higher fraction functional (Figure 4.1C ), necessarily approaching a flat line
when there are no crossovers. This highlights an improvement to our previous analysis because it
shows how the estimated recombinational tolerance depends on the number of sequence crossovers.
To estimate the effects of homologous substitutions, independent of the number of crossovers,
we sampled random homologous substitutions and calculated the average probability of folding at
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each level of mutation (Figure 4.1C ). The effects of random homologous substitutions still follow
the log-parabolic curve, although this curve dips over five orders of magnitude lower than the ex-
perimentally characterized β-lactamase library [191]. Fitting the log-parabolic equation [56], we
estimate the recombinational tolerance of random homologous substitutions to be ρ = 0.68 ± 0.01.
The recombinational tolerance is still greater than the neutrality, and thus homologous substitutions
are still more conservative than random substitutions, but to a lesser degree than previously esti-
mated. From this analysis, we propose an updated model for the conservative nature of intragenic
recombination which includes contributions from homologous substitutions (as shown previously) as
well as groups of coevolved residues varying simultaneously. The latter effect is expected to play a
major role in natural evolution where the number of intragenic crossover events per generation is
likely to be small.
Surprisingly, the random field model for the recombinational landscape also works reasonably
well to describe the effects of random mutations. With this model, random mutations will frequently
result in a non-parental amino acid and therefore cause deleterious novel interactions with all con-
tacting residues. This simplified model recapitulates the exponential decline in functional sequences
which was observed with the experimental β-lactamase data (Figure 4.1A) and other mutational
studies [37, 36, 43]. In addition, this model trivially captures the well-known fact that surface mu-
tations tend to be less deleterious than mutations in the protein core, because core residues tend to
have many more contacts. With a single model to explain the effects of both random and homol-
ogous substitutions, we can understand their differences in terms of residue contacts. The number
of deleterious contacts generated by a homologous substitution is less than or equal to the number
generated by a random mutation at the same position, with equality rarely being achieved. This
explanation is consistent with hypothesis that homologous substitutions are conservative because
they have been previously selected to be compatible with the protein fold [56].
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4.3.3 Effect of intragenic recombination across protein families
The factors that determine a protein family’s tolerance to recombination events are unknown. Table
4.1 reports the fraction of functional sequences compiled from nine recombination libraries, repre-
senting protein families of different functions, sizes, and fold classes. Eight of these libraries were
designed with the intent of maximizing the fraction of functional sequences, yet there is significant
variation (2–3 fold) in this fraction between libraries. While some of this variation is likely due to
experimental differences in classifying functional sequences from different enzyme classes, we expect
a significant proportion of this variation to arise from differences in parent fold, parent sequence
identity, and the specific crossover locations chosen in the library design. Using the random field
model, we derive an approximation for the expected value of the fraction of functional sequences
within a recombination library and use this to understand the factors that contribute to a protein
family’s tolerance to recombination.
Consider a recombination library L, generated by recombining sequence fragments from p parental
sequences at n crossover sites. We refer to the sequence fragments between crossover sites as ‘blocks’;
therefore the library is composed of b sequence blocks (b = n+ 1). Assume a Gaussian distribution
of sequence energies within the library, a good approximation when the library size (pb) is greater
than a few hundred. Here, the distribution of sequence energies within recombination library L can
be described by its mean
ML =
1
pb
∑
c∈L
Ec (4.8)
and variance
VL =
1
pb
∑
c∈L
(Ec −ML)2. (4.9)
The fraction of functional sequences within library L is given by evaluating the Gaussian cumulative
distribution function at zero, that is, the fraction of sequences having an energy less than 0.
Since the specific energy terms that shape the recombinational landscape are unknown, we use
the random field model to calculate the expected value of the fraction of functional sequences by
integrating over all possible energy terms εiP and ε
i
N . The expected value of the library mean is
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given by
E[ML] =
1
pb
∑
c∈L
E[Ec] = µPnC + (µN − µP )
∑
c nN,c
pb
(4.10)
where nC is the total number of contacts and nN,c is the number of novel contacts in chimera c.
The expected value of the library variance is given by
E[VL] =
1
pb
∑
c∈L
[
(E[Ec]− E[ML])2 + Var[Ec] + Var[ML]− 2 Cov[Ec,ML]
]
(4.11)
More specific details of Var[Ec], Var[ML], and Cov[Ec,ML] are given in the Supplementary Material.
With these two expectations, the expected value of the fraction of functional sequences can be
approximated with a Taylor series expansion
E[fF ] ≈ 1
2
[
1− erf
(
E[ML]√
2 E[VL]
)]
, (4.12)
where erf is the error function and the details of this Taylor series are given in the Supplementary
Material. All expectations and approximations were verified with extensive Monte Carlo sampling.
The expected value of the fraction of functional sequences within a library E[fF ] shows quan-
titative agreement with the experimentally determined values, as shown in Figure 4.2A. The Cel9
library is an outlier, which may be the result of the extreme electrostatic clashes that are present
in a significant proportion of the library (discussed in [192]). Within the random field model, both
parental and novel contacts contribute to the distribution of sequence energies within a recombina-
tion library and therefore the fraction of functional sequences. The highly deleterious novel contacts
dictate the mean of the library, while parental contacts, which typically outnumber novel contacts
50–100-fold, dominate the library variance. This suggests recombination events can cause loss of
function by two independent mechanisms: (1) by introducing new deleterious interactions between
sequence fragments, or (2) by introducing sequence fragments which already contain deleterious
interactions.
To better understand the variation in the fraction of functional sequences between the nine
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recombination libraries, we sampled random libraries, calculated E[fF ], and estimated the contri-
bution from protein fold, specific breakpoints, and parent sequence identity. For each protein fold,
we sampled 100 random two-parent sequence alignments with sequence identity ranging from 10–
90%, and for each of these alignments we sampled 100 random 7-crossover libraries, for a total
of 90,000 libraries. A three-way analysis of variance shows the protein fold (p < 0.001), specific
breakpoints (p < 0.001), and parent sequence identity (p < 0.001) all make significant contribu-
tions to the E[fF ]. Estimating the variance components, we find parent sequence identity to be
the main determinant of E[fF ] (contributing 92% of the variance), followed by specific breakpoints
(4%), and protein fold (2%). This strong dependence on parent sequence identity is the result of the
approximately exponential increase in the number of deleterious novel contacts as parent sequences
diverge. Interestingly, when the parent sequence identity is low, most of the nonfunctional chimeric
proteins are the result of inactivation mechanism (1), but when the parent sequence identity is high,
nonfunctional sequences are usually the result of inactivation mechanism (2). This is consistent with
the observation of high mutual information between a chimeric protein’s functional status and its
number of novel contacts for the β-lactamase library (low parent sequence identity) and the low
mutual information observed for the P450 library (high parent sequence identity) [193].
Using the random field model, we would like to evaluate the effectiveness of the library design
objective (to minimize the average number of novel contacts 〈Esch〉) in producing libraries of func-
tional chimeric proteins. At a fixed library variance, the model shows a super-exponential decline
in the fraction of functional sequences with increasing 〈Esch〉, similar to the trends seen in random
mutation libraries with an increasing number of mutations [37, 36, 43]. Since the entire range of
〈Esch〉 is not accessible for a particular set of parent sequences, we would like to understand the
effect of minimizing 〈Esch〉 on fF over randomly generated libraries with the same parents, number
of sequence blocks, and block size distribution. For all nine recombination libraries, we generated
1000 random libraries with similar features and estimated the fraction of functional sequences within
each. The model estimates a 1.3–5.8-fold increase in the fraction of functional sequences from 〈Esch〉-
minimized libraries over average (2–19-fold increase over the least functional libraries). As expected,
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the largest benefit is seen for libraries with more diverged parents (higher 〈Esch〉), with diminishing
returns as the parents become more similar (as 〈Esch〉 becomes lower). As 〈Esch〉 goes to zero, the
model predicts some non-zero fraction of nonfunctional sequences will remain, typically 10–30%.
These nonfunctional sequences are present because some recombination events combine multiple
deleterious parental contacts within a single protein.
4.3.4 Additive structure of recombinational landscape
Perhaps the most surprising finding from these recombination experiments has been the additive
structure of the recombinational landscape [86, 151, 159]. Linear models are able to explain a
majority of variation in thermostability and other properties, suggesting that sequence elements
make largely independent, additive contributions to a protein’s overall measured properties. In
quantitative genetics, this is referred to as additive genetic variance, which according to Fisher’s
fundamental theorem of natural selection determines a population’s response to selection [194, 195].
Additive landscapes are easier for evolving populations to climb because they are not stymied by
rugged, epistatic features. This additivity has been especially useful for engineering optimized
chimeric proteins because a small sampling of sequences provides sufficient information to make
accurate predictions across the entire library [86, 151, 159]. Here, we use the random field model to
understand the origin of the additive structure within the recombinational landscape.
Within the recombination library L described in the previous section, the total variance can
be partitioned into additive and epistatic components (VL = VA + VE). We define the landscape’s
degree of additivity A as the fraction of the total variance that is explained by additive effects
A ≡ VA
VL
. (4.13)
This dimensionless quantity, which ranges from 0 to 1, describes the smoothness of the landscape,
and is inversely related to the landscape ‘ruggedness’ defined in [196]. For four of the recombination
libraries, there is sufficient data to calculate the additivity of the thermostability landscape (see
Methods) and the results are presented in Table 4.1.
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The expected value of a library’s additive variance E[VA] can be found in a similar way as the total
variance (previous section), but only considering the contributions of additive effects (Supplementary
Material). The expected value of the additivity can be approximated with a Taylor series expansion
about E[VA] and E[VL]
E[A] ≈ E[VA]
E[VL]
. (4.14)
All expectations and approximations were verified with Monte Carlo sampling.
The expected value of the landscape additivity E[A] shows close agreement with the experimen-
tally determined values (Figure 4.2B). While the correlation is not statistically significant, due to
the limited data, all the E[A]s are large and within the experimentally observed ranges. In addition,
the five uncharacterized libraries also have large expected additivities (βlac13 = 0.44, βlac = 0.67,
Cel5 = 0.65, Cel9 = 0.94, Arg = 0.82), suggesting this additive structure within the recombinational
landscape may be quite general. Despite being generated by a purely pairwise energy function,
which is by definition epistatic, a majority of the variation within these recombination libraries can
be explained by additive effects. This surprising result can be attributed to two factors: sequence
conservation among the parents and the partitioning of interactions into structural modules. Non-
linear interactions that are conserved among all parents will not contribute to the variation of any
property within the library, and those interactions conserved among some parents will only make
minor contributions. Nonlinear interactions that are partitioned into structural modules will vary
together, and therefore contribute to only additive variation.
Coincidentally, the recombination library design objective, to minimize a library’s average SCHEMA
disruption 〈Esch〉, accounts for sequence conservation and attempts to partition interactions into
structural modules. In fact, the interactions that contribute to epistatic variation are the exact
same interactions counted in SCHEMA disruption, therefore the library design has the effect of
maximizing E[A]. However, sampling 1000 randomly generated libraries with the same parents,
number of sequence blocks, and block size distribution shows minimizing 〈Esch〉 only increases the
additivity modestly (0.05–0.2) over average. Therefore we conclude the additive structure observed
within recombination libraries is a general result of dividing the sequence into fragments, rather
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than the specific crossover sites chosen for the library design.
The additivity exhibited by the random field model does not hold for chimeric proteins that
adopt alternate structures (as described by a contact map). For example, nonfunctional sequences,
which account for a significant proportion of chimeras, will clearly not display additivity in properties
involving protein function. For many properties, such as thermostability (loss of enzymatic function
at elevated temperatures), we have observed additivity because the experimental measurements
require enzymatic activity, which greatly increases the likelihood that a set of enzymes will adopt
the same, or very similar structures. The subset sequences that adopt the same structure is referred
to as a neutral network [197, 35] and this may define the domain of the additivity within the
recombinational landscape.
4.4 Methods
4.4.1 Compiling the chimeric protein data set
The residue-residue contact map for each library was determined by identifying all protein chains
within the Protein Data Bank that share at least 50% sequence identity with any parent. Also
included were three unpublished P450 structures and two unpublished Cel5 structures, for a total
of 88 βlac13, 173 βlac, 91 P450, 39 CBHI, 24 CBHII, 6 Cel5, 16 Cel9, 21 Cel48, and 143 arginase
chains. For each chain, a residue pair was considered contacting if they contained any heavy atoms
within 4.5 A˚. The final contact map for each library is composed of residue pairs that are contacting
in more than 50% of all chains.
The number of functional and nonfunctional chimeric proteins was retrieved from previously
published results: βlac13 [191], βlac [198], P450 [80], CBHI [159], CBHII [151], Cel5 [199], Cel9
[192], Cel48 [200], Arg [201]. The fraction of functional chimeras was estimated using maximum
likelihood and 95% confidence intervals were calculated using the Clopper-Pearson method [202].
We could not accurately estimate the fraction of functional sequences for the CBHI library due to
the extreme bias in the chimera sampling [159]. The results from the βlac13 library were reanalyzed
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to account for library construction errors (see below).
The additivity of the P450, CBHI, CBHII, and Cel48 libraries was calculated using published
thermostability data [86, 159, 151, 200]. For each library, a block-based linear regression model [86]
was parametrized on all the available data. The resulting predictions are unbiased, so the total
variance can be partitioned into explained and residual components. The ratio of the explained
variance to total variance is the additivity A, and in this case is identical to the coefficient of
determination R2.
4.4.2 Estimation of parental and novel contact parameters
Given a data set which maps contact information to binary functional status, we want to estimate
the mean energy µP and variance σ
2
P of parental contacts and the mean energy µN and variance σ
2
N
for novel contacts. The true energy terms εiP and ε
i
N can be integrated out to give the marginalized
likelihood function
p(y|A, µP , σ2P , µN , σ2N ) =
∫∫
p(y|A, εP , εN ) p(εP |µP , σ2P ) p(εN |µN , σ2N ) dεP dεN , (4.15)
where y is the binary functional status and for notational simplicity all parental energy terms εiP
are combined in the vector εP , all novel energy terms ε
i
N are combined in the vector εN , and all
binary indicator variables (aic,P and a
i
c,N ) are combined into the matrix A. The mean and variance
of parental and novel contacts can be estimated by maximizing this marginalized likelihood function.
Since y is composed of binary data, the first term in the integrand is given by the logistic
likelihood function
p(y|A, εP , εN ) =
∏
c
s (ac,P · εP + ac,N · εN )yc s (−ac,P · εP − ac,N · εN )1−yc , (4.16)
where s is the logistic sigmoid function given by s(x) = 1/(1 + exp(x)). Assuming the energy
components are Gaussian distributed, the second and third terms of the integrand are given by
multivariate Gaussian distributions. Since the integral in equation 4.15 is analytically intractable,
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we can approximate it using Laplace’s method [203]. First we approximate the integrand with a
multivariate Gaussian about a stationary point and then we evaluate the Gaussian integral to yield
p(y|A, µP , σ2P , µN , σ2N ) ' p(y|A, εP,0, εN,0) p(εP,0|µP , σ2P ) p(εN,0|µN , σ2N )
(2pi)M/2√|H| , (4.17)
where εP,0 and εN,0 are the stationary points, M is the fixed number of contacts, and H is the Hessian
matrix evaluated at the stationary points. The stationary points were found using Newton’s method
and the marginalized likelihood function was maximized using the Nelder-Mead method.
4.4.3 Reanalyzing β-lactamase data to account for library construction
errors
The 13-crossover β-lactamase library (βlac13) had a significant amount of construction errors [191].
Sequencing of unselected chimeric genes found 9 of 13 to have frame shift mutations [56], which
almost certainly result in inactive proteins. Since a majority of frame shifts are incorporated at
the PCR step during library construction, it is likely these errors are present throughout all con-
structed chimeras [182]. The maximum likelihood estimate for the proportion of correctly con-
structed chimeras is 4/13 = 0.31, with 95% confidence intervals between 0.09 and 0.61 using the
Clopper-Pearson interval [202]. This sequencing data indicates there may be one to three sequence
fragments (chimera blocks) that contain frameshift mutations. Assuming all frame shifts cause
inactivation and exhaustive library coverage (over twelvefold sampling), the fraction of functional
chimeras can be estimated by the number of functional chimeras divided by the number of correctly
constructed chimeras. With these assumptions, we estimate the fraction of functional sequences to
be 7× 10−3 with 95% confidence intervals between 3× 10−3 and 22× 10−3 The same modification
can be performed on chimeras binned by the number of homologous substitutions (Figure 4.1A)
because the construction errors display little relation to the level of mutation.
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4.5 Discussion
By using a statistical description of the protein recombinational landscape, we can gain insight into
the behavior of an astronomical number of sequences, which could not be obtained experimentally or
even by homology-based structural modeling. A probabilistic contact potential was used to specify
the mean energy of individual chimeric proteins and how the energy of any sequence is expected to
co-vary with others (equations 4.6 and 4.7), defining a multivariate probability distribution over all
sequences accessible by recombination. While this random field model provides little information
about specific sequences, it does reveal the large-scale structure of the recombinational landscape,
which we used here to interpret the results from past recombination libraries. Within this random
field, the expected values of various library properties show excellent agreement with experimental
results across multiple protein families. This striking correspondence may arise because a library’s
properties depend on a large number of interactions, and the cumulative effect of these interactions
converges toward the expected value due to the law of large numbers.
The random field model was used to study the enrichment of functional sequences within the
recombinational landscape. As shown previously, we found the tolerance of proteins to recombi-
nation events to be influenced by the conservative effects of homologous substitutions, which have
been previously selected to be compatible with the protein fold [56]. However, a more significant
contribution comes from groups of coevolved residues varying together. This is especially relevant
for understanding natural evolution, where the number of crossover events is relatively low. Eval-
uating the random field model across protein families, we found parent sequence identity to be the
primary determinant for tolerance to recombination, while the specific crossover locations (library
design) and parent fold make statistically significant, but minor contributions.
Using the random field model, we explored the origins of the additive structure within the
recombinational landscape. Both sequence conservation among the parents and the partitioning of
nonlinear interactions into structural modules make significant contributions to this additivity. The
results presented here are for a random field that describes a protein’s free energy difference between
the functional and non-functional states, which is closely related to protein stability. However, the
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results are generally true for any landscape that is generated by higher-order, distance-dependent
interactions, which could include numerous biophysical quantities.
Previous studies of protein fitness landscapes have highlighted the abundance of nonfunctional
sequences [31, 32] and neutral sequence changes [37, 36, 82], suggesting a surface which is mostly
flat and filled with holes [204]. In contrast to this full landscape, the recombinational landscape
contains orders of magnitude fewer ‘holes’ (non-functional sequences). Despite the evidence for
neutrality, the functional variation displayed within recombination libraries reveals the large-scale
structure of the recombinational landscape, which arises from the cumulative effect of multiple
mutations. In addition, most of this functional variation can be explained by additive effects, which
are easily selected upon within evolving populations. While these results were observed in SCHEMA-
minimized libraries, which tend to be optimized for both functional sequences and additivity, the
random field model suggests these properties are generally true for recombination. These SCHEMA-
minimized libraries also emphasize the preference for some crossover sites over others, which could
explain the presence of recombination hotspots in natural genes [205, 177, 206]. The picture of the
recombinational landscape that has emerged from the random field model is a surface enriched in
functional sequences, which displays locally-epistatic behavior but has an overall additive structure.
The evolutionary benefit of intragenic recombination may arise because mutation and recombi-
nation effectively traverse different landscapes. While climbing the landscape by point mutations,
evolution encounters a large number of nonfunctional sequences in addition to epistatic landscape
features. In contrast, recombination explores sequences which are much more likely to be functional
within a landscape containing an abundance of adaptive pathways. Recombination can provide
faster adaptation than point mutation because it generates functional sequences with a large num-
ber of substitutions. Recombination may also find sequences that are inaccessible by adaptive point
mutation, by simultaneously incorporating multiple coupled mutations, essentially ‘jumping over’
epistatic landscape features. A similar effect was recently described for recombination at the genome
level [207], where the authors describe how landscapes arising from high epistasis within genes and
no epistasis between genes strongly favors recombination. Running simulations on these ‘modular’
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landscapes, the authors found recombination to provide an efficient route to genotypes that were
inaccessible by point mutation.
Future recombination libraries could be improved by refining the design objective or pushing the
library design to lower 〈Esch〉 via better optimization. While designing chimeric protein libraries by
minimizing 〈Esch〉 works well, contributing up to a six fold enrichment in functional sequences over
the average (or 30-fold relative to the least functional library), the library design objective could
be improved with a better classification of favorable/unfavorable contacts. The parental and novel
contact parameters estimated above show a significant overlap in density (Supplementary Figure
4.3), suggesting it is relatively common for parental contacts to be as deleterious as novel contacts,
and vice versa. A contact classification that maximized the difference between favorable/unfavorable
contacts would provide a more robust library design objective, resulting in libraries with even greater
numbers of functional sequences. New contact classifications can be explored using the maximum
marginal likelihood estimation method described above, with class separation being quantified by a
statistical distance metric such as the Kullback-Leibler divergence [208].
When the parent sequence identity is high, designing a library to maximize the number of func-
tional sequences becomes less important because any library will contain a substantial fraction of
functional sequences. For example, the random field model predicts a 1.25-fold enrichment in func-
tional sequences for 〈Esch〉-minimized CBHII (pairwise sequence identity: 65%, 67%, 82%) libraries
over randomly generated libraries. For libraries between closely related parents (> 70% identity),
alternative design objectives that seek to maximize the information content of the library, such as
the expected value of the variance, may be more useful. Libraries with maximized variance would
provide more information about the sequence properties of interest and potentially result in more
extreme (highly-optimized) chimeric proteins. Similar ideas could be applied to more specific prop-
erties, such as substrate specificity, where the library design objective could be to maximize residue
variation within the active site.
The most straightforward route to improving recombination library design comes from more ad-
vanced optimization protocols. All libraries discussed above were designed under the requirement
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that chimera blocks be contiguous in sequence, which is very limiting. By removing this design con-
straint, there are often libraries with the same parents, number of blocks, and block size distribution
that have an 〈Esch〉 of zero. Libraries with a 〈Esch〉 of zero are predicted to be between 70–90%
functional, depending on parent sequence identity. For non-contiguous block CBHII libraries, for
example, we estimate a 2.1-fold enrichment in functional sequences over random libraries, compared
to the 1.25-fold increase estimated for contiguous block libraries. In addition, as 〈Esch〉 approaches
zero, the library additivity A goes to one because all quadratic interactions are partitioned into struc-
tural modules. This suggests the predictive ability of linear regression models would be even more
accurate for these non-contiguous block libraries. On the downside, non-contiguous block libraries
cannot be made following standard construction protocols due to the large number of sequence frag-
ments. Typically, these libraries would require total gene synthesis of each desired member, which
makes constructing the full libraries prohibitively expensive.
Intragenic recombination is a powerful molecular diversification mechanism. The ubiquity of
intragenic recombination in nature and experimental evidence from protein recombination libraries
suggest that it provides distinct advantages over point mutation. In naturally evolving populations,
these two genetic variation mechanisms work together. Mutation provides new innovation, while
recombination efficiently sorts through the large combinatorial space of existing diversity. A better
understanding of how to balance mutation and recombination could assist in engineering highly-
optimized proteins.
4.6 Supplementary Material
4.6.1 Parameters estimated with the logistic likelihood function are pro-
portional to Gibbs free energy differences
Here, we show the parameters estimated by maximizing the logistic likelihood function can be
interpreted as Gibbs free energy differences (in arbitrary units) from the nonfunctional state. For
notational simplicity, we combine all energy terms (εiP and ε
i
N ) into the vector ε and all binary
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indicator variables (aic,P and a
i
c,N ) into the vector ac. With this notation, the energy of chimera c
is Ec = ac · ε.
Within a binary functional status data set D, we only observe if a chimeric protein c is functional
or not, which can be represented by the step function
yc =

1 if ∆Gc < 0 (functional),
0 if ∆Gc ≥ 0 (nonfunctional),
(4.18)
where ∆Gc is the Gibbs free energy difference between chimera c’s functional and nonfunctional
states. The logistic likelihood function of data set D is
p(D|ε) =
∏
c∈D
s(ac · ε)ycs(−ac · ε)1−yc , (4.19)
where the data set D consists of examples of the mapping from ac to yc, and s is the logistic sigmoid
function given by s(x) = 1/(1 + exp(x)). Note this logistic function is a reflection about the origin
(x = −x) of the standard logistic function because negative energy is favorable. Maximizing this
likelihood function with respect to ε finds the parameter set that was most likely to generate the
observed data.
This maximum likelihood (ML) parameter estimate can be found by minimizing the negative
log likelihood, which is a strictly convex function [209]. This convexity ensures that any parameter
set where the gradient of the negative log likelihood function is zero in all directions is a global
minimizer. The gradient of the negative log likelihood is given by
∇− log p(D|ε) =
∑
c∈D
ac [s(ac · ε)− yc] . (4.20)
This gradient is clearly equal to zero when s(ac·ε) = yc for all c ∈ D. This occurs when ac·αε = ∆Gc
for large α, and is approximately true for all positive α. Assume the Gibbs free energy difference
can be decomposed into each contact’s free energy contribution ∆Gc = ac · g. Then the maximum
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likelihood (ML) parameter estimate is simply a linear scaling these Gibbs free energy terms
εML =
1
α
g. (4.21)
4.6.2 Estimation of contact parameters on other recombination libraries
The parental and novel contact parameters (µP ,σ
2
P ,µN ,σ
2
N ) were estimated on three additional data
sets and all the results are presented in Supplementary Table 4.2. While the absolute values of the
parameters are quite different, the random field model is unchanged by linear rescaling (changing
units). Therefore, only the relative values of the parameters are important (depicted in Supplemen-
tary Figure 4.3). Within all four parameter sets, we see the mean of parental contacts is slightly
favorable and novel contacts are significantly deleterious. The means of these two distributions are
separated by approximately one standard deviation, indicating it is relatively common for parental
contacts to be as deleterious as novel contacts, and vice versa. All conclusions from the random field
model depend on only these qualitative relationships between parental and novel contacts.
4.6.3 Expected values of various landscape properties
4.6.3.1 Recombination library properties
Consider a recombination library L, generated by recombining b sequence fragments from p parental
sequences. From the definition of the library mean ML (equation 4.8), the expected value of the
library mean within the random field is
E[ML] =
1
pb
∑
c∈L
E[Ec] (4.22)
and the variance of the library mean is
Var[ML] =
1
p2b
∑
c1∈L
∑
c2∈L
Cov[Ec1, Ec2], (4.23)
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where the expected value of the random field E[Ec] is defined in equation 4.6, and the covariance
within the random field Cov[Ec1, Ec2] is defined in equation 4.7.
Similarly, the expected value of the library variance VL (equation 4.9) is given by
E[VL] =
1
pb
∑
c∈L
E
[
(Ec −ML)2
]
) (4.24)
which can be expanded to
E[VL] =
1
pb
∑
c∈L
[
(E[Ec]− E[ML])2 + Var[Ec] + Var[ML]− 2 Cov[Ec,ML]
]
(4.25)
where Var[Ec] = Cov[Ec, Ec] and
Cov[Ec,ML] = −E[Ec] E[ML] + 1
pb
∑
c2∈L
(E[Ec] E[Ec2] + Cov[Ec, Ec2]) . (4.26)
From this, we can substitute equations 4.22, 4.23, and 4.26 into equation 4.25 to get an expression
for the expected value of the library variance.
4.6.3.2 Fraction of functional sequences
Within library L, we assume the distribution of energies is Gaussian, which is a good approximation
when the library size pb is greater than a few hundred sequences. The fraction of functional sequences
is given by evaluating the Gaussian cumulative distribution function at zero
fF =
1
2
[
1− erf
(
ML√
2VL
)]
, (4.27)
where erf is the error function.
We can approximate the expected value of the fraction of functional sequences with a first-order
Taylor series of fF about E[ML] and E[VL]
E[fF ] ≈ 1
2
[
1− erf
(
E[ML]√
2 E[VL]
)]
. (4.28)
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Monte Carlo sampling was used to verify that this approximation is leading order.
4.6.3.3 Landscape additivity
The variance within library L can be partitioned into additive and epistatic components (VL =
VA + VE). We can define an energy function that describes only the additive energy
EA,c =
∑
i
bic,P ε
i
P +
∑
i
bic,N ε
i
N , (4.29)
where bic,P and b
i
c,N specify how the energy terms ε
i
P and ε
i
N contribute to additive energy of chimera
c. The b variables are analogous the the a variables in equation 4.1, however they are no longer
binary. Their values are are determined by the contribution that interaction i makes to overall
library L.
Each interaction i is specified by a residue-residue contact between positions pi1 and p
i
2. Within
the parent alignment, if the residues at positions pi1 or p
i
2 are conserved, then interaction i only
contributes to linear variation within the library. Oppositely, if the residues at positions pi1 and p
i
2
are nonconserved, then interaction i contributes to quadratic variation within the library. Merging
the two variables bic,P and b
i
c,N into a single variable, we define
bic =

aic if p
i
1 or p
i
2 conserved,
p(i|c, p1) + p(i|c, p2)− p(i) if pi1 and pi2 nonconserved,
(4.30)
where p(i) is the probability of interaction i within the entire library L, p(i|c, p1) is the probability
of interaction i in the subset of library L that has the same residue at position pi1 as chimera c, and
p(i|c, p2) is the probability of interaction i in the subset of library L that has the same residue at
position pi2 as chimera c. At the nonconserved contacts, bc effectively averages over all quadratic
variation that cannot be represented by an additive model.
With this additive energy function, we can define library L’s additive mean MA and variance
VA using the standard formulas (equations 4.8 and 4.9). The expected values E[MA] and E[VA] can
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be calculated using the same equations as the ‘Recombination library properties’ section (above).
Using the definition of library additivity (equation 4.13), we can approximate the expected value of
the additivity with a first-order Taylor series about E[VA] and E[VL]
E[A] ≈ E[VA]
E[VL]
. (4.31)
Monte Carlo sampling was used to verify that this approximation is leading order.
4.7 Figures and Tables
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Figure 4.1: Effect of homologous sub-
stitutions on the fraction of functional
sequences in a library of chimeric β-
lactamases. (A) The random field
model agrees well with experimental ran-
dom and homologous substitutions in
β-lactamase [56]. The parabolic curve
displays the effect of homologous sub-
stitutions and the error bars represent
the 95% confidence intervals of the frac-
tion of correctly constructed chimeras
(see Methods). The steep exponential
curves (and inset) show the effect of ran-
dom mutations and the error bars rep-
resent one standard error. (B) As par-
ent sequence identity decreases, the ho-
mologous substitution curves stretch to
higher levels of mutation and lower frac-
tion functional. Shown are the βlac13 li-
brary (crossover locations and contacts)
averaged over 100 random parent se-
quences with sequence identity rang-
ing from 20–80%. (C ) As the num-
ber of crossovers decreases, the homol-
ogous substitution curve shifts towards
a higher fraction functional. Shown are
the βlac13 library (parents and contacts)
averaged over 100 random crossover lo-
cations with the number of crossovers
varying from 6 to 27. The random ho-
mologous substitution curve was gener-
ated by averaging over 100 randomly
sampled sequences at each level of mu-
tation.
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Figure 4.2: Comparison between library properties and their expected values within the random
field model. Note diagonal lines represent x = y. (A) The random field’s expected fraction of
functional sequences shows quantitative agreement with experimental results. Error bars represent
the binomial 95% confidence intervals calculated using the Clopper-Pearson method [202]. Omitting
the Cel9 outlier yields a correlation coefficient of r = 0.95 with p < 0.005. (B) The expected
additivity agrees well with experimentally determined values (r = 0.78 with p = 0.21). While the
small data set limits the statistical significance of this correlation, all E[A]s are large and within the
ranges that are observed experimentally.
4.8 Supplementary Figures and Tables
number of
library sequences µP σP µN σN
P450 988 -0.7 51.9 52.0 58.3
βlac 553 -1.1 30.1 71.8 87.9
Cel48 63 -3.9 257.3 198.1 22.7
Cel5 48 -0.2 722.3 497.6 713.4
Supplementary Table 4.2: Contact parameters estimated from four recombination libraries. Note
the contact variation is presented as standard deviations, for direct comparison with the means. We
see qualitatively similar relationships for all four parameter sets (Supplementary Figure 4.3).
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Supplementary Figure 4.3: Comparison of contact parameters estimated on four different recombina-
tion libraries. Qualitatively, all parameter sets have slightly favorable parental contacts, significantly
deleterious novel contacts, and significant variation in both. Shown are the Gaussian probability
density functions with the associated parameters.
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Chapter 5
Gaussian process models of the
protein fitness landscape
5.1 Abstract
Understanding the map from protein sequence to protein function is important for understanding
natural evolution and engineering proteins with new and useful properties. We demonstrate that
this protein fitness landscape can be be inferred from experimental data using Gaussian processes,
a Bayesian learning technique. These Gaussian process landscapes can model a variety of protein
sequence properties including functional status, thermostability, enzymatic activity, and binding
affinity. By training on experimental data, these models achieve an unrivaled quantitative accuracy
across a large number of sequences. Furthermore, the explicit representation of model uncertainty
allows for efficient searches through the massive space of possible protein sequences. We develop
and test two protein sequence design algorithms motivated by Bayesian decision theory. The first
identifies small sets of protein sequences which are highly-informative about the landscape. The sec-
ond algorithm identifies optimized protein sequences by iteratively improving the Gaussian process
model in regions of the landscape that are predicted to be highly-optimized.
5.2 Introduction
The fitness landscape, which describes the map from genotype to phenotype, is an important concept
in evolutionary biology and optimization [26, 211]. At the molecular level, the properties of protein
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sequences form a high dimensional surface over protein sequence space [1]. This protein fitness
landscape could represent a protein’s contribution to organismal fitness, but may also describe any
biophysical property of protein sequences including thermostability, enzymatic activity, or binding
affinity. Understanding the structure of this surface is important for explaining how natural proteins
evolve because it describes the spectrum of possible phenotypes and the mutational accessibility
among them. This surface is also the objective function for protein engineering, which seeks to
identify protein sequences that are highly optimized for a wide variety of applications.
Identifying optimized sequences within the protein fitness landscape is extremely challenging for
several reasons. First, the space of possible protein sequences is incomprehensibly large and will
never be searched exhaustively by any means, naturally, in the laboratory, or even computationally
[25, 212]. Within this massive space of possible sequences, functional proteins are extremely scarce,
estimates range from 1 in 1011 to as low as 1 in 1077 [31, 32]. Of these functional sequences, most are
poorly optimized and there is believed to be an exponentially decreasing number of sequences with
higher levels of fitness [33, 213]. Within the protein fitness landscape, highly-optimized sequences
are vanishingly rare and hidden in the extreme abundance of nonfunctional and mediocre sequences.
Computational protein design uses models of protein function to guide the search through se-
quence space. These models typically contain an atomic structural representation of a protein and
energy-based scoring functions to quantify the target function [214, 6]. While there has been con-
siderable success in recent years using these computational searches to engineer functional proteins,
these methods still lack reliability and often result in sequences with properties that are far inferior
to natural proteins [6, 8, 215]. Many of these difficulties arise from the use of models which lack even
qualitative accuracy, much less the ability to reliably rank the performance of sequences. In general,
the factors that make one protein perform better than another are complex and largely unknown.
A major challenge for computational protein design is the development of models which accurately
describe the mapping from protein sequence to function [216].
Here, we introduce a new class of models for protein function that infer the protein fitness
landscape directly from experimental data. With examples of the mapping from sequence to function,
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the landscape can be learned using Gaussian process regression, a technique that has gained recent
popularity in machine learning where it falls into the broader class of kernel methods [217, 218].
The kernel function describes the covariance structure of the fitness landscape by specifying how
the properties of pairs of sequences are expected to co-vary. We develop a structure-based kernel
function inspired by the simple principle that sequences with similar structures are more likely to
have similar properties. These Gaussian process models provide a full probabilistic description of
the protein fitness landscape, including the mean and variance of any sequence. Importantly, a
sequence’s variance provides a measure of the model’s uncertainty, which can be used to guide the
search through sequence space using Bayesian decision theory.
Using chimeric cytochrome P450s, we demonstrate that Gaussian process landscapes can accu-
rately describe a variety of sequence properties including binary functional status, thermostability,
enzymatic activity, and binding affinity. By training directly on experimental data, these mod-
els implicitly account for all factors which contribute to a specific property, including those which
are unknown. This provides an unrivaled quantitative accuracy across a potentially astronomical
number of sequences. Using the Gaussian process model’s uncertainty as a guide, we develop two
algorithms which efficiently explore the protein fitness landscape. The first is an experimental de-
sign algorithm, which identifies the most informative points within the landscape before they are
measured. This is used to design a set of 29 highly-informative chimeric P450s. The second algo-
rithm identifies optimized protein sequences by iteratively improving the Gaussian process model in
regions of the landscape that are predicted to be highly-optimized. This algorithm is used to design
chimeric P450s with thermostabilities beyond what has been achieved by other protein engineering
methods.
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5.3 Results
5.3.1 Gaussian process model of the protein fitness landscape
Gaussian processes have gained recent attention in supervised machine learning, where they are
used for both regression and classification tasks [218]. These nonparametric models use a kernel, or
covariance function to define a prior probability distribution over function space. Given examples
of the target function, its posterior probability distribution can be inferred using Bayes’ theorem.
In general, kernel functions represent a notion of similarity between inputs, which allows them
to describe many types of complex relationships. This provides Gaussian processes with extreme
flexibility, and the ability to learn from structured objects including strings, sets, and graphs.
To model the protein fitness landscape with Gaussian processes, we must define a kernel function
which accurately captures the notion of distance between pairs of sequences. While the Hamming
distance would be a natural metric, the properties of proteins depend on sequence only though their
structure. Therefore, we propose a structure-based distance metric which assumes a fixed structure
within a protein family, as defined by a residue-residue contact map. With this contact map, the
structural distance between two proteins in the same family is defined as the number of contacting
residues with different amino acids. This structure-based distance metric is similar to the Hamming
distance, but it describes the effects of mutations more accurately. For example, the properties of
sequences that differ by a surface mutation are expected to be more similar than sequences that differ
by a core mutation. Most importantly, this distance metric can be represented as an inner-product
and therefore satisfies the requirements to be a valid kernel function for Gaussian process learning
[218].
Given experimental examples of the mapping from protein sequence to protein function, the full
protein fitness landscape can be inferred using Gaussian processes. For regression, the expected
value of the landscape f at sequence s is given by
E[f(s)] = kT (K + σ2nI)
−1y, (5.1)
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and the variance of the landscape is
Var[f(s)] = k(s, s)− kT (K + σ2nI)−1k (5.2)
where k is the structure-based kernel function, K is the kernel function evaluated at all pairs of
sequences in the training set (Ki,j = k(si, sj)), k is the kernel function evaluated at sequence s and all
sequences in the training data (ki = k(s, si)), σ
2
n is the variance of the experimental measurements,
and yi is the experimentally determined property of training set sequence si. From equation 5.1,
we see a sequence’s expected value is simply a linear combination of all the current data y, where
the coefficients depend on the structural distance between the sequence and each sequence in the
training set. This can be viewed as a spatial interpolation within the protein fitness landscape,
where sequences that are close in structure are likely to have similar properties. Interestingly, a
nearly identical method has been used for decades in geostatistics to infer the structure of terrestrial
landscapes [185]. The variance of a sequence (equation 5.2) can be interpreted as the difference
between what was known about the sequence before the experiments and what was learned about
the sequence from the experiments. As expected, Gaussian process models have high confidence in
regions of the landscape which are well sampled, and low confidence in regions that are not. For
the prediction of discrete-valued properties (classification), the Gaussian process posterior does not
have a simple, closed-form solution, but can be found using several well-established approximations
[219].
The performance of Gaussian process landscape models was tested on a previously published data
set of chimeric cytochrome P450 thermostabilities [86]. This Gaussian process model showed excel-
lent predictive ability (cross-validated r = 0.95, mean absolute deviation MAD = 1.4 ◦C), as shown
in Figure 5.1A. Previously, this data set was modeled using a linear regression model that associ-
ated weights to individual sequence fragments within the data set [86]. This linear regression model
worked well (cross-validated r = 0.90, MAD = 2.0 ◦C) and was used to identify highly stabilized
chimeric P450s. To compare the predictive performance of the two models, we sampled random sets
of training sequences from the data set, trained the linear and Gaussian process models, predicted
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the thermostability of the remainder of the data set, and quantified each model’s predictive ability in
terms of the correlation coefficient (r) and the mean absolute deviation (MAD). This was performed
with training sets varying from 2 to 60 sequences, and the results for each training set size were
averaged over 1000 random samples, Figure 5.1B. The Gaussian process model significantly outper-
forms the linear regression model, typically explaining 30% more of the variation in thermostability
across all training set sizes. On average, the linear regression model trained on all the data (218
sequences for 10-fold C.V.) has the same predictive ability as the Gaussian process model trained
on only 40 sequences. These substantial increases in predictive performance can be attributed to
the more accurate sequence-sequence covariance specification provided by the structure-based kernel
function. The performance of other kernel functions is shown in Supplementary Figure 5.4.
The most significant benefit of the Gaussian process model, over the linear regression model,
is predictions are not restricted to sequences composed of a fixed set of fragments (site-directed
recombination libraries). In fact, the Gaussian process model can predict the properties of any
sequence, however, these predictions will typically contain so much uncertainty (variance) they will
be of no use. A more useful prediction domain is the set of all sequences that can be generated by
recombining the three parent cytochrome P450s (CYP102A1, CYP102A2, and CYP102A3), which
still represents an astronomically large sequence space (> 1075 sequences). To test the predictive
ability in this new prediction domain, we trained a Gaussian process model on the data set described
in the previous paragraph (fixed set of sequence fragments) and predicted the thermostabilities of a
data set containing single- and double-crossover chimeric P450s between CYP102A1 and CYP102A2
[220] (no fixed set of sequence fragments). Each of these single- and double-crossover chimeric
P450s are composed of different sequence fragments, contain different crossover locations than the
training sequences, and on average differ from the closest sequence in the training set by 29.6
mutations (shown schematically in Supplementary Figure 5.5). The Gaussian process model shows
good predictive ability (r = 0.76, MAD = 3.0 ◦C) on these sequences that cannot be modeled with
sequence fragment-based linear regression (Figure 5.1C ). While the predictions are less accurate on
these sequences, the model is aware these predictions are in an uncertain region of sequence space as
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indicated by its large confidence intervals (Supplementary Figure 5.5). For these predictions, nearly
all experimental measurements (17/19) fall within the model’s 95% confidence intervals.
Next, we tested the ability of Gaussian process landscapes to classify the functional status (func-
tional/nonfunctional) of chimeric P450s. Here, a functional P450 must satisfy a number of require-
ments including sufficient expression, stability, and the ability to properly bind the heme prosthetic
group. We trained a Gaussian process model on a large, previously published functional status data
set [80] (see Methods). This Gaussian process classifier shows excellent predictive ability, correctly
classifying 89% of sequences (10-fold cross-validation). For comparison, a sequence fragment-based
logistic regression classifier only achieves 81% accuracy (10-fold cross-validation). Once again, this
Gaussian process functional status classifier is applicable to the astronomical number of sequences
accessible by recombining the three parent enzymes. By training directly on experimental data,
Gaussian process models implicitly capture the numerous and possibly unknown factors which de-
termine if a sequence will form a functional cytochrome P450.
5.3.2 Experimental design on holey landscapes
The utility of Gaussian process models relies on a thorough sampling of the very high dimensional
protein fitness landscape. If done inefficiently, this could require an unimaginable amount of exper-
imentation. Fortunately, we can take advantage of the Gaussian process landscape’s representation
of model uncertainty to select the most informative sequences before they are measured. This is
referred to as experimental design, and can significantly reduce the number of experiments required
to train a statistical model. There is a well-developed theory for designing informative experiments
using Gaussian process models, which has been applied to a number of problems including envi-
ronmental monitoring and outbreak detection [221, 222]. Experimental design can be posed as a
combinatorial optimization problem, where the objective quantifies the informativeness of a set of
observations, typically as a function of their covariance matrix. For many of these objective func-
tions, a simple greedy approximation algorithm can achieve near-optimal observation selection for
experimental design [152].
108
Considering the set of all possible sequences in the landscape L and a subset of these sequences S,
a logical measure of informativeness is the mutual information I(S;L), that is how much S reduces
the uncertainty in L. The set of sequences S that maximize this mutual information, subject to
|S| ≤ n, can be found efficiently using greedy maximization (n is the maximum allowed size of the
design). The resulting experimental designs contain sequences which are spaced as far as possible
within the fitness landscape.
The primary challenge of performing experimental design on the protein fitness landscape is the
abundance of nonfunctional sequences, which provide no information about the protein sequence
properties we wish to model. Fortunately, the Gaussian process functional status classifier, which
was presented in the previous section, can predict a sequence’s probability of functioning with high
accuracy. With this knowledge, a better experimental design objective is to maximize the expected
value of the mutual information E[I(S;L)] (see Methods). The set of sequences that maximize this
objective are highly-informative, while still having a high probability being functional.
Using a greedy approximation algorithm, we identified a set of 20 sequences which near-optimally
maximize the expected value of the mutual information (see Methods). These 20 sequences were
constructed and expressed. Seventeen produced functional cytochrome P450s. Building upon this set
of sequences, we performed a second experimental design containing 10 sequences, 9 which produced
functional cytochrome P450s. These 26 new cytochrome P450s, in addition to the three parent
enzymes, provide a highly-informative yet experimentally tractable sampling of the chimeric P450
landscape (shown schematically in Supplementary Figure 5.7). On average, the sequences within
this experimental design differ from each other by 106.1 mutations. In the following section this set
of sequences is used to train Gaussian process models for enzymatic activity and binding affinity.
5.3.3 Gaussian process landscapes for enzymatic activity and binding
affinity
We would like to test if Gaussian process landscapes can model sequence properties besides ther-
mostability and functional status. Each of the 29 sequences (3 parents and 26 chimeras) in the
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experimentally-designed set was expressed, purified and characterized for enzymatic activity and
binding affinity (Supplementary Table 5.2). Enzymatic activity (total substrate turnovers per en-
zyme) was measured on the following substrates: 2-phenoxyethanol, ethoxybenzene, ethyl phenoxy-
acetate, propranolol, chlorzoxazone, 11-phenoxyundecanoic acid (see Methods). Binding affinity
(Kd) measurements were performed on dopamine and serotonin (see Methods).
Gaussian process regression was used to model the logarithm of the enzymatic activity and
binding affinity for each compound. For all of these sequence properties, the Gaussian process models
displayed poor cross-validated predictive ability. Suspecting the presence of outliers, we searched
for aberrant observations within the data set (see Methods). From this analysis, we identified three
strong outliers (ED7, ED9, ED28) and two occasional outliers (ED10, ED12). Looking back at each
sequence’s absorbance spectra, four of these proteins (ED7, ED9, ED12, ED28) have Sort peaks that
are shifted from typical cytochrome P450s and the the remainder of the data set (Supplementary
Figure 5.8). ED7, ED12, and ED28 have blue-shifted Soret peaks, indicative a of high-spin heme,
which is normally observed with reduced solvent accessibility in the active site. ED9 has a red-
shifted Soret peak, which suggests the presence of a distal heme ligand. Regardless of the specific
mechanisms involved, these four outliers appear to be adopting conformations that are minimally
populated by the other chimeric P450s and therefore cannot be modeled with the remainder of the
data set.
Removing outliers from each data set and training the Gaussian process model on the remaining
sequences shows good predictive ability, Figure 5.2 and Supplementary Figure 5.9. Many of these
sequence properties are minimally correlated with each other (Supplementary Table 5.3) and with
thermostability, confirming that Gaussian process landscapes are able to model a wide variety of
sequence properties. As a final validation, we trained Gaussian process models on our experimentally
designed set of sequences and used these models to predict the enzymatic activity of a previously
published data set [85]. These predictions show reasonable agreement with the previously published
values (2-phenoxyethanol: r = 0.72, ethoxybenzene: r = 0.61, ethyl phenoxyacetate: r = 0.45,
propranolol: r = 0.13, chlorzoxazone: r = 0.46) and scatter plots are shown in Supplementary
110
Figure 5.10.
We would like to understand how Gaussian process models are able to capture complex properties
such as enzymatic activity and binding affinity. Close inspection of the parent structures reveals that
all active site residues are completely conserved and therefore all the chimeric P450s have identical
active sites. Furthermore, Poisson-Boltzmann calculations suggest minimal influence of long-range
electrostatic interactions (See Methods). It may be that the variation we observe within our data set
is arising due to minor differences in the chimeric P450s conformational preferences. The Gaussian
process model would be able to capture these differences if the system was dominated by two (or
maybe a few) conformational states. If we assume the energy of each conformational state can
be represented with a Gaussian process model, then differences between conformational states and
therefore conformational preferences can also be represented. By training on experimental data,
Gaussian process models can accurately account for these subtle differences. In contrast, modeling
these effects with energy-based scoring functions is currently extremely challenging, if not impossible.
5.3.4 Sequence optimization on Gaussian process landscapes
Given the exceptional predictive ability of Gaussian process landscapes, as demonstrated above, it
is compelling to use these models to design highly-optimized protein sequences. While these models
can predict the properties of an astronomical number of sequences, a majority of these predictions
are of little value because the model’s uncertainty (variance) is so large. This predictive uncertainty
can be reduced by experimentally sampling the landscape in previously uncharted regions. However,
the same experimental effort could also be directed towards designing optimized sequences. When
optimizing these uncertain functions, one is faced with the decision between trusting the current
model and therefore selecting highly-optimized sequences, or not trusting the model and selecting
highly-informative sequences. This is referred to as the exploitation-exploration dilemma, which is
challenging because there are no set criteria for how this decision should be made [223]. In general,
we would like to make the model good enough to design highly-optimized sequences, but no better.
In theoretical computer science, protein sequence design on Gaussian process landscapes is known
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as a multi-armed bandit problem because of its similarity to optimally playing slot machines in a
casino [224]. These multi-armed bandit problems have been applied to online advertising, clini-
cal trials, and robotic control [225, 226, 227]. The key feature of these problems is the trade-off
between acting optimally based on current knowledge or acquiring new knowledge–the exploitation-
exploration dilemma. When the objective is modeled as a Gaussian process, or any model which
explicitly accounts for uncertainty, optimal solutions can be found efficiently using upper confidence
bound (UCB) algorithms [228, 229]. With these iterative algorithms, the data point with the largest
upper confidence bound (mean plus multiple of standard deviation) is evaluated, then the model is
updated, and this process is repeated until convergence. This simple sampling rule simultaneously
chooses points which are predicted to be optimal and uncertain, and implicitly trades off exploita-
tion and exploration. When optimizing Gaussian processes, the UCB algorithm is guaranteed to
converge to the optimal solution and displays fast convergence for a wide variety of kernel functions
[229].
Theoretically, an upper confidence bound algorithm applied to a Gaussian process landscape
model can be used to design optimized protein sequences. Given the current experimental data, a
Gaussian process model can be trained and used to design a sequence that maximizes the upper
confidence bound. This sequence can be synthesized, experimentally characterized, and used to
update the model. This process can be repeated until convergence, or until the desired protein
sequence properties are achieved. In early iterations this search will be dominated by exploration of
the landscape, but as confidence grows the algorithm will begin to climb the landscape.
We tested the ability of upper confidence bound protein sequence design to optimize the ther-
mostability of chimeric cytochrome P450s. To avoid the high cost of gene synthesis, we restricted
our design space to single and double crossover chimeras that could be constructed from currently
available chimeric P450s, a set estimated to contain ∼1010 unique sequences. A Gaussian process
model was trained on the 261 currently available thermostability measurements. With this model,
UCB optimal sequences were found using a Monte Carlo search algorithm and five sequences were
chosen using a batch-mode UCB selection criteria [230]. After construction and expression, the
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thermostabilities of these sequences were measured. In this first round, we identified a sequence
(UCBr1c4) with a thermostability (T50) of 65.1
◦C, higher than any chimeric P450 characterized to
date. The Gaussian process model was then updated with these new data points, and the process
was repeated. This UCB sequence optimization was performed for four iterations, the results are
shown in Figure 5.3 and the sequences are represented schematically in Supplementary Figure 5.11.
While these 18 new sequences provide a diverse sampling of the thermostability landscape at
high elevations (on average 5.1 ◦C more stable than the most stable parent), none are significantly
more stable than the previously identified most stable chimeric P450 [86]. As a check of the current
Gaussian process model, we designed a sequence (LCB1) with a maximized lower-confidence bound -
a sequence predicted to be stabilized with high certainty. This sequence was constructed, expressed,
and characterized, resulting in a thermostability of 67.2 ◦C. LCB1 is nearly 3 ◦C more stable than
the previously identified most stable chimera and 12 ◦C more stable than the most stable parent.
This sequence differs from the previously identified most stable chimera by 10 mutations.
These results verify the Gaussian process model is working and suggest the upper confidence
bound sequence optimization is still in its exploration phase. The relatively slow convergence ob-
served here may be due to restrictions imposed by the sequence construction constraints. During
the sequence optimization, it was common to observe sequences in the current generation to be com-
posed of fragments from sequences of the previous generation, an indication that the accessibility
of sequences is limiting. This could of course be mitigated with total gene synthesis, but also high-
lights an interesting feature of constructing new sequences from previously constructed sequences:
the number of feasible sequences increases for each iteration of the UCB sequence optimization. The
sequence optimization algorithm could possibly be accelerated by considering a sequence’s poten-
tial to generate UCB optimal sequences in subsequent generations, in addition to its current UCB
optimality.
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5.4 Materials and Methods
5.4.1 Gaussian process regression and classification
To provide a notion of distance within Gaussian process landscapes, we developed a structure-based
kernel function. Here, a protein structure is represented with its residue-residue contact map. The
residue contact map for cytochrome P450 was generated using all structures in the Protein Data
Bank which have at least 50% sequence identity to one of the parents. Within each of these 91
protein chains, a residue pair was considered contacting if they contained any heavy atoms within
4.5 A˚. For the final contact map, a residue pair was considered contacting if the pair was contacting
in more than 50% of the P450 chains.
The structure of a specific sequence s can be described by the amino acids present for each
residue-residue contact, and this information can be encoded with a binary indicator vector x. The
structure-based kernel function is defined as
k(si, sj) = σpxi · xj , (5.3)
where the hyperparameter σp corresponds to the prior variance of a single contact, which describes
how quickly the landscape is expected to change.
When modeling continuous sequence properties (regression), we used the analytical solutions for
the posterior distribution given by equations 5.1 and 5.2 [218]. The hyperparameters σp and σn
were found by maximizing the marginalized likelihood function or cross-validation. When modeling
binary sequence properties (classification), we used Laplace’s method to approximate the poste-
rior distribution [218]. The kernel hyperparameter σp was found by maximizing the marginalized
likelihood function.
5.4.2 Experimental design
The experimental design objective was to find the set of sequences S that maximize the expected
value of the mutual information E[I(S;L)]. For our Gaussian process model, this is equivalent to
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maximizing the expected value of the Shannon entropy E[H(S)], which is given by
E[H(S)] =
∑
A∈P(S)
H(A) ∏
s∈A
ps
∏
s∈(S\A)
(1− ps)
 , (5.4)
where P(S) is the power set of S, ps is the probability that sequence s is functional based on the
Gaussian process functional status classifier, and the entropy H is calculated from the multivariate
Gaussian covariance, which is specified by the kernel function. Unfortunately, the cost of calculating
this objective grows exponentially with the number of sequences in the set S (due to the power set).
For sets of less than 10 sequences, the objective was calculated exactly. For sets of 10 sequences or
more, the objective was approximated by sampling.
To maximize this objective function, we can take advantage of the guaranteed performance of
greedy approximation algorithms for the maximization of submodular set functions [153]. The
Shannon entropy of Gaussian random fields is a submodular set function [231]. Since submodular
functions are closed under non-negative linear combinations [221], the expected value of the entropy
is also submodular.
In an effort to minimize sequence construction, we restricted the experimental design to the 4716
sequences that could be easily constructed from existing chimeric P450s (single-crossover overlap
extension PCR between the sequences presented in [80, 86] with library-specific primers). For the
first experimental design, we conditioned the landscape’s covariance matrix on the parent sequences
(assuming they had been observed) and selected 20 sequences using an accelerated greedy algorithm
[232]. Of these 20 chimeric sequences, 17 produced folded cytochrome P450s. For the second
experimental design, we conditioned the landscape’s covariance matrix on the parent sequences
and the 17 new chimeras, and then selected 10 additional sequences using an accelerated greedy
algorithm.
5.4.3 Cloning, expression, and purification of chimeric P450s
All chimeric cytochrome P450 genes were constructed from fragments of previously published chimeric
P450s, which were originally constructed from the heme domains of CYP102A1, CYP102A2, and
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CYP102A3 [220, 80, 86]. Single- and double-crossover chimeric genes were assembled using overlap
extension PCR and cloned into pCWori (P450-specific vector [128]) or pET22b expression vectors
containing a C-terminal 6xHis tag. The correct construction of all genes was confirmed by DNA
sequencing with forward and reverse primers.
Plasmid DNA was transformed into E. coli BL21(DE3), and the resulting transformants were
used to inoculate a Luria broth (LB) starter culture supplemented with 100 µg/ml ampicillin. These
starter cultures were grown overnight shaking at 37 ◦C and then diluted 1:100 in fresh terrific broth
(TB) containing 100 µg/ml ampicillin and 500 µM δ-aminolevulinic acid. These TB cultures were
grown for 3 hours at 37 ◦C, then protein expression was induced with 500 µM IPTG for 24 hours
shaking at 30 ◦C. After protein expression, the cells were collected by centrifugation and stored at
-20 ◦C.
For the enzymatic activity and binding affinity measurements (chimeric P450s ED1–ED30),
frozen cell pellets were thawed and resuspended in 25 mM Tris, 200 mM NaCl, 20 mM imida-
zole, pH 8.0 containing 0.5 mg/ml lysozyme, and 0.05 mg/ml DNAse I. Clarified cell lysates were
prepared by sonification for 2 minutes, followed by centrifugation at 75,000 RCF for 30 minutes.
These clarified cell lysates were loaded onto a 5 mL HisTrap HP (high performance) Ni Sepharose
column (GE Healthcare) and washed with 50 mL wash buffer (25 mM Tris, 200 mM NaCl, 20 mM
imidazole, pH 8.0). The immobilized proteins were eluted with 25 mL elution buffer (25 mM Tris,
200 mM NaCl, 150 mM imidazole, pH 8.0). The peak fractions were pooled and buffer exchanged
into 25 mM Tris, pH 8.0. Next, the proteins were loaded onto a 5 mL HiTrap Q HP anion exchange
column (GE Healthcare) and washed with 20 mL 25 mM Tris, pH 8.0. The immobilized proteins
were eluted with a 50 mL linear gradient of 25 mM Tris, 1 M NaCl, pH 8.0. The peak fractions were
pooled, buffer exchanged into phosphate buffered saline, pH 7.4, concentrated to ∼100 µM, flash
frozen in liquid nitrogen, and stored at -80 ◦C.
For the thermostability measurements (chimeric P450s UCBr1cX-UCBr4cX and LCB1), frozen
cell pellets were thawed and resuspended in 100 mM potassium phosphate, pH 8.0. Clarified cell
lysates were prepared by sonification for 2 minutes, followed by centrifugation at 75,000 RCF for 15
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minutes. Thermostability measurements were performed with these freshly prepared cell extracts.
5.4.4 Characterization of P450 enzymatic activity
Purified cytochrome P450s were thawed and diluted into 100 mM EPPS, pH 8.0. Fresh stocks of
substrates were prepared in 50% (v/v) DMSO and 50% (v/v) acetone. P450 peroxygenase reac-
tions were performed in 100 mM EPPS, pH 8.0 with a final concentration of 2 µM P450, 4 mM
H2O2, 1% DMSO, 1% acetone, and varying substrate concentrations. The following final substrate
concentrations were chosen based on the compound’s solubility: 100 mM 2-phenoxyethanol, 50 mM
ethoxybenzene, 10 mM ethyl phenoxyacetate, 4 mM propranolol, 5 mM chlorzoxazone, and 2 mM
11-phenoxyundecanoic acid. Reactions were carried out for two hours at room temperature and then
stopped with quench buffer (final concentration of 50 mM NaOH, 2 M urea). Hydroxylation of each
substrate, at the appropriate positions, leads to phenolic byproducts. These phenolic compounds
can be coupled to 4-aminoantipyrene (4-AAP) to form a red compound, which is detectable at 500
nm [233]. The ‘enzymatic activity’ values are the raw absorbance increase at 500 nm, which is
proportional to the total substrate turnovers per enzyme after two hours. All measurements were
performed in triplicate and the median enzymatic activity values are reported.
5.4.5 Characterization of P450 binding affinity
Purified cytochrome P450s were thawed and diluted into 2X phosphate buffered saline (PBS), pH 7.4.
Fresh stocks of dopamine and serotonin were also prepared in 2X PBS, pH 7.4. All binding assays
were performed in 2X PBS, pH 7.4 with a final concentration of 4 µM P450 and logarithmically-
spaced ligand concentrations ranging from 2.8 µM to 500 mM. For each titration, the proportion of
bound P450 was determined by the relative shift in the Soret peak [100]. The dissociation constant
(Kd) was determined by fitting a two-state binding model to this ligand-binding curve. All binding
assays were performed in at least triplicate and the median Kd values are reported.
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5.4.6 Characterization of P450 thermostability
The cytochrome P450 concentration within freshly prepared cell extracts was determined using
CO-difference spectroscopy [234]. Cell extracts were diluted to 4 µM with 100 mM potassium
phosphate, pH 8.0 and arrayed into 96-well PCR plates. Using a gradient thermocycler, the samples
were heated over multiple temperatures (typically 55–70 ◦C) for 10 minutes. The samples were then
centrifuged and the remaining P450 was quantified using CO-difference spectroscopy [234]. The T50
(temperature where 50% of the protein is inactivated in 10 minutes) was determined by fitting a
shifted sigmoid function to the thermal inactivation curves. All measurements were performed in at
least triplicate and the median T50 values are reported.
5.4.7 Outlier detection
Outlying sequences were identified based on two different criteria. The first was calculated by
removing a sequence (or set of sequences) from the data set, training the Gaussian process model
on the remainder of the data, and evaluating the predictive likelihood of the omitted data points
[235]. Here, outliers are data points that are very unlikely given the remainder of the data set. The
second criteria was based on the leave-one-out cross-validated predictive accuracy within the data
set when various sequences were removed. By this criteria, outliers are data points that significantly
improve the predictive accuracy of the model when they are removed from the data set.
These two criteria were used to detect the presence of outliers in all six enzymatic activity and
both binding affinity data sets. ED7, ED9, and ED28 were classified as outliers in all eight of these
data sets. In addition, ED12 was an outlier for enzymatic activity on 2-phenoxyethanol, and ED10
was an outlier for enzymatic activity on ethoxybenzene and ethyl phenoxyacetate. Four of these
outliers have Sort peaks that are shifted relative to the remainder of the data set (Supplementary
Figure 5.8).
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5.4.8 Poisson-Boltzmann calculations
In an effort to understand the observed variation in the chimeric P450s properties, we performed
Poisson-Boltzmann calculations to estimate the contribution of long-range electrostatic interactions.
DelPhi was used to calculate the electrostatic component of the free energy of binding between
dopamine and all chimeras within the data set (three parents and ED1-ED30) [236]. The dopamine
ligand was used because a crystal structure of a CYP102A1 variant bound to dopamine was available
[237]. The results for dopamine should apply to the other ligands and substrates because they are
of similar size and net charge.
Using the crystal structure of a CYP102A1 variant bound to dopamine as a template, we mod-
eled the structure of each chimeric P450 using CHOMP [238]. These structural models had fixed
backbones with rotamers optimized with respect to the Rosetta energy function. The atomic radii
of the heme and dopamine atoms were chosen to match the equivalent atom types in the DelPhi
parameter file. The partial charges of the heme and dopamine atoms were calculated with the Elec-
trostatic Potential (ESP) module of NWChem [239]. All Poisson-Boltzmann calculations were run
with a 100 mM salt concentration. The binding energy for each chimeric P450 was calculated by
taking the sum of the grid energy for individual dopamine and protein molecules and subtracting
this from the grid energy of the bound complex.
Across all chimeric P450s within the data set, the standard deviation in the electrostatic compo-
nent of the binding free energy is calculated to be 0.12 kcal/mol and the total range is 0.42 kcal/mol.
Experimentally, we observe the standard deviation of the binding free energy to be 0.66 kcal/mol
with a total range of 2.17 kcal/mol. From these calculations, we estimate that long-range electro-
static interactions could be contributing to ∼20% of the energetic differences between the chimeric
P450s.
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5.5 Discussion
We have demonstrated the ability to model the protein fitness landscape with quantitative accu-
racy using Gaussian process regression and classification. Within the landscape, the relationship
between pairs of sequences is specified by a structure-based kernel function, which is derived from
the principle that sequences with similar structures are more likely to have similar properties. With
this metric over sequence space, a full probabilistic description of the landscape can be inferred
from experimental data. These Gaussian process landscapes are able to describe various protein
sequence properties including functional status, thermostability, enzymatic activity, and binding
affinity. These results suggest Gaussian process models may be applicable to most properties that
display significant variation within an experimental data set.
The predictive ability of these Gaussian process landscape models is unprecedented. There are
currently no models which can achieve this level of accuracy across such a large and diverse set of
sequences. In addition, Gaussian processes explicit representation of model uncertainty provides a
valuable guide for knowing when a prediction should be trusted. Gaussian process models improve
upon previously developed statistical models [86, 151] by providing increased predictive accuracy
across a significantly larger portion of sequence space. Since Gaussian process models must be trained
on data from a specific protein family, they are less general than the models traditionally used for
protein design. However, this loss of generality comes with substantial increases in accuracy for a
wide variety of sequence properties. Many properties are extremely difficult to model accurately with
energy-based scoring functions because their origins are unknown or may involve subtle (possibly
dynamic) structural changes which are not easily represented with current methods. Since Gaussian
process models are trained on experimental data, they capture all the factors which contribute to
the sequence property being modeled, whether they are known or not.
The performance of Gaussian process landscapes could possibly be improved by the use of al-
ternate kernel functions. The structure-based kernel function is based on the assumption that a
residue-level contact potential is able to describe the properties of protein sequences. While this
assumption has a biophysical basis [240], it excludes the possibility of higher-order interactions. The
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use of polynomial kernels can very easily include interactions up to any order [218]. A promising
direction for kernel development might be to make use of any prior knowledge of interactions from
current statistical or physical models. If implemented properly, this could significantly reduce the
amount of experimental data required to learn or optimize the landscape.
The Bayesian treatment of uncertainty in Gaussian process landscapes allows for efficient ex-
plorations in the high-dimensional protein sequence space. We developed an experimental design
algorithm which is able to identify the most informative sequences within the landscape. This al-
gorithm was used to generate a set of 29 highly-informative chimeric cytochrome P450s. Gaussian
process models can also be used to design optimized protein sequences using upper confidence bound
(UCB) algorithms. UCB sequence design iteratively climbs unknown landscapes by deciding when
to continue exploring or when to exploit the current model. This algorithm was used to design a
chimeric P450 nearly 3 ◦C more stable than an already highly-optimized chimeric P450, and 12 ◦C
more stable than the most stable parent P450.
Improving the upper confidence bound protein design algorithm is an important area to explore.
While fully synthesized genes provide unlimited sequence accessibly, their cost is still prohibitively
high. For this reason we constructed new sequences from sequences that had already been con-
structed. Doing this optimally requires forward-looking sequence selection strategies, which consider
a sequence’s current utility and its potential to produce high-utility sequences in future generations.
This has been done with the UCT (upper confidence bounds applied to trees) algorithm, which
estimates how a decision will affect future outcomes by sampling randomly down the decision tree
[241]. Even simpler heuristics can probably hasten the sequence optimization. For example, imagine
sampling sequences which have lower-confidence bounds greater than the current maxima, or if they
do not exist, performing standard UCB optimization. This strategy exploits earlier than UCB, with
the intention of building off of any improvements.
By modeling multiple sequence properties, we obtain a more complete description of a protein.
Instead of modeling each property individually (as we did above), all properties and their relation-
ships can be modeled simultaneously using multi-task learning [242]. These models provide improved
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predictive ability because they take advantage of any correlations that might exist between proper-
ties. This more holistic description of a protein is important when designing sequences which must
satisfy a number of criteria, as most proteins do. These models also highlight the multifaceted nature
of the protein fitness landscape by revealing how different properties are related throughout sequence
space. This information can help explain the presence of evolutionary trends and constraints. For
example, we have previously evolved a cytochrome P450 for high dopamine binding affinity, which
inadvertently resulted in high serotonin binding affinity as well [100]. This result is not surprising,
given the strong correlation between dopamine and serotonin binding affinity observed within our
sampling of the landscape (Supplementary Table 3). However, this is only a trend in the landscape,
not a constraint: P450s have been engineered with high affinity and specificity for serotonin or
dopamine [237].
While all the results presented here are based on chimeric proteins, Gaussian process models
are applicable to any set of sequences which fold into the same three-dimensional structure. Other
training sets could include naturally occurring homologs, point mutant libraries, or computationally
designed libraries. For example, training these models on large libraries of point mutants would
allow prediction of the effect of combinations of mutations, accounting for both additive and pairwise
interactions. In general, predictions should be restricted to sequences that contain the same amino
acids at each position as observed in the training set, which will minimize the model’s uncertainty.
This makes chimeric protein libraries particularly desirable training sets because they uniformly
sample a massive combinatorial space. On top of this, the sequences within chimera libraries have
a high probability of functioning [56] and display significant functional diversity [85, 86].
Protein sequence space is vast, and hidden within it are engineering solutions to a wide-variety
of problems and even clues about the evolutionary history of life. To find these things, we must un-
derstand the mapping from protein sequence to function, which involves an extraordinarily complex
balance of numerous physical interactions. While this mapping is extremely challenging to describe
from a physical perspective, statistical models overlook these details and instead learn what the
experimental data is telling them. As technology for high-throughput experimentation advances,
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this class of models could play an increasing role in understanding how proteins function.
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Figure 5.1: Predictive ability of Gaussian process models. (A) The Gaussian process model shows
excellent predictive ability (r = 0.95, MAD = 1.4 ◦C) on a previously published cytochrome P450
data set. Shown are 10-fold cross-validated predictions. (B) A comparison of the Gaussian process
and linear regression models was made by sampling random training sets of various sizes and eval-
uating the predictive performance. For each training set size, the results are averaged over 1000
random samples. (C ) A Gaussian process model was trained on the data set from panel A and used
to predict the stability of a set of sequences that cannot be represented with the linear regression
model. This model shows good predictive ability (r = 0.76, MAD = 3.0 ◦C) on these sequences
which could not be modeled with previous methods. Confidence intervals for these predictions are
shown in Supplementary Figure 5.6
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Figure 5.2: Gaussian process models for P450 enzymatic activity and binding affinity. All plots show
leave-one-out cross-validated predictions and the red points correspond to the three parent sequences.
(A) Predictions for enzymatic activity on 2-phenoxyethanol (r = 0.77), outliers ED7, ED9, ED12,
ED28 were not included. (B) Predictions for enzymatic activity on 11-phenoxyundecanoic acid
(r = 0.74), outliers ED7, ED9, ED28 were not included. (C ) Predictions for binding affinity on
dopamine (r = 0.79), outliers ED7, ED9, ED2 were not included. (D) Predictions for binding
affinity on serotonin (r = 0.78), outliers ED7, ED9, ED28 were not included. The correlation
coefficients for predictions on the other substrates are: ethoxybenzene: 0.77, ethyl phenoxyacetate:
0.80, propranolol: 0.70, chlorzoxazone: 0.38 (scatter plots are shown in Supplementary Figure 5.9).
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Figure 5.3: Upper confidence bound sequence optimization. The first column shows the thermosta-
bilities of the three parent cytochrome P450s. The next two columns show the results from a large
sampling of a P450 recombination library, followed by sequences that were predicted to be stabi-
lized using a linear regression model [86]. The next four columns show four rounds of batch-mode
upper confidence bound sequence optimization, providing a diverse sampling of thermostabilized se-
quences. Note for UCB rounds 1 and 4, one chimeric P450 was not evaluated because of difficulties
encountered during the sequence construction. The final column shows the single lower-confidence
bound prediction (LCB1). LCB1 has a thermostability of 67.2 ◦C, which is significantly stabilized
relative to all previously identified chimeric P450s. All UCB and LCB sequences are represented
schematically in Supplementary Figure 5.11.
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5.7 Supplementary Figures
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Supplementary Figure 5.4: The correlation coefficient of Gaussian process models as a function of
training set size (calculated as in Figure 5.1B). The structure-based kernel function (green) outper-
forms the hamming distance (blue), structure-based kernels with the incorrect structure (magenta),
and the linear regression model (red).
Supplementary Figure 5.5: Schematic representation of the single- and double-crossover chimeric
P450s between CYP102A1 and CYP102A2. 14 of these sequences are from [220] and the remaining
five sequences are unpublished (presented in Supplementary Table 5.1). Parents CYP102A1 and
CYP102A2 are represented with red and green sequence fragments, respectively.
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Supplementary Figure 5.6: Uncertainty in Gaussian process predictions. The error bars show the
95% confidence intervals for the predictions shown in Figure 5.1C. 17/19 experimental measurements
fall within the model’s 95% confidence intervals.
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Parents
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Supplementary Figure 5.7: Schematic representation of the folded chimeric P450s within the exper-
imentally designed set of sequences. Parents CYP102A1, CYP102A2, CYP102A3 are represented
with red, green, and blue sequence fragments, respectively.
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Supplementary Figure 5.8: Absorbance spectra of the 26 chimeric P450s within the experimentally
designed set of sequences. Three of the chimeras (ED7, ED12, and ED28) have a blue-shifted soret
peak, indicative a of high-spin heme, which is normally associated with reduced solvent accessibility
in the active site. ED9 has a red-shifted soret peak, which suggests the presence of a distal heme
ligand.
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Supplementary Figure 5.9: Additional Gaussian process models for P450 enzymatic activity. All
plots show leave-one-out cross-validated predictions and the red points correspond to the three parent
sequences (A) Predictions for enzymatic activity on ethoxybenzene (r = 0.77), outliers ED7, ED9,
ED10, ED28 were not included. (B) Predictions for enzymatic activity on ethyl phenoxyacetate
(r = 0.80), outliers ED7, ED9, ED10, ED28 were not included. (C ) Predictions for enzymatic
activity on propranolol (r = 0.70), outliers ED7, ED9, ED28 were not included. (D) Predictions for
enzymatic activity on chlorzoxazone (r = 0.38), outliers ED7, ED9, ED28 were not included.
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5.8 Supplementary Tables
>C60, T50=58.9
MKETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKEACDESRFDKNL
SQALKFVRDFAGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPED
MTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVD
KIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKA
AEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRD
KTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKET
LTLKPEGFVVKAKSKKIPLGGIPSPST
>C142, T50=50.3
MKETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKEVCDEERFDKSI
EGALEKVRAFSGDGLATSWTHEPNWRKAHNILMPTFSQRAMKDYHEKMVDIAVQLIQKWARLNPNEAVDVPED
MTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVD
KIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKA
AEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRD
KTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKET
LTLKPEGFVVKAKSKKIPLGGIPSPST
>C60 354, T50=46.7
MKETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKEACDESRFDKNL
SQALKFVRDFAGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPED
MTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVD
KIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKA
AEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDRISVLIPQLHRD
RDAWGKDAEEFRPERFEHQDQVPHHAYKPFGNGQRACIGMQFALHEATLVLGMILKYFTLIDHENYELDIKQT
LTLKPGDFHISVQSRHQEAIHADVQAAE
>C142 354, T50=48.1
MKETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKEVCDEERFDKSI
EGALEKVRAFSGDGLATSWTHEPNWRKAHNILMPTFSQRAMKDYHEKMVDIAVQLIQKWARLNPNEAVDVPED
MTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVD
KIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKA
AEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDRISVLIPQLHRD
RDAWGKDAEEFRPERFEHQDQVPHHAYKPFGNGQRACIGMQFALHEATLVLGMILKYFTLIDHENYELDIKQT
LTLKPGDFHISVQSRHQEAIHADVQAAE
>C200, T50=47.4
MKETSPIPQPKTFGPLGNLPLIDKDKPTLSLIKLAEEQGPIFQIHTPAGTTIVVSGHELVKEVCDEERFDKSI
EGALEKVRAFSGDGLATSWTHEPNWRKAHNILMPTFSQRAMKDYHEKMVDIAVQLIQKWARLNPNEAVDVPGD
MTRLTLDTIGLCGFNYRFNSYYRETPHPFINSMVRALDEAMHQMQRLDVQDKLMDENKRQFQEDIKVMNDLVD
KIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKA
AEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRD
KTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKET
LTLKPEGFVVKAKSKKIPLGGIPSPST
Supplementary Table 5.1: Thermostabilities (T50) and sequences of unpublished single- and double-
crossover chimeric P450s between CYP102A1 and CYP102A2. Thermostabilities were measured
following the procedure presented in the Methods section.
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Supplementary Figure 5.10: Gaussian process model predictions on an independent enzymatic ac-
tivity data set [85]. Note the data set contained normalized activity values, whose logarithm should
be monotonic with the Gaussian process predictions, but not necessarily linear. (A) Predictions
for enzymatic activity on 2-phenoxyethanol (r = 0.72). (B) Predictions for enzymatic activity
on ethoxybenzene (r = 0.61). (C ) Predictions for enzymatic activity on ethyl phenoxyacetate
(r = 0.45). (D) Predictions for enzymatic activity on propranolol (r = 0.13). (E ) Predictions for
enzymatic activity on chlorzoxazone (r = 0.46).
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1
Supplementary Figure 5.11: Schematic representation of the sequences generated during four rounds
of upper confidence bound sequence optimization and the highly-stabilized LCB1 sequence. The
CYP102A1, CYP102A2, CYP102A3 parents are represented with red, green, and blue sequence
fragments, respectively. Note for UCB rounds 1 and 4, one chimeric P450 was not evaluated because
of difficulties encountered during the sequence construction.
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EOB EPOA PROP CHLOR 11POD DOP 5HT
activity activity activity activity activity affinity affinity
2PE activity 0.5730 0.7943 0.6170 0.0595 0.5659 -0.4883 -0.1834
EOB activity 0.7642 0.2337 0.1111 0.4691 -0.1555 0.0065
EPOA activity 0.4324 0.2300 0.2922 -0.3520 -0.0291
PROP activity 0.2503 0.6434 -0.6178 -0.5486
CHLOR activity 0.1469 -0.1800 -0.3022
11POD activity -0.2853 -0.3477
DOP affinity 0.8042
Supplementary Table 5.3: Pairwise correlations between the measured enzymatic activities and
binding affinities. The substrate names are abbreviated as 2PE: 2-phenoxyethanol, EOB: ethoxy-
benzene, EPOA: ethyl phenoxyacetate, PROP: propranolol, CHLOR: chlorzoxazone, 11POD: 11-
phenoxyundecanoic acid, DOP: dopamine, 5HT: serotonin. Some properties show strong correla-
tions, such as 2-phenoxyethanol activity and ethyl phenoxyacetate activity or dopamine affinity and
serotonin affinity. However, many of the pairwise correlations are less than the predictive ability of
the model, suggesting the model is able to capture independent sequence properties.
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